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“One sometimes finds what one is not looking for” 
 
Sir Alexander Fleming (1881-1955) 
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General introduction & outline of the thesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
The development of anti-infective therapies is an ancient research field that already 
fascinated Greek physicians, Egyptians and the Chinese thousands of years ago (1-4). 
However, observations within this field remained empirical until the early 20
th
 century 
when researchers such as Ehrlich, Fleming, Domagk and later Waksman, discovered 
independently several useful agents for treatment of infections (5-7). The discovery of 
penicillin by Alexander Fleming in 1928, the first natural antibiotic, is a major hallmark as it 
was such a powerful albeit small-spectrum antibiotic (8,9). Between 1938 and 1941 Florey 
and Chain succeeded in the purification of benzylpenicillin and up scaling its production; a 
prerequisite of industrial production of benzylpenicillin. The success of benzylpenicillin 
initiated a surge in research and development in the anti-infectives field, and led to the 
commercial production of antibiotics after World War 2. For his contribution, Fleming was 
rewarded the 1945 Nobel Prize for medicine and physiology, together with Florey and 
Chain (10,11). However, already in the early 1950s, Staphylococcus aureus isolates from 
hospital patients were noted to become penicillin-resistant and this percentage has 
increased rapidly over the following years (12). Over the past 60 years, the usage of 
benzylpenicillin and other antibiotics, in both humans as well as in the veterinarian field, 
has resulted in the emergence of multi-drug resistance of a variety of microorganisms. 
Given their rapid generation time and their spontaneous mutation rate, they evolve and 
adapt, and in stressful environments select for useful genotypes among multiple mutants. 
Infections with these antibiotic-resistant microorganisms present a major problem for 
both the medical community as well as for society (13).  
The identification of, for instance, pan-resistant Acinetobacter baumannii, carbapenem-
resistant Gram-negative bacteria and multi-drug resistant Staphylococcus aureus and 
Mycobacterium tuberculosis underscores the need for reconsidering current usage of 
antibiotics. It also shows that novel antibiotics with a mode of action different from 
current anti-infectives are urgently needed (14-16). The development of new antimicrobial 
agents has mainly focused on ways to eliminate the pathogen, either by a direct 
microbicidal activity or by stopping the microorganisms in their growth, allowing the 
hosts’ immune system to clear the invaders. Obviously, the development and spread of 
multi-drug resistant microorganisms nullifies these modes of elimination and 
development of new drugs that rely on this strategy has lagged behind because of a lack 
of new microbial targets to aim at. Thus, in the last decennium research has shifted 
toward exploring the possibility for an alternative way of coping with infections, a way 
that has proven its merit in human evolution: employment of naturally occurring human
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antimicrobial peptides/proteins as possible alternative for current antibiotics (17,18). In a 
way this is a logical extension to the earlier anti-infective research, as it should be realized 
that antibiotics (like benzylpenicillin) were generally isolated from microorganisms that 
likely had evolved these compounds as a way of defense against other microorganisms 
competing for a niche or nutrients. Besides the direct antimicrobial activity of human 
antimicrobial peptides, attention has shifted toward the immune modulatory properties 
of some antimicrobial peptides (19). It is hypothesized that elimination of a pathogen by 
enhancement of the hosts’ immune response will less likely result in resistance of  
pathogens against these peptides.    
The human immune system 
The human immune system has evolved over millions of years as a way to protect the host 
from invasive pathogens, tissue injury, toxic components, and harmful derailment of body 
cells. It is able to detect a wide variety of molecules that can be distinguished as self or 
non-self and as being either harmful or safe (20). If recognized as harmful, the immune 
system undertakes action to neutralize or actively fight and eliminate these causative 
agents. To this end, the host has developed a complex system that involves both innate 
and adaptive immunity. The innate immune system is directly available to react in a 
largely non-specific, rapid way and is effective for most problems. It recognizes invaders 
and starts a general immune response that, however, does not confer to long-lasting 
immunity to eliminate these pathogens (21). Although considered to operate in a non-
specific manner, it has become clear that the recognition of pathogens by so-called 
pattern recognition receptors on cells elicits an immune response titrated to the specific 
pathogen. In this sense, also a reaction of the innate immune system carries certain 
specificity. Basically, the innate immune system comprises of three components: a 
physical barrier like skin and mucosa, the non-cellular immune response, including the 
complement system, and the cellular component, i.e. immune cells. Cells that are part of 
the innate immune response are leukocytes, for example granulocytes, monocytes, 
macrophages, dendritic cells and mast cells. However, the distinction of three components 
is somewhat arbitrarily, as there exists an intricate cross-talk between all these 
components in most if not all immune reactions. Within minutes after the pathogen has 
penetrated the host, the non-cellular and cellular response of the innate immune system 
is activated. This occurs by detection of typical molecular structures on the membranes of 
these microorganisms by pattern recognition receptors of the host cells. This detection of 
invading microorganisms is performed by a variety of cells including macrophages and 
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dendritic cells that reside in the tissues. Upon encountering and subsequent recognition of 
a pathogen they phagocytose the pathogen and start to produce mediators as cytokines, 
chemokines, growth factors and antimicrobial peptides/proteins. These mediators will 
attract and activate immune cells from the circulation like neutrophils and monocytes. 
Typically, neutrophils are the first type of cells of the immune system to arrive at the site 
of infection. One of their main tasks is to phagocytose and intracellular kill pathogens 
thereby clearing the tissue of the infectious agent. Phagocytosis occurs by engulfment of 
the pathogen by the cell membrane. The pathogen is -while being surrounded by the 
membrane- then internalized. Intracellular, the phagosome which surrounds the pathogen 
fuses with a lysosome to become the so-called phagolysosome. Within the lysosome, a 
low pH is created, that together with the production of toxic reactive oxygen species, 
proteolytic enzymes and antimicrobial peptides, promotes death of the pathogen. Besides 
phagocytosis, upon activation, neutrophils also release inflammatory mediators that 
activate local cells and induce monocytes to exit the blood stream and recruit them into 
the injured tissue (22,23). Dependent on the local environment, these latter cells will 
differentiate into macrophages or dendritic cells; both are phagocytic cells, however 
where the main function of macrophages is to clear infection by phagocytosis and alarm 
the innate immune system upon activation by the pathogen, dendritic cells bridge 
between innate and adaptive immunity during infection (24). They process the 
internalized pathogen or foreign material and migrate toward the lymph nodes where T 
lymphocytes can recognize the presented components of the processed materials on their 
cell-surface in the context of MHC-molecules. T lymphocytes thus activated will 
subsequently expand and mediate an immune response specifically directed against this  
pathogen (25). This is the initiation phase of the adaptive immune response, which 
comprises of two major types of lymphocytes, the B lymphocyte and the T lymphocyte. B 
lymphocytes are part of the humoral component of the adaptive immune response; their 
main function is to produce antibodies. T lymphocytes are the main cellular component of 
the adaptive response, and can exist in three different stages, 1) naïve cells that have 
matured but have not seen an antigen yet, 2) effector cells, that have been activated by 
antigen and are involved in, e.g., the elimination of a pathogen and 3) memory cells, that 
have encountered their specific antigen in the past and now carry long-lived memory (26). 
T lymphocytes can be roughly divided into CD4+ T cells and CD8+ T cells. CD4+ T cells 
recognize exogenous antigens, while CD8+ T cells recognize endogenous antigens, i.e. 
antigens that are processed within the phagolysosomal pathway, or processed from within 
the cytoplasm of antigen presenting cells, respectively. CD4+ T cells modulate the immune 
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Fig. 1 Simplified representation of the major characteristics of monocytes and monocyte-derived cells in vitro 
Activated monocytes produce cytokines and chemokines upon encounter of pathogens, followed by 
phagocytosis and intracellular killling. Monocytes can differentiate into either macrophages or immature 
dendritic cells, depending on the presence of growth factors and cytokines. Upon recognition of a pathogen by 
their pathogen recognition receptors, macrophages will start to produce cytokines and chemokines and also 
phagocytose and intracellular kill pathogens. Monocytes, macrophages and dendritic cells use reactive oxygen 
species among others for killing of the pathogen. The processing of pathogens will mature the immature 
dendritic cells. Mature dendritic cells produce cytokines and chemokines and present pathogenic structures on 
their cell-surface using their MHC-molecules. When brought into co-culture with CD4+ T cells, these T cells may 
recognize the antigen that is presented by the mature dendritic cells and respond by producing cytokines that 
can direct innate immune cells.  
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response by the production of mediators, like cytokines that direct several innate immune 
cells. There are several subtypes of CD4+ T cells that have a phenotype that is important 
for the elimination of different types of pathogens (27). Most well-known are the T helper 
(Th)1, Th2, Th17 and regulatory T cells (Treg) (28,29). The Th1 response is characterized by 
the production of IFN-γ, which results in an enhanced cellular immune response (30). The 
Th2 response is characterized by the production of IL-4 among others, which results in an 
enhanced humoral immune response (30). The Th17 response is characterized by the 
production of IL-17, which induces the release of inflammatory mediators that affect 
innate immune cells thereby linking innate and adaptive immunity (31). And lastly Tregs 
suppresses ongoing immune responses thereby regulating the homeostasis of the immune 
system (32). In Fig. 1, a simplified representation of immune processes that are relevant to 
the work presented in this thesis is displayed.  
 
Antimicrobial peptides in general 
After the first reports of an antimicrobial substance in chicken egg white in 1909 by 
Laschtschenko, observations on interaction of nasal mucus with bacteria led to the 
discovery of the first human antimicrobial protein, lysozyme, in the early 20
th
 century by 
Fleming (33,34). The discovery of this antimicrobial protein initiated research leading to 
the characterization of a variety of antimicrobial proteins like lactoferrin (35-37). While 
antimicrobial protein discovery was already developing from the early 20
th
 century, it 
needed several decades more before the first antimicrobial peptide was discovered. This 
discovery resulted from research on host defense mechanisms of insects, and led to the 
isolation of cecropins from silk moth pupae about three decades ago by Hans Boman and 
co-workers (38). Further research showed that expression of antimicrobial peptides was 
not unique to insects. Over the following years Robert Lehrer and co-workers discovered 
defensins in human neutrophils (39,40) shortly after followed by Michael Zasloff who 
reported in the late ‘80s a potent antimicrobial peptide called magainin in the skin of frogs 
(41). These studies established the basis of antimicrobial peptide research which has 
culminated at present-day in the identification of far over a thousand antimicrobial 
peptides. An online database that is reporting all antimicrobial peptides from natural 
sources can be consulted at http://aps.unmc.edu/AP/main.php. Due to their diversity, 
several classes of antimicrobial peptides are distinguished, based on their structure, origin 
and amino acid composition. Antimicrobial peptides can be naturally occurring or are 
derived from enzymatic cleavage of naturally occurring antimicrobial proteins. Also, new 
peptides can be designed in silico (42-44). In general, antimicrobial peptides are cationic 
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and active against many types of microorganisms, often including the presently emerging 
multi-drug resistant microorganisms. The mechanism of action of the peptides is divers, 
but generally the mechanism involves direct action on the membrane of microorganisms, 
inducing leakage of intracellular content followed by cell death (45). In addition, the 
peptides can be internalized and induce cell death by acting on intracellular components 
(46). It was long thought that antimicrobial peptides possess antibacterial activity only 
(47,48); however research has shown that their activity extends to antifungal (49,50), 
antiviral (51), antiparasitic (52) and antitumor (53-55) activity. Some of them were shown 
to exert modulatory effects on cells of the human immune system (56,57). The latter is 
now increasingly recognized as being an important contribution to the clearance of 
infections. For possible therapeutic application of antimicrobial peptides, it will thus be 
important to understand the interactions of these peptides with the hosts’ immune cells. 
 
The human cathelicidin LL-37 
An example of a natural occurring antimicrobial peptide is LL-37. This peptide is the single 
member of the cathelicidin family identified in humans. It is stored in neutrophils, 
monocytes, mast and epithelial cells as an (inactive) pro-peptide called hCAP18/LL-37, 
which is cleaved extracellular by enzymes to its active form. LL-37 is an amphiphatic alpha-
helical peptide that has a wide range of biological activities (58). It is able to affect a 
variety of organisms, like bacteria including those residing in biofilms (59,60), viruses like 
HIV (61) and fungi (62). Moreover, it is able to neutralize bacterial endotoxins (63,64). In 
addition to its antimicrobial properties LL-37 also exerts activities on a variety of cells of 
the human immune system. These effects are mediated through an array of cell-surface 
receptors (66-70) and an intracellular target (71). Since LL-37 is naturally occurring in 
humans and is expressed by a variety of immune cells, its main actions are directly on or 
synergistically with the immune system. For example, LL-37 can act as a chemoattractant 
by recruiting neutrophils, monocytes and T cells (72). In addition, it suppresses the Toll-
like receptor induced cytokine production by human peripheral blood mononuclear cells 
(73). It is also able to modulate the differentiation of dendritic cells by enhancement of 
their endocytic capacities and promotion of Th1 responses in vitro (74). However, when 
dendritic cells were incubated with LL-37 it inhibited their maturation and the toll-like 
receptor-induced cytokine response (75). LL-37 can also induce secondary necrosis in 
apoptotic neutrophils and can induce apoptosis in infected airway epithelium, thereby 
promoting the clearance of respiratory pathogens (76). These are all just examples of the  
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Fig. 2 Historical events that motivated research into antimicrobial proteins and peptides (Modified from 
Lehrer) (65) 
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involvement of LL-37 in immune processes that will lead to recruitment of leukocytes to 
the site of infection, the promotion of wound healing and to modulate adaptive immunity.  
 
Immunomodulatory effects of other antimicrobial peptides 
Human defensins are natural occurring antimicrobial peptides that display a triple-
stranded beta-sheet structure. Three groups have been identified based on their disulfide 
bonds, firstly, alpha-defensins that are produced by neutrophils, natural killer cells, T cells, 
epithelial cells and paneth cells. Secondly, beta-defensins that are produced by leukocytes 
and epithelial cells and, thirdly, theta-defensins that are found in leukocytes, but have 
only been identified in rhesus macaque, baboons and orangutans (65,77). Defensins have 
shown to act as chemoattractants for neutrophils, mast cells, dendritic cells and T cells 
and are able to enhance keratinocyte migration and proliferation (56). In addition they 
play an important role in gut and in skin diseases (78-80). Besides natural occurring 
peptides, also other antimicrobial peptides that were developed based on the structure of 
natural occurring peptides/proteins have shown to display immunomodulatory activities. 
Immune defense regulator-1 (IDR-1) and IDR-1002 are both designed peptides that display 
immune enhancing properties. IDR-1 lacks direct antimicrobial activity but is effective 
against infections. In the absence of monocytes and macrophages this peptide lost its 
activity against these infections, indicating that it displays immunomodulatory properties. 
Further research showed that it was able to enhance the LPS-stimulated chemokine and 
IL-10 production by peripheral blood mononuclear cells thereby controlling inflammation 
(43). IDR-1002 was able to induce similar effects as IDR-1 but much stronger (81). Since 
more and more antimicrobial peptides are linked to effects on the immune system, 
antimicrobial peptide research is shifting toward the development of new anti-infective 
agents based on these immunomodulating peptides.  
 
The lactoferrin-derived antimicrobial peptide hLF1-11 
The synthetic peptide hLF1-11 is one promising antimicrobial peptide developed as a 
potential therapeutical candidate with activity against several multi-drug resistant 
microorganisms, including fluconazole-resistant Candida albicans, multi-drug resistant 
Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus (MRSA). hLF1-11 
comprises the first 11 N-terminal amino acids (GRRRRSVQWCA) of human lactoferrin and 
shows antimicrobial activity. Lactoferrin is an 80 kDa iron-binding glycoprotein and 
member of the transferrin family (82). Lactoferrin is provided to newborns by breast-
feeding and it is a major component of neutrophil-specific granules. It is present in high 
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concentrations (1-10 mg/ml) in many mucosal secretions, being synthesized by mucosal 
gland epithelial cells (83). Lactoferrin is part of the innate defense system and has a large 
diversity of mechanisms of action. For example, lactoferrin plays a role in the host defense 
by sequestering environmental iron through its two high-affinity ferric iron binding sites, 
thereby inhibiting microbial growth (84). It displays direct antimicrobial activity and can 
interact with the bacterial endotoxin (i.e., lipopolysaccharide, LPS). In addition, it reduces 
the negative charge of Gram-positive bacteria, thereby favoring contact between 
lysozyme and the underlying peptidoglycan (82) and displays anti-inflammatory activities 
by reducing pro-inflammatory cytokines and induction of IL-10 production (85). Small 
amounts of lactoferrin are expressed on the surface of resting neutrophils, mediating the 
binding of these cells to various structures (86). More importantly, lactoferrin is the source 
of peptides with antimicrobial activity, since by acid-pepsinolysis it generates the 
antimicrobial peptide lactoferricin H (residues 1 to 47). This region contains two cationic 
domains; four arginines at residues 2-5 and two arginines, a lysine and valine at residues 
28-31. Both domains show antimicrobial activity, though hLF1-11 (comprising the first 
cationic domain) was over 10 times more efficient against various multi-drug resistant 
bacterial strains than hLF21-31 (comprising the second cationic domain) (87,88).  
 
Antibacterial activities of hLF1-11 
Direct antibacterial activity of hLF1-11 has been demonstrated by a number of studies 
using a variety of microorganisms including several multi-drug resistant pathogens. Its 
antibacterial activity was first tested in in vitro killing experiments using the Gram-positive 
Listeria monocytogenes and MRSA and the Gram-negative Escherichia coli and Klebsiella 
pneumoniae, in which the peptide killed these pathogens at relatively low concentrations 
(88). These experiments were later successfully reproduced using various Gram-negative 
multi-drug resistant A. baumannii strains by Dijkshoorn et al. demonstrating the activity of 
hLF1-11 against some clinically relevant multi-drug resistant strains (89). However, as the 
antimicrobial activity of hLF1-11 is salt-sensitive, these experiments were all performed in 
vitro at low salt conditions (~10 mM NaCl). At physiological salt concentrations (~155 mM 
NaCl) this peptide is ineffective in vitro at similar concentrations against all bacterial 
strains. Remarkably, it proved to be very active against a variety of bacterial strains when 
tested in animal models. The peptide was tested in a thigh-muscle infection mice model 
against several multi-drug resistant A. baumannii strains and against MRSA. In this 
infection model the relevant microorganism is injected in the right thigh muscle, followed 
by an intravenous injection of the peptide 24 hours later. The next day, the thigh muscle is 
 18 | G e n e r a l  i n t r o d u c t i o n  
 
removed and the number of surviving microorganisms is determined microbiologically. 
hLF1-11 was highly active against the various A. baumannii strains in this in vivo infection 
model, as it reduced bacterial counts in a dose-dependent manner (89). When tested 
against MRSA the peptide showed a dose-dependent bactericidal effect, with a maximum 
effect of 2-3 log reduction using a concentration of 0.4-40 μg of peptide/kg of body 
weight. Moreover, when the peptide was administered to animals on a daily basis for four 
consecutive days, the infection was almost completely cleared ((90) and own 
observations).   
 
Antifungal activities of hLF1-11 
Invasive fungal infections, such as those caused by Aspergillus fumigatus and Candida 
albicans are recognized as an important cause of morbidity and mortality, in the immuno-
compromised host in particular. Treatment of these infections is frequently hampered by 
the limitations of current anti-fungals, either due to intrinsic resistance, interactions with 
other drugs, adverse effects, etc. Therefore, the antifungal effect of the hLF1-11 peptide 
has been tested against these pathogens as well. In vitro hLF1-11 was more active than 
hLF21-31 in killing A. fumigates and C. albicans, as 10- and 5-times higher concentrations 
of hLF21-31 than hLF1-11 were necessary to obtain similar antifungal activity (87,91). In 
vivo hLF1-11 was tested in a C. albicans neutropenic mice model in which a maximum of 
1.5 log reduction was obtained when using 0.4 μg of hLF1-11/kg of body weight. This 
effect was even more extreme (up to 4 log reduction) when IL-10 was neutralized by 
injection of IL-10 neutralizing monoclonal antibodies. This result was in agreement with 
the observation that IL-10 serum levels increased upon injection with high doses of hLF1-
11 (49). In addition, hLF1-11 was found to act synergistically with fluconazol against 
fluconazole-resistant C. albicans in vitro (92). Besides direct killing of C. albicans, the 
peptide is also capable of reducing the virulence of C. albicans by inhibition of the 
morphological transition of this yeast. C. albicans is able to switch morphology from a 
round-shaped conidial form to a more virulent elongated hyphal shape. hLF1-11 was able 
to reduce the morphology switch of C. albicans in vivo to the hyphal state, thereby 
reducing its virulence (49). The inhibition of conidia to hyphae transition could be 
reproduced in vitro at physiological salt concentrations, indicating that besides its 
antimicrobial properties, hLF1-11 also displays pathogen modulatory properties that could 
contribute to its overall antimicrobial effects.  
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Safety of hLF1-11 
In vivo toxicity studies in mice and rats have shown that hLF1-11 can be safely 
administered at a 100 fold higher dose than appears therapeutically effective in these 
animals. hLF1-11 has also been tested for safety in two phase I studies in healthy human 
male volunteers. In both studies the subjects received an i.v. dose of hLF1-11 or placebo; 
concentrations were different in the studies. Both showed that the peptide was safe and 
well tolerated; any adverse events were graded mild. Phase IIa safety has also been 
established using a first patient population (hematopoietic stem cell recipients) receiving a 
single (high) dosis of hLF1-11 (93). The next phase II trial will focus on treatment of MRSA 
and systemic fungal infections.  
 
Hypothesis 
As hLF1-11 has proven safe in the first small phase I studies in humans and will now be 
further tested for a potential therapeutic application, we wanted to establish the 
mechanism(s) of action of this candidate peptide. Since hLF1-11 is able to reduce the 
infectious load in mice within 48 hours, the time span of innate immunity, but is unable to 
kill these pathogens in vitro at physiological salt concentrations, we hypothesized that 
hLF1-11 displays immunomodulatory properties on cells of the innate immune system.  
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Outline of the thesis 
In this thesis we investigate the interactions of hLF1-11 and LL-37 with immune cells, in 
order to gain insight in their mechanism of antimicrobial action. In chapter 1 the history 
and current knowledge on antimicrobial proteins and peptides and in particular LL-37 and 
hLF1-11, is described. Also, the background on basic immunological responses and 
processes has been provided and some insight on current knowledge on interactions of 
antimicrobial peptides with the human immune system is given. As put forward in our 
hypothesis, we expect immunomodulatory effects of hLF1-11 on cells of the innate 
immune system and therefore we first investigated effects of hLF1-11 on murine and 
human monocytes of which the results are described in chapter 2. Upon entering the 
tissue, monocytes can differentiate toward macrophages or dendritic cells. The effect of 
hLF1-11 on monocytes prompted us to investigate whether the interaction between 
monocytes and hLF1-11 has consequences for the functions of the resulting macrophages. 
Described in chapter 3 are the results regarding the effect of hLF1-11 on monocyte-
macrophage differentiation. As the effects of LL-37 on monocytes differ from those of 
hLF1-11, we determined whether the differentiation of monocytes into macrophages was 
also differentially modulated by LL-37 as compared to hLF1-11. The results of this 
investigation are described in chapter 4. Furthermore, as monocytes can also differentiate 
into dendritic cells, in chapter 5 we report the results of our study into the effect of hLF1-
11 on monocyte-dendritic cell differentiation. After establishing several immuno-
modulatory effects on mononuclear phagocytes, we investigated the possible cellular 
target of hLF1-11 on human monocytes that likely mediates the modulatory actions of 
hLF1-11 on these cells. Results of this investigation are described in chapter 6. Finally, the 
main findings of this thesis are summarized and discussed in chapter 7 and a Dutch 
summary can be found in chapter 8.  
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Abstract Earlier we reported that the peptide corresponding to the first eleven N-terminal amino 
acids of human lactoferrin (hLF1-11) is active against multi-drug resistant pathogens in mice. The 
mechanisms underlying this anti-infective activity remain unclear. Since hLF1-11 is ineffective 
against pathogens at physiological salt concentrations and hLF1-11 directs differentiation of 
monocytes toward a macrophage subset with enhanced effector functions, we investigated the 
effects of hLF1-11 on human and murine monocytes. Results revealed that human and murine 
monocytes exposed for 1 h to hLF1-11 and then stimulated with the Toll-like receptor (TLR)-ligand 
LPS for 18 h, displayed enhanced cytokine and chemokine production as compared to control 
(peptide-treated) monocytes. We also found that expression of mRNA, cell-surface receptor 
expression, and NF-κB activation by hLF1-11-exposed human monocytes were enhanced as 
compared to control (peptide-treated) monocytes. Furthermore, the kinetics of the cytokine 
production was unchanged as mRNA levels and protein levels paralleled the enhanced response of 
hLF1-11-exposed monocytes to LPS. The cytokine production by human monocytes in response to 
TLR4, TLR5, and TLR7 stimulation, but not to TLR2 stimulation, was elevated by hLF1-11. In 
concordance, translocation of NF-κB subunits to the nucleus was enhanced in hLF1-11-exposed 
monocytes after TLR stimulation, except for TLR2, as compared to control (peptide-exposed) 
monocytes. In conclusion, monocytes were primed by hLF1-11 for an enhanced inflammatory 
response upon TLR4, TLR5, and TLR7 stimulation, but not TLR2 stimulation. Such effects of hLF1-11 
on monocyte reactivity should be taken into account when considering the clinical development of 
this peptide for a therapeutic intervention in patients. 
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Introduction 
Human lactoferrin (hLF), an ~80-kDa iron-binding glycoprotein, is a member of the 
transferrin family. It is found predominantly in the secreted fluids of mammals such as 
milk, tears, saliva, bronchial mucus, and seminal plasma and is also stored in the 
secondary granules of polymorphonuclear leukocytes. hLF is an important contributor to 
host defense due to its wound healing, endotoxin binding, antimicrobial, and 
immunomodulatory properties (1-3). The antimicrobial activity of hLF is based on at least 
two mechanisms: 1) iron sequestration, thereby depriving bacteria from this nutrient, 
inhibiting growth of the infectious agent and 2), direct interaction with the bacterial cell 
membrane resulting in cell lysis. In addition, hLF displays immunomodulatory effects on 
cells of both the innate and acquired immune response (2,4). Several peptides 
representing different domains of human lactoferrin can mimick antimicrobial, 
immunomodulatory or other properties of lactoferrin and may even be more potent than 
the parent protein (5,6). In this connection we reported that the peptide corresponding to 
the first eleven N-terminal amino acids of human lactoferrin (hLF1-11) is more active than 
hLF in reducing pathogenic load in mice (7) and hLF1-11 exerts immunomodulating activity 
on monocyte-macrophage differentiation (8). Others have found enhanced antimicrobial 
activity of peptides comprising amino acids 19–31 as compared to human lactoferrin (9). 
In addition, Nilsson et al. (10) have developed a human lactoferrin derived peptide PXL01 
that prevented postsurgical adhesion formation in rats. In search for antimicrobial agents 
that are effective against infections with multi-drug resistant pathogens, we reported 
hLF1-11 to effectively reduce microbial load in infections with methicillin-resistant 
Staphylococcus aureus (MRSA) (7), multi-drug resistant Acinetobacter baumannii (11) and 
fluconazole-resistant Candida albicans (12) in mice. hLF1-11 is ineffective in vitro at 
physiological salt concentrations and, as discussed by Lupetti et al., it may exert its 
antimicrobial effects partly by affecting the early innate immune response of the host. 
Since the peptide is also effective in clearing infections in neutropenic mice, we 
considered the possibility that the peptide displays immunomodulatory activity by 
affecting the functional activities of mononuclear phagocytes, i.e., monocytes and 
macrophages. The mononuclear phagocyte system includes blood monocytes that have 
differentiated from committed progenitor cells in the bone marrow. Monocytes circulate 
in the blood and upon recruitment by inflammatory mediators they enter tissues to 
differentiate into macrophages or (immature) dendritic cells (DCs). Recognition of 
pathogens through their pathogen-associated molecular patterns (PAMPs) by these cells 
requires pattern recognition receptors, such as C-type lectins and Toll-like receptors (TLRs) 
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(13). TLR2 and TLR4 are major TLRs on mononuclear phagocytes and DCs involved in 
sensing bacterial pathogens. This interaction initiates activation and translocation of 
transcription factors like NF-κB. Activation of these transcription factors will initiate the 
transcription of many genes leading to the production of a variety of inflammatory 
mediators, such as chemokines and cytokines (14), thereby regulating the inflammatory 
process (15,16). Previous investigations showed that incubation of monocytes with hLF1-
11 modulated the GM-CSF driven differentiation of these cells resulting in a macrophage 
subset that showed enhanced recognition and clearance of pathogens (8). These effects 
were already obtained after incubation of monocytes with hLF1-11 for 60 min prior to the 
start of the 7-day culture system. In this study we investigated whether hLF1-11 primes 
monocytes with respect to an enhanced inflammatory response to various PAMPs. 
 
Materials and methods 
Peptides The synthetic peptide comprising the first eleven amino acids of human 
lactoferrin (further referred to as hLF1-11; GRRRRSVQWCA, 1374 Da) was purchased from 
Peptisyntha (Torrance, CA) and the control peptide (GAARRAVQWAA, 1155 Da) from 
Isogen (De Meern, The Netherlands). The purity of the peptides was determined by 
reverse-phase high performance liquid chromatography and exceeded 97%. Both peptides 
are endotoxin free. Immediately before use the peptides were dissolved in phosphate 
buffered saline (PBS; pH 7.4; Department of Pharmacy, LUMC) to a stock concentration of 
1 mg/ml. 
 
Stimuli The following TLR2 ligands were used: purified lipoteichoic acid (LTA; 
Staphylococcus aureus), lipomannan (Mycobacterium smegmatis), and synthetic 
PAM2CSK4. The TLR4 ligands, i.e., purified lipopolysaccharide (LPS) and diphosphoryl lipid 
A (DPLA; both E. coli), the TLR5 ligand recombinant flagellin (Salmonella typhimurium) and 
the synthetic TLR7 ligand CL087 were also included in this study. All TLR-stimuli were 
purchased from Invivogen (San Diego, CA) except DPLA (Sigma-Aldrich, Zwijndrecht, The 
Netherlands). Stocks of LPS (5 mg/ml), LTA (5 mg/ml), PAM2CSK4 (1 mg/ml), lipomannan 
(1 mg/ml), CL087 (1 mg/ml), and flagellin (2 μg/ml) were prepared in distilled water, and 
stored at -20°C. A stock of DPLA (1 mg/ml) was prepared in DMSO and stored at 4°C.  
 
Mice The animal experiment was approved by the Leiden Experimental Animal Committee 
and done in compliance with Dutch laws related to the conduct of animal experiments. 
Fresh blood was taken via heartpunction from SPF, female Swiss mice aged 9 weeks old 
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(Charles River, Maastricht, The Netherlands) and collected in citrate tubes (BD biosciences, 
Heidelberg, Germany).  
 
Isolation of mouse monocytes Mouse monocytes were isolated by Ficoll amidotrizoate 
density centrifugation (ρ=1.077 g/ml, Department of Pharmacy, LUMC). Cells in the 
interphase were washed and the CD3+ cells were depleted from this cells suspension 
using magnetic antiCD3 coated MACS beads (Miltenyi Biotec, Bergisch Gladbach, 
Germany) according to manufacturer’s instructions. The remaining cells were washed and 
the monocytes were further purified using magnetic antiCD11b coated MACS beads 
(Miltenyi Biotec), resulting in a suspension of ~95% monocytes.  
 
Isolation of human monocytes Human monocytes were isolated from buffycoats 
(Sanquin, Amsterdam, The Netherlands) from healthy donors by Ficoll amidotrizoate 
(Department of Pharmacy, LUMC) density centrifugation. Cells in the interphase were 
washed and the monocytes were further purified using magnetic antiCD14 coated MACS 
beads (Miltenyi Biotec) according to manufacturer’s instructions resulting in a suspension 
of >96% monocytes. The viability of this cell suspension exceeded 98% as determined by 
Annexin V and PI staining 2 h after isolation.  
 
Experimental set-up Murine and human monocytes were resuspended in RPMI-1640 
(Invitrogen, Breda, The Netherlands) supplemented with 2 mM L-glutamine (Invitrogen), 
100 U/ml penicillin (PAA GmbH, Pasching, Germany), 100 mM streptamycin (PAA GmbH), 
and 10% inactivated fetal calf serum (Invitrogen), further referred to as standard medium. 
Monocytes were cultured at a concentration of 1x10
6
 cells/ml of standard medium at 37°C 
and 5% CO2. The cells were exposed to the peptides immediately at the start of culturing 
and 1 h thereafter the cells were stimulated with one of the TLR ligands. 18–20 h later the 
supernatants were collected for assessment of cytokine and chemokine levels. The human 
monocytes were assessed for cell-surface receptor expression or were further processed 
to obtain nuclear and cytoplasmic fractions, or RNA was isolated using RNeasy microkit 
(Qiagen, Valencia, CA) according to manufacturer’s instructions. 
 
Determination of cytokine and chemokine levels Levels of murine IL-1α, IL-1β, IL-6, IL-10, 
IL-12p70, MCP-1, MIP-1β, RANTES, and TNF-α were determined using Bio-plex (Bio-Rad, 
Hercules, CA) with a lower level of detection of 10–20 pg/ml. Levels of human IL-1β, IL-
1RA, IL-6, IL-8, IL-10, IL-12p70, MCP-1, MIP-1β, RANTES, and TNF-α were determined using 
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Bio-plex with a lower level of detection of 5–15 pg/ml. In addition, levels of the anti-
inflammatory cytokine IL-10 and the pro-inflammatory cytokines IL-12p40 and TNF-α in 
supernatants of human monocytes were determined using ELISA (cytosets from 
Invitrogen; Breda, The Netherlands) with a lower level of detection of 25 pg/ml. All assays 
were performed according to manufacturer’s instructions. Cytokine levels are expressed 
as concentration or as fold induction over control cells to correct for donor variation in 
cytokine production. 
 
Curve fitting analysis To determine the effect of hLF1-11 on the responsiveness of 
monocytes to LPS, two characteristics (i.e., Emax and EC50) of the LPS-induced IL-10 release 
were calculated by non-linear regression with the dose–response model according to the 
Hill’s equation: E = Emax x C/(EC50 + C). Where E is the observed IL-10 production at a given 
LPS concentration C, Emax is the estimated maximal IL-10 production, and EC50 is the 
estimated LPS concentration at which 50% of the maximal IL-10 response is reached (17).   
 
Determination of gene-expression levels Quantative PCRs (Q-PCRs) were used to analyze 
samples for expression of human IL-10, IL-12p40, TNF-α, and the housekeeping genes 
GAPDH and RPL13A. Total RNA was extracted from cultured monocytes and RNA levels in 
the samples were measured on a Nanodrop 2000 spectrophotometer (Nanodrop 
Technologies, Wilmington, DE). Next, cDNA synthesis was performed on 0.5 μg of RNA 
with an Iscript cDNA synthesis kit (Bio-Rad) according to manufacturer’s instructions. Q-
PCRs were performed on a MyIQ (Bio-Rad). The reaction mixture consisted of SybrGreen 
(Roche, Indianapolis, IN), 1 mM dNTPs (Invitrogen), 400 nM primers (Isogen, De Meern, 
The Netherlands) and 0.5 U amplitaq gold/test in polymerase Gold buffer or—for TNF-α 
only—in polymerase buffer II (Applied Biosystems, Foster City, CA). The sequences of the 
primers are: GAPDH: (Forward, F) AAG GTC GGA GTC AAC GGA TTT and (Reverse, R) ACC 
AGA GTT AAA AGC AGC CCT G. RPL13A: (F) CCT GGA GGA GAA GAG GAA AGA GA and (R) 
TTG AGG ACC TCT GTG TAT TTG TCA A. IL-10: (F) GGT GAT GCC CCA AGC TGA and (R) TCC 
CCC AGG GAG TTC ACA. IL-12p40: (F) CGG TCA TCT GCC GCA AA and (R) CAA GAT GAG CTA 
TAG TAG CGG TCC T. TNF- a: (F) GGT GCT TGT TCC TCA GCC TC and (R) CAG GCA GAA GAG 
CGT GGT G. Each cDNA sample was analyzed in duplicate. The results were analyzed using 
Bio-Rad software. Gene-expression levels were corrected for both GAPDH and RPL13A 
expression. 
 
34 | h L F 1 - 1 1  p r i m e s  m o n o c y t e s  
 
Determination of NF-κB activation and translocation The levels of NF-κB in the cytoplasm 
and nucleus were assessed to determine transcription activation and translocation in 
monocytes upon hLF1-11 or control peptide stimulation. Cytoplasmic and nuclear 
fractions of the human monocytes were obtained using the nuclear extract kit (Active 
Motif, Rixensart, Belgium) and tested for NF-κB p50, p52, p65, B-Rel, and Rel-C levels using 
NF-κB transcription factor assay kit (Active Motif) according to manufacturer’s 
instructions. Values are expressed as the optical density of the sample minus background.  
 
Flow cytometric analysis of cell-surface molecule expression by human monocytes 
Monocytes were collected and resuspended in cold PBS with 0.2% BSA, washed twice and 
then incubated with the selected fluorescently-labeled monoclonal antibodies for 30 min 
on ice in the dark. The following monoclonal antibodies were used: PE-conjugated 
antibodies against CD11b, CD32, CD86 and CD163 and FITC-labeled antibodies against 
CD14, CD16, CD64 and CD80 were obtained from BD biosciences (Heidelberg, Germany). 
FITC-conjugated antibodies against CD282 and CD284 were obtained from HyCult (Uden, 
The Netherlands). Cell-surface molecule expression was assessed by flow cytometry using 
FACSCalibur and BD CellQuest software (BD biosciences). Results are expressed as median 
fluorescence intensity (MFI). 
 
Statistical analysis Differences between the values for the hLF1-11-exposed and those for 
control peptide-exposed and control monocytes were compared with the repeated 
measures ANOVA and the Bonferroni’s multiple comparison post-hoc tests. For 
experiments without the control peptide-exposed cells the differences between hLF1-11-
exposed monocytes and control cells were tested for significancy with the paired t-test. In 
all experiments p values of < 0.05 were considered significant. 
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Results 
Effect of hLF1-11 on cytokine and chemokine production by LPS-stimulated murine 
monocytes Since (i.v. administered) hLF1-11 is effective against infections in mice, we 
determined whether the peptide activates monocytes by comparing cyto- and chemokine 
production by hLF1-11-exposed and control (peptide-exposed) murine monocytes in 
response to LPS. Results revealed that hLF1-11-exposed cells produced significantly more 
IL-6, IL-10, MIP-1β, and RANTES, but not IL-1α, IL-1β, MCP-1, IL-12p70, and TNF-α after LPS 
activation than control or control peptide-exposed cells did (Fig. 1).  
 
Fig. 1 Effect of hLF1-11 on cytokine production 
by murine monocytes in response to LPS 
Monocytes were exposed to 100 μg/ml hLF1-11 
(dark gray boxes) or 100 μg/ml control peptide 
(CP; light gray boxes), or no peptide for 1 h and 
then stimulated with 100 ng/ml LPS for 18 h. 
Thereafter, levels of IL-1α, IL-1β, IL-6, IL-10, IL-
12p70, MCP-1, MIP-1β, RANTES, and TNF-α were 
determined by a multiplex assay. IL-6, IL-10, MIP-
1β, and RANTES production was significantly 
enhanced by hLF1-11-exposed monocytes as 
compared to control (peptide-exposed) 
monocytes. Values are expressed as fold increase of cytokine production compared to no peptide. Data are 
expressed as boxes and whiskers: boxes represent medians and second and third interquartiles, whiskers 
represent range of experiments within 4–7 different donors. *p < 0.05 for the difference between hLF1-11-
exposed and control (peptide-exposed) cells 
 
Effect of hLF1-11 on cytokine and chemokine production by LPS-stimulated human 
monocytes Since we consider administration of hLF1-11 to humans, we next determined 
whether exposure to hLF1-11 also affects the cyto- and chemokine production by human 
monocytes in response to LPS. Results showed that hLF1-11-exposed monocytes produced 
significantly higher levels of the various cytokines and chemokines in response to LPS than 
control (peptide-exposed) monocytes did, except for TNF-α (Fig. 2A). However at earlier 
time-points after LPS stimulation, TNF-α production was significantly enhanced by hLF1-
11-exposed monocytes. Unstimulated cultured monocytes produced IL-1RA, IL-8, and MIP-
1β and addition of hLF1-11 at the start of the culture resulted in cells producing 
significantly less of these chemokines than control (peptide-exposed) monocytes did (Fig. 
2B). All further experiments were performed with human monocytes. 
36 | h L F 1 - 1 1  p r i m e s  m o n o c y t e s  
 
Fig. 2 Effect of hLF1-11 on cytokine 
production by human monocytes in 
response to LPS Monocytes were exposed to 
various concentrations of hLF1-11 (dark gray 
boxes) or 100 μg/ml control peptide (CP; light 
gray boxes) or vehicle for 1 h and thereafter 
stimulated with 100 ng/ml LPS (a) for 18 h. 
Levels of IL-1β, IL-1RA, IL-6, IL-8, IL-10, IL-
12p70, MCP-1, MIP-1β, RANTES, and TNF-α in 
these cell culture supernatants were 
determined by multiplex assay. IL-12p70 was 
not detectable and IL-8 levels were above the 
highest values in the standard curve. In 
unstimulated cells (b) only IL-1RA, IL-8, and 
MIP-1β production was detectable and this 
was less in hLF1-11-exposed monocytes than 
in control monocytes. Values are fold 
increases of cytokine production compared 
to control monocytes. Data are expressed as 
boxes and whiskers: boxes represent medians 
and second and third interquartiles, whiskers 
represent range of experiments within 4–7 
different donors. *p < 0.05 for the difference 
between hLF1-11-exposed and control 
(peptide-exposed) cells. 
 
 
 
 
 
 
 
 
 
 
C h a p t e r  2 | 37 
 
Effect of hLF1-11 on LPS recognition by human monocytes To investigate whether hLF1-
11 affects the recognition of LPS, we incubated monocytes exposed to hLF1-11, control 
peptide or no peptide with various concentrations of LPS (0.1–1000 ng/ml) and measured 
IL-10 production by these cells. Results revealed that hLF1-11-exposed monocytes 
displayed enhanced cytokine production in response to the various LPS concentrations, 
i.e., Emax for control cells amounted to 0.43 ± 0.10 ng IL-10/ml and for hLF1-11-exposed 
cells amounted to 0.80 ± 0.13 ng IL-10/ml, without affecting the sensitivity of these 
monocytes to LPS, i.e., EC50 for control cells amounted to 0.82 ± 0.33 ng LPS/ml and for 
hLF1-11-exposed cells amounted to 1.22 ± 0.47 ng LPS/ml (Fig. 3). 
 
Fig. 3 Effects of hLF1-11 on cytokine 
production by human monocytes 
stimulated with various LPS 
concentrations Monocytes were 
exposed to hLF1-11 (dark gray boxes) 
or no peptide (open boxes) for 1 h and 
then stimulated with various 
concentrations LPS for 18 h. Thereafter 
supernatants were collected and 
assessed for IL-10 levels. Data are 
expressed as boxes and whiskers: 
boxes represent medians and second 
and third interquartiles, whiskers 
represent range of experiments within five different donors. *p < 0.05 for the difference between hLF1-11-
exposed and control cells. 
 
Interaction of hLF1-11 with LPS in human monocyte cultures To exclude the possibility 
that hLF1-11 exerts its effects on cytokine production by interacting with LPS, two 
experiments were performed. First the order of stimulation was reversed, freshly isolated 
monocytes were stimulated with LPS and 1 h thereafter the cells were exposed to hLF1-11 
and secondly LPS and hLF1-11 were added together to the cell culture. IL-10 production by 
these cells was measured as readout. Results showed equal IL-10 production by these cells 
as compared to LPS stimulation of monocytes pre-incubated with hLF1-11 (n = 7–8, data 
not shown). In addition, we studied the possibility that binding of hLF1-11 to LPS in the 
supernatant may contribute to the hLF1-11-induced cytokine increase. Therefore, 
monocytes were exposed to hLF1-11 and 60 min later unbound peptide was removed by 
harvesting the supernatant and washing the cells once with RPMI. Immediately thereafter 
monocytes were stimulated with LPS and IL-10 production was measured. Results 
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revealed that removal of unbound hLF1-11 from the monocyte cultures did not 
significantly affect the hLF1-11-induced increase in IL-10 levels (n = 7–8, data not shown). 
 
Effect of hLF1-11 on the kinetics of cytokine production To obtain some insight into the 
mechanisms underlying the effects of hLF1-11 on the cytokine production by LPS-activated 
monocytes, we investigated the effect of hLF1-11 on the kinetics of cytokines. Therefore, 
mRNA and protein levels of IL-10, IL-12p40 (both late-phase cytokines), and TNF-α (early-
phase cytokine) of hLF1-11 and control (peptide-exposed) monocytes were assessed at 
various time-intervals after LPS stimulation. The results revealed that hLF1-11-exposed 
monocytes displayed increased cytokine levels, but did not show different kinetics of the 
cytokine-production, i.e., the start of detectable cytokine production and their peak 
concentrations were seen at similar time points (Fig. 4). In addition, the results for mRNA-
expression of IL-10, IL-12p40 and TNF-α revealed that the peptide increased the quantity 
of gene expression of IL-10, IL- 12p40 and TNF-α, but did not affect the kinetics of mRNA 
production (Fig. 4). These results indicate that hLF1-11 enhances the LPS response but 
does not change its kinetics. 
 
Effect of hLF1-11 on the LPS-induced NF-κB activation and translocation in monocytes To 
investigate whether the enhanced cytokine production by hLF1-11 in human monocytes 
corresponded with an enhanced NF-κB activation, we determined the levels of NF-κB 
subunits in the nuclei and cytoplasm of hLF1-11 and control (peptide-exposed) monocytes 
at 30 and 60 min after LPS stimulation. The results revealed that hLF1-11-exposed 
monocytes displayed significantly enhanced activation and translocation of NF-κB p50, 
p52 and p65 at 60 min after LPS exposure (Fig. 5). Surprisingly, hLF1-11-exposed 
unstimulated monocytes displayed decreased NF-κB p65 translocation in monocytes as 
compared to control (peptide-exposed) monocytes. 
 
Fig. 4 Effects of hLF1-11 on the kinetics of cytokines by LPS-stimulated human monocytes Monocytes were 
exposed to hLF1-11 (dark gray boxes), control peptide (CP; light gray boxes) or no peptide (open boxes) for 1 h 
and then stimulated with 100 ng/ml LPS. At several intervals the supernatants were collected for determination 
of the IL-10 (A), IL-12p40 (B), and TNF-α (C) levels and total RNA was extracted from the monocytes in order to 
quantify mRNA expression of these cytokines. Cytokine levels are expressed in ng/ml (right hand panel) and gene 
expression as relative expression over control monocytes at 1 h (left hand panel). Data are medians and 
interquartile range within four different donors. *p  < 0.05 for the difference between hLF1-11-exposed and 
control (peptide-exposed) cells.► 
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Fig. 5 Effect of hLF1-11 on 
NF-κB translocation in 
human monocytes Freshly 
isolated monocytes were 
exposed to hLF1-11 (dark 
gray boxes), control 
peptide (CP; light gray 
boxes), control peptide 
(open boxes) for 1 h and 
then stimulated with LPS 
for 30 or 60 min. Then 
cytoplasmic (left) and 
nuclear (right) fractions of 
the monocytes were 
prepared and assessed for 
their NF-κB p50, p52, and 
p65 levels. Values have 
been corrected for 
background. Data are 
expressed as boxes and 
whiskers: boxes represent 
medians and second and 
third interquartiles, 
whiskers represent range 
of experiments within four different donors. *p < 0.05 for the difference between hLF1-11-exposed and control 
cells. 
 
Effect of hLF1-11 on cytokine production by human monocytes in response to various 
TLR-ligands To find out if the effects of hLF1-11 on human monocytes are specific for LPS 
or TLR4, monocytes were exposed to hLF1-11, control peptide or no peptide, followed by 
stimulation with either LTA, PAM2CSK4, lipomannan, purified LPS, DPLA, flagellin or CL087 
and 18 h thereafter IL-10 production was measured in the supernatants. Results showed 
that hLF1-11-induced enhancement of cytokine production was observed when the 
monocytes were stimulated with the TLR4-ligands LPS and DPLA, the TLR5-ligand flagellin 
and the TLR7-ligand CL087, but not with the TLR2 ligands LTA or PAM2CSK4. Since 
monocytes hardly produce cytokines in response to lipomannan these data were not 
included in the graph (Fig. 6A). Investigations into NF-κB activation and translocation in 
response to these TLR-ligands revealed that hLF1-11-exposed monocytes display 
significantly enhanced activation and translocation of NF-κB p65 after LPS, flagellin or 
CL087, but not after LTA stimulation (Fig. 6B).  
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Fig. 6 Effect of hLF1-11 on cytokine production and NF-κB translocation by human monocytes in response to 
different TLR-stimuli Freshly isolated monocytes were exposed to hLF1-11 (dark gray boxes), control peptide (CP; 
light gray boxes), or no peptide (open boxes) for 1 h and then stimulated with LTA, PAM2CSK4 (PAM), LPS, 
diphosphoryl lipidA (DPLA), flagellin (Flag), and CL087. About 18 h thereafter IL-10 levels in the cell supernatants  
were assessed. Values are fold increases of cytokine production compared to control (no peptide) (A). In 
addition, monocytes were exposed for 60 min to LPS, LTA, flagellin, CL087 or not, then cytoplasmic (left panel) 
and nuclear (right panel) fractions of the monocytes were prepared and assessed for NF-κB p65 levels (B). Values 
have been corrected for background. Data are expressed as boxes and whiskers: boxes represent medians and 
second and third interquartiles, whiskers represent range of experiments within 4–12 different donors. *P < 0.05 
for the difference between hLF1-11-exposed and control peptide-exposed cells 
 
Effect of hLF1-11 on cell-surface expression by human monocytes To further characterize 
the effects of hLF1-11 on human monocytes we assessed the expression of various cell-
surface receptors on human monocytes. Results showed that hLF1-11 significantly 
enhanced expression of CD11b, CD14, CD16, CD32, CD80, CD86, CD282 (TLR2), and CD284 
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(TLR4), but not CD64 and CD163 in response to LPS (Table 1). hLF1-11 had no effect on 
cell-surface receptor expression by unstimulated monocytes (Table 1). 
 
Table 1 Cell-surface receptor expression by hLF1-11-exposed human monocytes 
 
Results, expressed as fold increase compared to background fluorescence, are median and range of at least five 
experiments. Values are significantly different (**p < 0.01 and ***p < 0.001) from control and control peptide-
exposed monocytes. 
 
Discussion 
Earlier we reported that incubation of human monocytes with hLF1-11 directs GM-CSF-
driven differentiation toward a macrophage subset that displays enhanced cytokine and 
chemokine production and phagocytosis and clearance of C. albicans and S. aureus (8). 
These findings motivated us to investigate the effects of hLF1-11 on monocytes. From the 
results of this study we concluded that hLF1-11 primes monocytes for enhanced 
cytokine/chemokine production in response to TLR4, TLR5, TLR7, but not TLR2, ligands. 
This conclusion is based on the following findings. First, incubation of human monocytes 
with the hLF1-11 peptide dose dependently increased production of an array of cytokines 
and chemokines as well as the expression of various cell-surface receptors in response to 
LPS. In the absence of a stimulus hLF1-11 did not enhance the cytokine production or cell-
surface receptor expression on monocytes in fact; it even lowered the chemokine 
production by these cells. Apparently monocytes are altered by the peptide, but activation 
of the cell by a microbial stimulus is needed to reveal their increased potential. Since hLF1-
11-exposed cells started to produce cytokines at similar LPS levels as control cells, we 
concluded that hLF1-11-exposed monocytes respond with higher capacity, but not more 
sensitive, toward LPS than control monocytes. We cannot offer a definitive explanation for 
our observation that hLF1-11-exposed monocytes discriminate between on the one hand 
TLR4, TLR5, and TLR7-mediated responses and on the other hand TLR2-mediated 
No stimulus LPS (100 ng/ml) 
No hLF1 -11 CP No hLF1 -11 CP
CD11b CR3 92 (51 -115) 76 (47 -130) 86 (70 -137) 52 (32 -125) 87 (74 -126)** 55 (47 -108) 
CD163 Scavenger receptor 5 (3 -8) 5 (3 -9) 5 (3-9) 2 (2 -3) 2 (2-4) 2 (2 -4) 
CD64 FCγRI 4 (3 -6) 4 (3 -4) 4 (3-5) 3 (3 -4) 4 (3-5) 3 (2 -4) 
CD32 FCγRII 34 (13 -57) 31 (17 -53) 34 (17 -46) 53 (34 -84) 67 (37 -97)*** 52 (33 -90) 
CD16 FCγRIII 5 (3 -7) 8 (7 -9) 5 (4-7) 1 (1 -2) 2 (1-3)** 1 (1 -2) 
CD80 B7.1 1 (1 -2) 1 (1 -2) 1 (1-2) 8 (5 -14) 12 (9-23)** 8 (5 -14) 
CD86 B7.2 14 (9 -21) 16 (9 -22) 15 (10 -21) 12 (7 -19) 21 (14 -28)*** 12 (9 -20) 
CD282 TLR2 10 (7 -11) 10 (6 -11) 10 (7-12) 5 (4 -7) 8 (5-8)*** 5 (4 -7) 
CD284 TLR4 10 (6 -11) 9 (7 -11) 10 (7-11) 5 (5 -7) 8 (7-8)*** 6 (5 -7) 
CD14 LPS co-receptor 18 (10 -24) 19 (10 -26 18 (10 -28) 16 (11 -19) 19 (17 -27)** 17 (14 -18) 
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responses. Most likely hLF1-11 interacts with components of the signal transduction route 
that is shared by TLR4, TLR5, and TLR7, but not by TLR2. In agreement with this suggestion 
we found that activation and translocation of NF-κB subunits to the nucleus of monocytes 
upon TLR4, TLR5, and TLR7 stimulation, but not TLR2, stimulation, was enhanced in hLF1-
11-exposed monocytes as compared to control monocytes. Further research is needed to 
clarify these results. Secondly, hLF1-11 is also able to prime murine monocytes for 
enhanced cytokine/chemokine production; this is in agreement with the suggestion that 
the immunomodulatory properties of hLF1-11 contribute to its effects against infections 
(12). Third, priming of human and murine monocytes by hLF1-11 is sequence-specific as 
the control peptide, which lacks in vivo activity, did not affect the cytokine responses of 
monocytes to TLR-stimulation. Of note, the optimal concentration of hLF1-11 in this study 
(100 μg/ml) is similar to the peak concentration of hLF1-11 reached in the blood of mice 
injected with effective doses of hLF1-11 (12). However, it should also be realized that the 
concentration of the peptide at the site of infection is not known. Nevertheless, others 
reported that a dose of 5 mg of hLF1-11 had a favorable side-effect profile for human 
subjects (18) and though this is lower than we used, we have no reason to assume that a 
higher dose would necessarily lead to undue adverse effects. Moreover, the present 
concentration of hLF1-11 is similar to that of other cationic antimicrobial peptides used in 
in vitro and in vivo experiments, e.g. IDR-1/IDR-1002 (19,20). Several findings of this study 
pertain to a possible explanation for these effects of hLF1-11 on monocytes. Since the N-
terminus of lactoferrin is the major binding site for LPS, lipid A, and heparin (21) and 
complexes of lactoferrin with LPS have been found to activate macrophages through TLR4 
(22), we investigated the possibility that such complexes are responsible for the enhanced 
production of cytokines by monocytes. However, as washing steps in between hLF1-11 
and LPS and reversing the order of these factors did not affect the priming effect of hLF1-
11 on human monocytes, complexes between hLF1-11 and LPS are not likely to be 
responsible for the enhanced cytokine production. Although the mRNA levels for IL-12p40, 
IL-10 and TNF-α reflected an enhanced response of hLF1-11-exposed monocytes to LPS as 
compared to control (peptide-exposed) monocytes, the kinetics by which these cytokines 
are produced were not, indicating that the mRNA half-life for cytokines is similar in hLF1-
11-exposed monocytes and control monocytes. Together, no definitive explanation for the 
molecular basis of priming of monocytes by hLF1-11 can be offered. Therefore, our 
present studies focus on the interactions of hLF1-11 with its (intra-)cellular targets. Most 
studies on immunomodulatory effects by lactoferrin were performed using lactoferrin 
from bovine origin. Since bovine and human lactoferrin differ in the amino acid 
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composition of the N-terminus, comparison of our results with those from studies with 
bovine LF is not preferred. Some studies have investigated effects of hLF on cytokine and 
chemokine production by mononuclear leukocytes. Interestingly, Haversen et al. reported 
that hLF almost completely prevented the production of various cytokines, i.e., TNF-α, IL-
1β, IL-6, and IL-8, by THP-1 monocytic cells upon stimulation with LPS. In addition, mRNA 
levels of these cytokines were reduced by hLF as well as the LPS-induced binding of NF-κB 
to the TNF-α promoter (23). In agreement, Crouch et al. (24) had found that lactoferrin 
was able to inhibit cytokine production, like TNF-α and IL-1, by activated mononuclear 
cells in response to LPS. Comparison of these effects by hLF and our results found with 
hLF1-11 suggests that domains of human lactoferrin other than its N-terminal 11 amino 
acids also mediate immunomodulatory effects of lactoferrin on monocytes. Scott et al. 
(19) showed that the cationic host defense peptide IDR-1 significantly enhanced cytokine 
and chemokine production by human monocytes and translocation of the NF-κB p50 
subunit which shows similarities with results found with hLF1-11. In contrast, Mookherjee 
found the cathelicidin LL-37 to significantly inhibit the proinflammatory cytokine 
production by LPS-stimulated monocytes (25). In addition, in the monocytic cell line THP-
1, NF-κB activation by LL-37 was decreased. Together, this shows how different 
antimicrobial peptides can have diverse effects on human monocytes. In summary, we 
found that hLF1-11 primes monocytes so that upon encountering microbial stimuli the 
cells produce enhanced levels of proinflammatory and anti-inflammatory cytokines and 
chemokines. The proinflammatory cytokines and chemokines, such as IL-8, TNF-α, and 
RANTES, will recruit and activate other immune cells, resulting in enhanced clearance of 
the infection. The anti-inflammatory cytokines, such as IL-10 and IL-1RA, may contribute 
to the protection of the surrounding tissue against the spill-over of enzymes and radicals, 
thus counterbalancing the overstimulation of leukocytes by proinflammatory cytokines. 
Together, different antimicrobial peptides exert their effects on immune cells and their 
diverse actions should be taken into account when considering the clinical development of 
these peptides for therapeutic intervention in patients. 
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Abstract The human lactoferrin-derived peptide hLF1-11 displays antimicrobial activities in vitro and 
is effective against infections with antibiotic-resistant bacteria and fluconazole-resistant Candida 
albicans in animals. However, the mechanisms underlying these activities remain largely unclear. 
Since hLF1-11 is ineffective in vitro at physiological salt concentrations, we suggested modulation of 
the immune system as an additional mechanism of action of the peptide. We investigated whether 
hLF1-11 affects human monocyte-macrophage differentiation and determined the antimicrobial 
activities of the resulting macrophages. Monocytes were cultured for 7 days with GM-CSF in the 
presence of hLF1-11, control peptide, or saline for various intervals. At day 6, the cells were 
stimulated with lipopolysaccharide (LPS), lipoteichoic acid (LTA), or heat-killed C. albicans for 24 h. 
Thereafter, the levels of cytokines in the culture supernatants, the expression of pathogen 
recognition receptors, and the antimicrobial activities of these macrophages were determined. The 
results showed that a short exposure of monocytes to hLF1-11 during GM-CSF-driven differentiation 
is sufficient to direct differentiation of monocytes toward a macrophage subset characterized by 
both pro and anti-inflammatory cytokine production and increased responsiveness to microbial 
structures. Moreover, these macrophages are highly effective against C. albicans and Staphylococcus 
aureus. In conclusion, hLF1-11 directs GM-CSF-driven differentiation of monocytes toward 
macrophages with enhanced effector functions. 
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Introduction 
Antimicrobial proteins/peptides have attracted attention as candidates for the 
development of new agents to treat infections with drug-resistant pathogens, as their 
modes of action differ from those of current anti-infectives (1-4). In this connection, we 
reported that a peptide comprising the first 11 N-terminal residues of human lactoferrin 
(hLF1-11) is active in (neutropenic) mice with methicillin-resistant Staphylococcus aureus 
(MRSA) (5), multi-drug resistant Acinetobacter baumannii (6), and invasive fluconazole-
resistant Candida albicans infections (7). The peptide also displays antimicrobial activity 
against these pathogens in vitro (8,9,5), but only at sub physiological salt concentrations. 
The antimicrobial properties of hLF1-11 in vivo may therefore be explained by a 
modulatory effect of the peptide on the hosts’ immune cells. hLF1-11, which has a half-life 
in mice of approximately 9 min (10), is effective 24 h after intravenous (i.v.) injection, and 
considering that the actions of macrophages are crucial in the defense against these 
pathogens, we hypothesized that hLF1-11 modulates monocyte-macrophage 
differentiation. The mononuclear phagocyte system includes blood monocytes that have 
differentiated from committed myeloid progenitor cells. Monocytes circulate in the blood 
and, upon entering tissues, undergo further differentiation to become macrophages. The 
phenotype and functional activities of these macrophages are controlled by local factors, 
such as cytokines, chemokines, and growth factors (11-14). Most macrophages in the 
tissues are in an anti-inflammatory state. However, upon encountering pathogens, tissue 
damage, or other danger signals, granulocyte-macrophage colony-stimulating factor (GM-
CSF) is rapidly produced. This directs the differentiation of monocytes toward 
macrophages with a proinflammatory phenotype that produce large amounts of the 
proinflammatory cytokines interleukin 12p40 (IL-12p40) and tumor necrosis factor alpha 
(TNF-α) and small amounts of the anti-inflammatory cytokine IL-10 (12, 14). Monocytes 
and macrophages display distinct biological functions, enabling them to undertake crucial 
actions in the innate immune response when pathogen associated molecular patterns 
(PAMPs) are detected through pathogen recognition receptors, such as toll-like receptors 
(TLRs) and C-type lectin receptors (15, 16). These interactions lead to activation of the 
macrophage, which is associated with the production of cytokines, chemokines, and 
growth factors, attracting more immune cells to the site of infection, thereby regulating 
the immune response. In addition, macrophages clear an infection by binding, 
phagocytosis, and intracellular killing of pathogens. To further unravel the mechanisms of 
action of the hLF1-11 peptide, we investigated whether hLF1-11 modulates the 
differentiation of monocytes into macrophages and, if so, what are the functional 
C h a p t e r  3 | 51 
 
characteristics of these macrophages. We found that hLF1-11 directs GM-CSF-driven 
monocyte differentiation toward a macrophage subset that produces both pro and anti-
inflammatory cytokines, demonstrates enhanced recognition of pathogenic structures, 
and shows increased clearance of bacteria and fungi. 
 
Materials and methods 
Peptides and stimuli The human lactoferrin-derived peptide (hLF1-11; GRRRRSVQWCA) 
was obtained from Peptisyntha (Torrance, CA), and the control peptide (GAARRAVQWAA) 
lacking in vitro and in vivo antimicrobial activity (7) was obtained from Isogen (De Meern, 
The Netherlands). The purity of both peptides was >97% as determined by high-
performance liquid chromatography (HPLC). Stocks of the peptides were made in 
phosphate-buffered saline (PBS) (Department of Pharmacy, LUMC, Leiden, The 
Netherlands) and stored at -20°C. Endotoxin concentrations were below detection level. 
The following stimuli were used: lipopolysaccharide (LPS) from Escherichia coli (Sigma-
Aldrich, Zwijndrecht, The Netherlands), ultrapure lipoteichoic acid (LTA) from 
Staphylococcus aureus (Invivogen, San Diego, CA), and heat-killed (30 min at 100°C) 
Candida albicans (strain Y01-19; Pfizer Inc., Groton, CT).  
 
Mononuclear phagocyte cultures Peripheral blood mononuclear cells (PBMCs) were 
isolated from buffy coats of healthy donors using Ficoll-Hypaque density gradient 
centrifugation (ρ=1.077 g/ml). Monocytes were further purified by CD14-positive selection 
using magnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to 
the manufacturer’s protocol (>95% pure; viability, >96%). Macrophages were prepared by 
culturing monocytes with recombinant human GM-CSF (rhGM-CSF) according to the 
protocol of Verreck et al. (16). In short, monocytes were incubated for 7 days in RPMI 
1640 (Gibco Invitrogen, Breda, The Netherlands) containing 10% heat-inactivated fetal 
bovine serum (FBSi) (Greiner Bio-one), 2 mM penicillin, 2 mM streptomycin (both PAA 
GmbH, Pasching, Germany), 2 mM L-glutamine (Gibco Invitrogen), and 5 ng/ml rhGM-CSF 
(Biosource, Camarillo, CA), referred to below as culture medium. 
 
Experimental setup To investigate the effects of hLF1-11 on GM-CSF-driven monocyte-
macrophage differentiation, monocytes were incubated in culture medium with hLF1-11, 
control peptide, or saline. On day 6, the cells were stimulated with LPS (up to 100 ng/ml), 
LTA (up to 1 μg/ml), or heat-killed C. albicans (up to 1x10
7
 CFU/ml) for 20 h; thereafter, 
the supernatants were collected for assessment of the production of cytokines, i.e., IL-10, 
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IL-12p40, and TNF-α levels, using commercially available enzyme-linked immunosorbent 
assay (ELISA) cytosets (Biosource) and MCP-1 using a single-plex assay (Bio-Rad 
Laboratories, Hercules, CA) according to the manufacturers’ instructions. The surface 
molecule expression and antimicrobial activities of macrophages were determined on day 
7 without stimulation on day 6. Where indicated, monocytes were exposed to hLF1-11 for 
10 or 60 min, washed, reincubated in culture medium, and stimulated with LPS or not on 
day 6. hLF1-11 did not affect the viability of GM-CSF-incubated monocytes after 24 h, as 
determined by annexin V/propidium iodide (PI) staining. 
 
Flow cytometric analysis of cell surface molecule expression by macrophages 
Macrophages were collected and resuspended in cold PBS with 0.2% bovine serum 
albumin (BSA), washed twice, and incubated with the selected fluorescently labeled 
monoclonal antibodies for 30 min on ice in the dark. The following monoclonal antibodies 
were used: phycoerythrin (PE)-conjugated antibodies against CD11b and CD163 and 
fluorescein isothiocyanate (FITC)-labeled antibodies against CD14 and CD206 were 
obtained from BD Biosciences (Heidelberg, Germany). PE-conjugated antibody against 
Dectin-1 was obtained from R&D Systems. FITC-conjugated antibody against CD282, and 
CD284 were from HyCult (Uden, The Netherlands). Cell surface molecule expression was 
assessed by flow cytometry using a FACSCalibur and BD CellQuest software (BD  
Biosciences). 
 
Assays for the phagocytosis and clearance of C. albicans by macrophages Phagocytosis of 
C. albicans by macrophages was assessed by fluorescence activated cell sorter (FACS) 
analysis, as described for the phagocytosis of apoptotic cells by macrophages (17), with 
modifications. In short, overnight cultured C. albicans cells were washed twice in PBS and 
then labeled with 0.5 μM carboxy fluorescein succinimidyl ester (CFSE) (Invitrogen) for 30 
min at 37°C in the dark, centrifuged, and resuspended in RPMI 1640 supplemented with 
20% human serum (HuS). The macrophages were collected, washed twice in PBS/0.2% 
BSA, and labeled with PE-conjugated antibody against CD11b for 30 min (on ice in the 
dark). Next, the macrophages were mixed with C. albicans in a 1:1 ratio and incubated for 
various intervals at 37°C under slow rotation in the dark. The percentage of macrophages 
associated with C. albicans was assessed by determining the percentage of double-
positive (CD11b+ CFSE+) macrophages by two-color flow cytometry. Furthermore, 
experiments were performed at 4°C to quantify the binding of C. albicans to the 
macrophages. In addition, the percentage decrease in the number of free C. albicans cells 
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over 60 min, as determined by FACS, was taken as a measure of the capacity of the 
macrophages to clear C. albicans. 
 
Assays for the phagocytosis and killing of S. aureus by macrophages For phagocytosis of 
S. aureus, pHrodo-labeled S. aureus was obtained from Invitrogen and resuspended 
according to the manufacturer’s protocol. pHrodo is a dye that is nonfluorescent at 
neutral pH and bright red in acidic environments (e.g., phagolysosomes). In short, equal 
volumes of macrophages (1x10
5
) with 5-times-diluted pHrodo-labeled S. aureus stock 
were incubated for several intervals at 37°C or as a control at 4°C. Thereafter, the pHrodo 
fluorescence of the macrophages was assessed by FACS analysis. The percentage of 
pHrodo-positive macrophages and the median of the pHrodo fluorescence intensity of this 
population were obtained. In addition, equal numbers of S. aureus LUH2141 (LUMC, The 
Netherlands) and macrophages were incubated at 37°C under rotation. At several 
intervals, macrophages were lysed using ice-cold water with BSA (0.01%) and vortexed for 
30 s. Thereafter, the lysates were serially diluted and plated onto agar plates. The next 
day, the viable bacteria were counted, and the percentage of killed bacteria was 
determined.  
 
Statistics The Friedman nonparametric test, followed by Dunn’s multiple comparison post 
test and, where indicated, by the Wilcoxon signed-rank test, was used to determine the 
differences between the various groups. Data are expressed as median and range. Two-
sided p values are reported, and the level of significance was set at p < 0.05.  
 
Results 
hLF1-11 promotes the development of macrophages with an altered cytokine profile To 
find out if hLF1-11 modulates GM-CSF-driven macrophage  differentiation, we first 
assessed the cytokine production of macrophages differentiated in the absence or 
presence of hLF1-11 (referred to below as hLF1-11 macrophages) in response to LPS or 
heat-killed C. albicans using a multiplex cytokine assay (data not shown). Since the 
production of a variety of cytokines and chemokines by hLF1-11 macrophages was 
enhanced, we selected for convenience three cytokines to read out pro and anti-
inflammatory cytokine production. Our results showed that hLF1-11 macrophages 
produced significantly (p< 0.05) larger amounts of IL-10 (Fig. 1A), but not IL-12p40 (Fig. 1B) 
and TNF-α (Fig. 1C), in response to LPS than control macrophages and control peptide-
macrophages did. When stimulated with LTA, the production of both IL-10 (p< 0.05) and 
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IL-12p40 (p< 0.001), but not TNF-α was significantly upregulated by hLF1-11 macrophages 
compared to control macrophages (Fig. 1D to F). In addition, hLF1-11 macrophages 
produced larger amounts of IL-10 (p< 0.01) and TNF-α (p< 0.001) in response to heat-killed 
C. albicans than control macrophages did, while IL-12p40 (p< 0.05) was upregulated only 
at 10 μg/ml hLF1-11 (Fig. 1G to I). 
 
 
Fig. 1 Cytokine profiles of hLF1-11-exposed GM-CSF-driven macrophages in response to LPS, LTA, and heat-
killed C. albicans Monocytes were cultured with rhGM-CSF in the presence of hLF1-11 (1, 10, and 100 μg/ml) 
(light-gray bars), control peptide (CP; 100 μg/ml) (dark-gray bars), or saline (open bars) for 6 days. Thereafter, the 
cells were stimulated with 100 ng/ml LPS (A to C), 1 μg/ml LTA (D to F), or 1x10
7
 heat-killed C. albicans cells (G to 
I) for 20 h, and then the supernatants were collected and assessed for IL-10 (A, D, and G), IL-12p40 (B, E, and H), 
and TNF-α (C, F, and I) levels. The data are expressed as boxes and whiskers; the boxes represent medians and 
second and third interquartiles, and the whiskers represent the range within experiments with 8 or 9 different 
donors. *p<0.05; **p<0.01; ***p<0.001. 
 
hLF1-11 promotes the development of macrophages with enhanced recognition of 
various microbial stimuli To gain insight into the responsiveness of hLF1-11 macrophages 
to LPS, we measured the production of IL-10 in response to increasing concentrations of 
LPS. Our results revealed that 0.1 ng/ml of LPS was sufficient to significantly (p<0.01) en- 
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Fig. 2 Responsiveness of hLF1-11-incubated GM-
CSF-driven macrophages to LPS, LTA, or heat-killed 
C. albicans Monocytes were incubated with rhGM-
CSF and either with (gray bars) or without (open 
bars) hLF1-11 (100 μg/ml) and stimulated on day 6 
with various concentrations of LPS (A), ultrapure LTA 
(B), or heat-killed C. albicans (C). After 20 h, the 
supernatants were collected and assessed for the 
indicated cytokine. The lowest dose of the various 
stimuli that induced a significant response of hLF1-
11 macrophages was compared with the responses 
of the control macrophages at the same dose. NS, 
not significant. The data are expressed as boxes and 
whiskers; the boxes represent medians and second 
and third interquartiles, and the whiskers represent 
the range within experiments with 6 to 9 different 
donors. *p<0.05. 
 
hance IL-10 production by hLF1-11 
macrophages, but not by control 
macrophages (Fig. 2A). Interestingly, 
expression of CD14 and TLR4, which are 
involved in the recognition of LPS, was 
significantly (p< 0.05) upregulated by 
hLF1-11 macrophages compared to 
control (peptide)-macrophages (Fig. 3A 
and B). Next, we investigated the 
responsiveness of hLF1-11 and control 
macrophages to LTA. Since macrophages 
hardly produce cytokines in response to 
lower concentrations of LTA, we chose 
the chemokine monocyte chemotactic 
protein 1 (MCP-1), based on the multiplex results, as a readout. The results revealed that 
upon stimulation with 10 ng/ml LTA, hLF1-11 macrophages, but not control macrophages, 
produced significantly (p< 0.05) more MCP-1 than upon stimulation with 1 ng/ml (Fig. 2B). 
hLF1-11 macrophages and control macrophages did not differ in expression of TLR2 (Fig. 
3C). Additionally, we investigated the responsiveness of the macrophages to heat-killed C. 
albicans using TNF-α production as readout. The results showed that hLF1-11 
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macrophages, but not control macrophages, produced significantly (p< 0.05) more TNF-α 
when stimulated with 1x10
6
 heat-killed C. albicans cells (Fig. 2C).  Interestingly, receptors 
involved in C. albicans recognition, such as the C-type lectin receptor Dectin-1 and the 
complement receptor CD11b, but not the macrophage mannose receptor CD206, were 
significantly (p< 0.05) upregulated on hLF1-11 macrophages (Fig. 3D and F). Together, 
these data indicate that hLF1-11 promotes the development of macrophages with 
increased responsiveness to different microbial stimuli.  
 
 
 
Fig. 3 Comparison of surface molecule expression by hLF1-11 or control peptide-exposed GM-CSF-driven 
macrophages Monocytes were cultured in the presence of rhGM-CSF and hLF1-11 (100 μg/ml; dark gray boxes), 
control peptide (100 μg/ml; light gray boxes), or no peptide (saline; open boxes). On day 7, macrophages were 
harvested and the expression of CD14 (A), TLR4 (CD284) (B), TLR2  (CD282) (C), Dectin-1 (D), mannose receptor 
CD206 (E), and complement receptor 3 CD11b (F) by these cells was assessed using flow cytometry. The results 
are expressed as the median fluorescence intensity corrected for background fluorescence. The boxes represent 
medians and second and third interquartiles, and the whiskers represent the range within experiments with 8 or 
9 different donors. *p < 0.05; **p< 0.01. 
 
hLF1-11 promotes the development of macrophages that are highly effective against C. 
albicans and S. aureus Since hLF1-11 macrophages showed increased responsiveness to 
several pathogenic structures, we next determined whether the antimicrobial activities of 
hLF1-11 macrophages were also enhanced compared to control macrophages. Our results 
revealed that after 15 and 30 min, significantly (p< 0.05) more hLF1-11 macrophages than 
control macrophages had taken up C. albicans. At 60 min, no difference was observed in 
the percentages of hLF1-11 and control macrophages associated with C. albicans. 
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Experiments performed at 4°C revealed that less than 5% of the macrophages bound C. 
albicans at all intervals. Moreover, at 60 min, significantly (p< 0.05) fewer free C. albicans 
cells were present in samples containing hLF1-11 macrophages than in those containing 
control macrophages, indicating that hLF1-11 macrophages had cleared more C. albicans 
within 1 h than control macrophages (Table 1). In addition, we determined whether hLF1-
11 macrophages displayed enhanced antimicrobial activities against S. aureus compared 
to control macrophages. The results revealed that at 60 and 120 min of incubation, the 
percentage of S. aureus phagocytosing hLF1-11 macrophages was significantly (p< 0.05) 
higher than that of control macrophages (Table 1). However, fluorescence levels within 
hLF1-11 macrophages and control macrophages did not differ; indicating that the 
phagocytosis per macrophage was not enhanced (Table 1). When these experiments were 
performed at 4°C, no bacterial fluorescence could be detected in macrophages. Notably, 
after 60 min of incubation, hLF1-11 macrophages killed S. aureus significantly better than 
control macrophages; however, after 120 min, the cells were equally effective (Table 1). 
 
Table 1 Antimicrobial activities of hLF1-11-macrophages 
C. albicans S. aureus
Peptide % Phagocytosing macrophages % Cleared 
C. albicans
t = 60
% Phagocytosing 
macrophages Bacteria per cell (MFI)
# % Killing
t =15 t = 30 t = 60 t = 60 t = 120 t = 60 t = 120 t = 60 t = 120
None 13 (3-34) 38 (11-48) 53 (30-61) 52 (9-77) 35 (19–57) 63 (27–81) 123 (82–198) 218 (157–256) 9 (0–34) 27 (7–48)
hLF1-11 12 (14-34)** 41 (27-57)* 54 (45-66) 71 (49-82)* 49 (36–81)* 72 (56–91)* 138 (123–200) 231 (181–328) 21 (14–40)* 30 (6–51)
Control 13 (2-34) 28 (12-49) 47 (28-60) 56 (4–79) 30 (24–58) 66 (26–74) 138 (78–205) 250 (176–276) 9 (0–27) 17 (8–44)
 
 
Results are expressed as median (range) for at least five experiments. *p < 0.05 , **p< 0.01 is significantly 
different from control macrophages. 
#
 MFI, median fluorescence intensity. 
 
Time-dependent effect of the presence of hLF1-11 during macrophage differentiation 
Since our in vivo results suggested the possibility of a priming effect by hLF1-11 on 
mononuclear phagocytes (13), we investigated whether a short exposure of monocytes to 
the hLF1-11 peptide during differentiation could induce effects similar to those of the 
continuous presence of this peptide during culture. Our results showed that the presence 
of hLF1-11 for 60 min, but not 10 min, at the start of differentiation was sufficient to 
induce a significant (p< 0.05) increase in LPS-induced IL-10 production similar to cells that 
were exposed to hLF1-11 during the whole period of differentiation (Fig. 4A). In 
agreement with this, the presence of hLF1-11 for 60 min, but not 10 min during 
differentiation was sufficient to significantly (p< 0.05) enhance the phagocytosis of C. 
albicans by the resulting macrophages (Fig. 4B). These data indicate that a short exposure 
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of monocytes to hLF1-11 is sufficient to direct GM-CSF-driven differentiation of monocytes 
toward macrophages with an altered phenotype. 
 
Fig. 4 Effect of the presence of hLF1-11 on the GM-CSF-driven differentiation of monocytes into macrophages 
(A) Monocytes were cultured in the presence of rhGM-CSF. At the start of the culture, hLF1-11 was added (100 
μg/ml, filled bars) for 10 min or 60 min or for constant exposure for 7 days. Saline was used as a control (open 
bars). On day 6, the cells were stimulated with 100 ng/ml LPS, and 20 h thereafter, the supernatants were 
collected and assessed for IL-10 concentrations. The results are expressed as boxes and whiskers. The boxes 
represent medians and second and third interquartiles, and the whiskers represent the range of experiments 
with 7 different donors. *, p< 0.05; **, p< 0.01. (B) The potential for the macrophages co-incubated for various 
intervals with hLF1-11 to phagocytose C. albicans was assayed using flow cytometry. In short, cells were 
harvested on day 7, labeled with antiCD11b, and co-incubated with CFSE-labeled C. albicans for 15 min to 
determine the percentage of macrophages associated with C. albicans. The data are medians and second and 
third interquartiles, and the whiskers represent the range within experiments with 7 different donors. *, p< 0.05; 
**, p< 0.01. 
 
 
Discussion 
The main conclusion to be drawn from the present results is that hLF1-11 directs GM-CSF-
driven monocyte differentiation toward macrophages demonstrating enhanced effector 
functions. This conclusion is based on the following observations. First, hLF1-11 was able 
to modulate the production of a variety of cytokines and chemokines by macrophages in 
response to three different microbial stimuli. Interestingly, IL-10 production was 
significantly enhanced by hLF1-11 macrophages in response to all these stimuli; 
proinflammatory cytokine production was either enhanced or unchanged. This indicates a 
general enhancement of the inflammatory response by hLF1-11 rather than a shift toward 
an anti-inflammatory phenotype. No definitive conclusion can be drawn as to whether the 
additional IL-10 production is beneficial for the control of infection (18). In this 
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connection, Scott et al. (19) suggested that increased IL-10 levels (induced by the IDR-1 
peptide) could help control inflammation, while immune responses were enhanced. 
Second, hLF1-11 macrophages can detect lower concentrations of the microbial stimuli 
than control macrophages, suggesting that these cells respond to an infection more 
adequately than control cells. Third, the results of the phagocytosis and killing 
experiments showed that hLF1-11 directs GM-CSF-driven differentiation toward a subset 
of macrophages that are highly effective against C. albicans and S. aureus. The fourth main 
finding of this study is that the effects of hLF1-11 on monocyte-macrophage 
differentiation were already achieved by 60 min of exposure of the monocytes to the 
peptide at the start of a 7-day culture system. These actions may contribute to the anti-
infective effects of the peptide against infections in mice, as reported earlier (7). However, 
further investigations are required to discover if this mechanism could play a role in vivo. 
The optimal concentration of hLF1-11 in this study (100 μg/ml) is within the therapeutic 
range of hLF1-11 used in animals. A dose of 5 mg had a favorable side-effect profile (20) 
and though this is lower than what we used, we do have good reasons to suppose that the 
present dose does not lead to undue adverse effects. Moreover, the present 
concentration of hLF1-11 is similar to that of other cationic antimicrobial peptides in in 
vitro experiments (e.g., IDR-1 [19]). Unfortunately as our attempts to unravel the signal 
transduction in monocytes after incubation with hLF1-11 have not been successful, we 
cannot offer a mechanistic explanation for the ability of hLF1-11 to affect human 
monocyte-macrophage differentiation. Interestingly, the functional properties of hLF1-11 
macrophages show striking similarities to a set of responses of macrophages resulting 
from stimulation with foreign or nonself molecular patterns, characterized as the adaptive 
component of innate immunity as described by Bowdish et al. (11). This set includes 
upregulation of certain receptors on macrophages, resulting in a general enhancement of 
host immunity, such as the ability to clear bacteria and to produce cytokines. Our results 
indicate that the hLF1-11 peptide induces such properties during GM-CSF-driven 
differentiation of monocytes into macrophages, creating a subset with increased affinity 
for (a broader class of) pathogens, thereby possibly strengthening the innate immune 
response of the host to a subsequent infectious challenge. Furthermore, the present 
results are important for the further development of this peptide as a therapeutic agent 
for treatment of infections in patients with compromised immune systems.  
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Abstract The human cathelicidin LL-37 has broad-spectrum antimicrobial activity. It also participates 
at the interface of innate and adaptive immunity by chemoattracting immune effector cells, 
modulating the production of a variety of inflammatory mediators by different cell types, and 
regulating the differentiation of monocytes into dendritic cells. In this study, we investigated the 
effects of LL-37 on the differentiation of human monocytes into anti-inflammatory macrophages 
(Mφ-2; driven by M-CSF) versus proinflammatory macrophages (Mφ-1; driven by GM-CSF) as well as 
on fully differentiated Mφ-1 and Mφ-2. Results revealed that monocytes cultured with M-CSF in the 
presence of LL-37 resulted in macrophages displaying a proinflammatory signature, namely, low 
expression of CD163 and little IL-10 and profound IL-12p40 production on LPS stimulation. The 
effects of LL-37 on M-CSF-driven macrophage differentiation were dose- and time-dependent with 
maximal effects observed at 10 mg/ml when the peptide was present from the start of the cultures. 
The peptide enhanced the GM-CSF–driven macrophage differentiation. Exposure of fully 
differentiated Mφ-2 to LL-37 for 6 d resulted in macrophages that produced less IL-10 and more IL-
12p40 on LPS stimulation than control Mφ-2. In contrast, LL-37 had no effect on fully differentiated 
Mφ-1. Peptide mapping using a set of 16 overlapping 22-mer peptides covering the complete LL-37 
sequence revealed that the C-terminal portion of LL-37 is responsible for directing macrophage 
differentiation. Our results furthermore indicate that the effects of LL-37 on macrophage 
differentiation required internalization of the peptide. Together, we conclude that LL-37 directs 
macrophage differentiation toward macrophages with a proinflammatory signature. 
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Introduction  
Macrophages (and dendritic cells [DCs]) in tissues continuously monitor their 
microenvironment for invading pathogens and other danger signals. On pathogen 
encounter, they trigger the migration of neutrophils and monocytes into the affected site 
and regulate an adequate innate immune response. In this regulatory process, 
macrophages may serve a dual purpose. Initially, they contribute to the elimination of 
pathogens and the elicitation of an inflammatory reaction. When the infection recedes 
due to removal of pathogens and cell debris, however, their function may shift toward 
resolution of inflammation and tissue repair (1). Macrophages can thus exhibit pro and 
anti-inflammatory properties to a degree that is determined by stimuli from their local 
microenvironment, such as pathogens, inflammatory mediators as well as other factors. In 
line with this notion, two clearly distinct types of human macrophages, designated as Mφ-
1, namely, macrophages with a proinflammatory signature, and Mφ-2, which are 
macrophages having an anti-inflammatory/proangiogenic signature, have been derived 
from cultured human blood monocytes by incubation with GM-CSF and M-CSF, 
respectively (2). Mφ-1s are fried egg-shaped macrophages that profoundly produce IL-
12p40 and little IL-10 on stimulation by LPS and support Th cell type 1 (Th1) responses. 
Mφ-2 display a stretched, spindle-like morphology and are characterized by the marked 
production of IL-10 and little IL-12p40 on LPS stimulation (2), poor Ag-presenting 
capacities, and promotion of T regulatory cell responses (3). A hallmark of Mφ-2 is the cell-
surface expression of CD163, the scavenger receptor involved in the clearance of free 
hemoglobin from the circulation (4) and supposedly functionally associated with anti-
inflammatory processes (5). Cationic antimicrobial peptides, such as cathelicidins (6), play 
important roles in the defense against infections by eliminating a wide range of pathogens 
(7, 8). hCAP-18/LL-37 is the only cathelicidin identified in humans and it is produced by 
neutrophils, monocytes, mast cells, and epithelial cells. It is stored in these cells as a 
propeptide, which can be cleaved extracellular by enzymes like proteinase 3, resulting in 
the formation of LL-37 and a cathelin part. LL-37 is an amphipathic α-helical peptide that 
can affect both planktonic bacteria and those residing in biofilms (9, 10), viruses such as 
HIV (11) and fungi (12), and it can neutralize LPS and lipoteichoic acid (LTA) (13). In 
addition to its antimicrobial actions, LL-37 participates at the interface of innate and 
adaptive immunity by modulating cytokine and chemokine production by a range of cell 
types, chemoattracting various immune effector cells (14) and mesenchymal stem cells 
(15), regulating autophagy in conjunction with vitamin D (16), and stimulating 
angiogenesis and wound healing (17). Others reported that LL-37 enhances the GM-
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CSF/IL-4–driven differentiation of blood monocytes to immature DCs (18), whereas 
inhibiting the maturation of immature DCs by TLR ligands (19). Furthermore, this peptide 
enhances the responses of monocytes (and macrophages) to GM-CSF and IL-1β (20, 21), 
but suppresses those to IFN-γ (22), indicating that LL-37 affects the responses of 
mononuclear phagocytes to cytokines differentially. All effects of LL-37 on human cells 
may be mediated through specific cell-surface receptors (14, 23–26) or intracellular 
receptors (27). The effects of LL-37 on macrophage differentiation are not known. As LL-37 
can be abundantly present at sites of inflammation/infection (28–30) and monocyte–
macrophage differentiation depends on factors from the local microenvironment, in this 
study, we investigated the effects of LL-37 on the differentiation of monocytes to pro and 
anti-inflammatory macrophages.  
 
Materials and Methods 
LL-37 and derived peptides Human LL-37, control scrambled peptide (LG-37), as well as 
the set of 16 overlapping 22mer peptides covering the complete amino acid sequence of 
LL-37 were prepared by solid phase synthesis on an automated peptide synthesizer (SyroII, 
Multisyntech, Witten, Germany) as described (31). The sequences of the various peptides 
are summarized in Table I. The purity of the various peptides was at least 87%, as 
determined by reverse-phase high performance chromatography, and their molecular 
mass was confirmed by Maldi-Tof mass spectrometry. Stocks (50 mg/ml) of the peptides 
prepared in DMSO were kept at -80°C until use. 
 
Isolation of human monocytes PBMCs from healthy donors were isolated from buffy 
coats (Sanquin Blood Bank, Leiden, The Netherlands) by Ficoll Amidotrizoate (ρ = 1.077 
g/ml; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 
Leiden, The Netherlands) density centrifugation at 700 x g for 20 min. Cells in the 
interphase were washed three times with PBS (pH 7.4), and monocytes were isolated 
using antiCD14–coated MACS microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) 
according to manufacturer’s instructions. Next, monocytes (puritiy >96%, viability >98% as 
determined by annexin V and PI staining 2 h after isolation) were centrifuged and 
resuspended in RPMI 1640 supplemented with 2 mM glutamine, 2 mM penicillin and 
streptomycin, and 10% (weight/volume) heat-inactivated FCS (all from Life Technologies, 
Invitrogen, Breda, The Netherlands), further referred to as standard medium.  
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Macrophages Mφ-1 were obtained by culturing 1 x 10
6
 monocytes/ml in 75 cm
2
 Cell-Star 
tissue culture flask (Greiner Bio-One, Frickenhausen, Germany) or 1 x 10
6
/ml in 12-well 
tissue culture plates (Costar, Corning B.V. Life Sciences, Schiphol-Rijk, The Netherlands) in 
standard medium containing 10 ng/ml rhGM-CSF (Invitrogen, Carlsbad, CA) for 6 d in a 5% 
CO2 incubator at 37°C. To generate Mφ-2, 50 ng/ml rhM-CSF (R&D Systems, Abingdon, 
U.K.) was added to standard medium instead of rhGM-CSF (2). At day 3 of culture and at 
day 6, Mφ-1 and Mφ-2 were either harvested with trypsin/EDTA and used in the 
experiments or washed and stimulated with LPS from Escherichia coli (1–100 ng/ml; 
Sigma-Aldrich, St. Louis, MO), a sonicate of Mycobacterium tuberculosis [lysate of heat-
inactivated M. tuberculosis H37Rv; 5 μg/ml, (32)], LTA (1 μg/ml; Invivogen, San Diego, CA), 
zymosan A from Saccharomyces cerevisiae (ZymA; 10 μg/ml; Sigma-Aldrich), or PAM3CSK4 
(PAM3; 100 ng/ml; Invitrogen) for an additional 24 h and then harvested. Where indicated 
the modulating effect of LL-37(-derived peptides) and the scrambled peptide LG-37 on 
macrophage differentiation was studied by addition of the peptides to the culture medium 
at various intervals during the cell culture. 
 
Measurement of cell-surface molecule expression by macrophages To verify the 
differentiation of monocytes into Mφ-1 or Mφ-2, the expression of various cell-surface 
markers by macrophages was assessed using PE-conjugated mAbs directed against CD163 
(BD BioSciences, Heidelberg, Germany) and FITC- or PE-conjugated mAbs directed against 
CD1a, CD14, CD80, and CD86 (BD Pharmingen). Cultured macrophages were incubated 
with these mAbs diluted in PBS containing 0.2% (w/v) BSA for 30 min on ice. Samples were 
measured on a FACSCalibur (Becton and Dickinson, La Jolla, CA) and analyzed with 
CellQuest Pro 4.0.2 software. 
 
Measurement of cytokine production by macrophages IL-10 and IL-12p40 levels in the 
supernatants of the cell cultures were assessed using CytoSets ELISA kits (Invitrogen) 
according to manufacturer’s instructions. The lower limits of detection in these ELISA were 
5 pg/ml.  
 
Detection of cell viability Monocytes were cultured in standard medium supplemented 
with rh(G)M-CSF and 50 μg/ml LL-37 or LG-37, equimolar concentrations of LL-37-derived 
peptides, or vehicle (diluted DMSO) for 24 h and then harvested. Thereafter, the cells 
were stained with 1 μg/ml FITC-annexinV (Sigma-Aldrich) and 1 μg/ml propidium iodide 
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(PI; Sigma-Aldrich) in 10 mM HEPES (pH 7.4) and the mean fluorescence intensity (MFI) 
determined on the FACSCalibur. Results are the percentage of PI-negative monocytes.  
 
Involvement of cell-surface receptors in the effects of LL-37 on macrophage 
differentiation Inhibitors/activators of the G-protein–coupled fMLP receptor FMLR-1, the 
epidermal growth factor receptor (EGFR), and the ATP-gated purinergic receptor P2X7 
were used to determine whether one of these three cell-surface receptors mediated the 
effects of LL-37 on M-CSF-driven macrophage differentiation. For this purpose, the FPRL-1 
agonist WKYMV(DMet)-NH2 (10 μM; Phoenix Pharmaceuticals, Belmont, CA) and the 
FPRL-1 antagonist WRWWWW-NH2 (10 μM; Phoenix Pharmaceuticals) were used. The 
possible involvement of Gi-proteins in the modulation of M-CSF–driven macrophage 
differentiation by LL-37 was determined in mononuclear phagocytes preincubated with 1–
10 μg/ml pertussis toxin from Bordetella pertussis (Sigma-Aldrich) for 30 min at 37°C. The 
EGFR tyrosine kinase-inhibitor AG1478 [4-(3-chloroanilino)-6,7-dimethomethyl-
benzylamine; Merck Biosciences, Nottingham, U.K.] at a concentration of 1 μM and the 
nonselective P2X7-antagonist suramin (naphthalene sulfonic acid derivate; Sigma-Aldrich) 
at a concentration of 30 μM were used to investigate whether EGFR or the P2X7 on 
monocytes mediates the modulatory effects of LL-37 on the M-CSF–driven macrophage 
differentiation.  
 
Involvement of intracellular uptake of LL-37 in its effects on macrophage differentiation 
To investigate whether LL-37 needs to be taken up by monocytes for its effects on the M-
CSF–driven macrophage differentiation, monocytes were preincubated for 30 min with 5 
μg/ml cytochalasin-D (Sigma-Aldrich, stock 5 mg/ml DMSO). Next, the cells were washed 
to remove unbound cytochalasin-D and thereafter the cells were incubated for 6–7 d in 
M-CSF–containing medium supplemented with 10 μg/ml LL-37 or not.  
 
Statistical analysis Statistical analyses were performed by Wilcoxon’s matched pairs test 
or Friedman repeated measures test, as appropriate, to determine the difference between 
groups using GraphPad Prism 4.0 (San Diego, CA) software. Differences were considered 
significant when p < 0.05.  
 
Results 
Effects of LL-37 on the differentiation of monocytes to Mφ-1 and Mφ-2 To determine the 
effects of LL-37 on the differentiation of monocytes to Mφ-2 or Mφ-1, we incubated 
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monocytes for 6 d with M-CSF 
or GM-CSF in the presence of 
either LL-37, the scrambled 
peptide LG-37 (Table I), or no 
peptide. Thereafter, we 
studied the morphology and 
quantified the expression of 
the cell-surface molecules 
CD163 and CD14 as well as 
the LPS-stimulated production 
of IL-10 and IL-12p40 by the 
resulting macrophages. Light 
microscopy revealed Mφ-2 to 
display an elongated, spindle-
like morphology, whereas the presence of LL-37, but not LG-37, during differentiation by 
M-CSF led to fried egg-shaped macrophages, which is the typical morphology of Mφ-1 (Fig. 
1A). In line with this, the presence of LL-37 during M-CSF–driven macrophage 
differentiation led to macrophages expressing significantly less CD163 and CD14 than 
control macrophages did (Fig. 1B). Furthermore, macrophages differentiated by M-CSF in 
the presence of LL-37 produced significantly less IL-10 and more IL-12p40 on LPS 
stimulation than macrophages differentiated by M-CSF in the presence of LG-37 (results 
not shown) or no peptide (Fig. 2A); without LPS stimulation no effect of LL-37 on the 
production of these cytokines was seen (Table II). These effects were already observed 
with 5 μg/ml LL-37 and maximal at ≥10 mg/ml LL-37 (Figs. 1A, 1B, 2A). The most profound 
effects of LL-37 on the cytokine profile of the resulting macrophages were observed when 
the peptide was present from the start of the monocyte cultures with M-CSF; addition of 
LL-37 at later intervals during the 6 d culture of monocytes with M-CSF resulted in 
macrophages displaying a less distinct proinflammatory cytokine profile (Fig. 2B). Of note, 
inwell crystal violet staining indicated comparable numbers of macrophages in the 
different wells within experiments (results not shown).  
 
Cytokine production by LL-37–differentiated macrophages in response to various 
bacterial stimuli To determine whether the modulatory effect of LL-37 on the M-CSF–
driven macrophage differentiation with respect to the cytokine profile was restricted to 
LPS/TLR4, we used other bacterial stimuli, such as M. tuberculosis, LTA, PAM3, and ZymA.  
Peptide NH2 Sequence COOH                                                    
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
LG-37 LGFRSEIKFRVRKFRLPTSLDFKKKGEKIQIDLNVRE
1 LLGDFFRKSKEKIGKEFKRIVQ
2 LGDFFRKSKEKIGKEFKRIVQR
3 GDFFRKSKEKIGKEFKRIVQRI
4 DFFRKSKEKIGKEFKRIVQRIK
5 FFRKSKEKIGKEFKRIVQRIKD
6 FRKSKEKIGKEFKRIVQRIKDF
7 RKSKEKIGKEFKRIVQRIKDFL
8 KSKEKIGKEFKRIVQRIKDFLR
9 SKEKIGKEFKRIVQRIKDFLRN
10 KEKIGKEFKRIVQRIKDFLRNL
11 EKIGKEFKRIVQRIKDFLRNLV
12 KIGKEFKRIVQRIKDFLRNLVP
13 IGKEFKRIVQRIKDFLRNLVPR
14 GKEFKRIVQRIKDFLRNLVPRT
15 KEFKRIVQRIKDFLRNLVPRTE
16 EFKRIVQRIKDFLRNLVPRTES
Table 1 LL-37 derived synthetic peptides used in the study 
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Fig. 1 Effects of LL-37 on the M-CSF–driven and GM-CSF–driven monocyte–macrophage differentiation 
regarding morphology and cell-surface molecule expression Monocytes were cultured for 6 d in medium 
containing GM-CSF (to generate Mφ-1) or M-CSF (to generate Mφ-2) in the presence of LL-37, the scrambled 
peptide (LG-37), or no peptide (none), and then either subjected to microscopic analysis of the morphology or 
harvested for assessment of CD163 and CD14 expression. Representative phase contrast microscopic images 
revealing the effects of LL-37 on the morphology of the resulting macrophages after 6 d of culture (A). 
Magnification 310 (upper half of image) and 320 (bottom half of image). FACS profiles of a representative 
experiment (of five individual experiments) demonstrating the LL-37-induced changes in membrane expression 
of CD163 and CD14 by macrophages at day 6 of the culture of monocytes with M-CSF (B). The vertical dotted 
lines represent the MFI. Boxed numbers represent the MFI (expressed in arbitrary units) of the analyzed cells. 
Mean background fluorescence of cells incubated with an isotype-matched control mAb ranged from two to four 
arbitrary units. 
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The results revealed that exposure of macrophages differentiated by M-CSF in the 
presence of LL-37 to these stimuli resulted in macrophages displaying significantly 
decreased IL-10 production (M. tuberculosis lysate and LPS [i.e., stimuli signaling through 
TLR4 and TLR2] but not the stimuli signaling through TLR2, TLR2/1, and TLR2/6) and more 
IL-12p40 production than macrophages differentiated by M-CSF alone (Table II). 
Interestingly, LL-37 did not influence the GM-CSF–driven macrophage differentiation as 
judged by cell morphology (Fig. 1A) and expression of CD163 and CD14 (results not shown) 
by the resulting macrophages. However, these LL-37–exposed macrophages produced 
significantly less IL-10, and more IL-12p40, on stimulation with the various stimuli than 
control macrophages did (Fig. 2A, Table II). 
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◄Fig. 2 Effects of LL-37 on the M-CSF–driven and GM-CSF–driven monocyte–macrophage differentiation 
regarding LPS-stimulated IL-10 and IL-12p40 production Monocytes were cultured for 6 d in medium containing 
M-CSF (to generate Mφ-2) or GM-CSF (to generate Mφ-1) in the presence of LL-37 (gray boxes) or no peptide 
(white boxes). At day 6, these cultures were stimulated for 24 h with 100 ng/ml LPS and the levels for IL-10 and 
IL-12p40 in the culture supernatants were measured by ELISA (A). Box plots display the median, the second and 
third interquartiles, and the lowest and highest cytokine concentrations. n = 5 independent experiments. *p <  
0.05. Monocytes were cultured for 6 d with M-CSF together—for the indicated intervals—with LL-37. At day 6, 
macrophages were washed and then stimulated with LPS for 24 h. Thereafter, levels of IL-10 and IL-12p40 in the 
culture supernatants were measured by ELISA (B). Box plots display the median, the second and third 
interquartile, and the lowest and highest cytokine concentrations. n = 5 independent experiments. *p < 0.05. 
 
Table 2 Cytokine production by GM-CSF– and M-CSF–differentiated macrophages in response to different 
microbial stimuli 
 
  Cytokine production (pg/ml) by M-CSF  Cytokine production (pg/ml) by GM-CSF 
  -differentiated macrophages   -differentiated macrophages 
      
 
Peptide  Stimulus n           IL-10               IL-12p40          IL-10            IL-12p40 
 
None  None  11        0 (0-61)          5 (0-14)        0 (0-2)         3 (0-21) 
LL-37  None  11        3 (0-47)          4 (0-109)        0 (0-7)         0 (0-22) 
 
None  M. tuberculosis  7 1254 (492-5403)      41 (0-570)   293 (19-2609)   4950 (2409-13835)  
LL-37  M. tuberculosis  7  397* (291-560)     690* (144-1679) 117* (0-699)   5760 (99-18449) 
  
None  LTA   5   478 (297-504)        36 (0-41)      79 (31-126)   1856 (486-4561) 
LL-37  LTA   5 186* (76-533)    633* (476-886)      0* (0-38)   1649 (445-5194) 
 
None  PAM3   5   153 (15-271)         130 (0-294)      66 (14-226)   1960 (1102-2563) 
LL-37  PAM3   5   142 (57-366)  1185* (299-3449)      8* (0-38)   1620 (1095-2256) 
 
None  ZymA    7   102 (0-1409)        12 (0-334)      32 (0-832)     610 (19-4139) 
LL-37  ZymA    7   104 (0-321)        36 (0-113)      4* (0-237)    307* (6-4835)    
   
None  LPS  11 1848 (450-3839)      67 (0-542)    282 (0-587)   4740 (1489-10801) 
LL-37  LPS  11  561* (74-2969)  2133* (669-9228)    29* (0-156)   4878 (1478-19384) 
 
 
 
Monocytes were cultured for 6 d in medium containing M-CSF or GM-CSF in the presence of 10 μg/ml LL-37 or no 
peptide (none). At day 6, the cells were incubated with medium supplemented with 5 μg/ml M. tuberculosis 
lysate, 1 μg/ml LTA, 100 ng/ml PAM3, 10 μg/ml ZymA, 100 ng/ml LPS, or no stimulus (none) for 24 h. The 
concentrations of the indicated cytokines in the supernatants were quantified by ELISA. Values are medians and 
range. n = number of different donors. *p <  0.05, compared with similar macrophages not incubated with LL-37 
but exposed to the same stimulus. 
 
LL-37 modulates fully differentiated Mφ-2 To investigate the ability of LL-37 to redirect 
fully differentiated macrophages we added this peptide (10 μg/ml) or scrambled peptide 
LG-37 to fully differentiated Mφ-2 and Mφ-1 and maintained the cells for an additional 6 d 
in culture medium. At the end of this second culture period, macrophages were washed 
and then stimulated for 24 h with LPS. Results revealed that culturing of fully 
differentiated Mφ-2 with LL-37 for 6 d resulted in macrophages that produced significantly 
less IL-10 and more IL-12p40 on LPS stimulation than Mφ-2 cultured with scrambled 
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peptide or no peptide (Fig. 3). In contrast, culturing of fully differentiated Mφ-1 with LL-37 
did not affect IL-10 and IL-12p40 production by the resulting macrophages in response to 
LPS (Fig. 3). 
 
 
Fig. 3 Effects of LL-37 on fully differentiated macrophages Fully differentiated Mφ-2 and Mφ-1 were cultured for 
an additional 6 d in medium supplemented with LL-37 (10 μg/ml; gray boxes), LG-37 (10 μg/ml; hatched boxes), 
or no peptide (white boxes) and then stimulated with LPS (100 ng/ml) for 24 h. Thereafter, the levels of the 
indicated cytokines in the culture supernatants were assessed by ELISA. Box plots display the median, the second 
and third interquartile, and the lowest and highest cytokine concentrations. n = 7–8 independent experiments. 
*p < 0.05. 
 
Effects of LL-37–derived peptides on the M-CSF–driven macrophage differentiation To 
determine which domain of LL-37 is responsible for the effects on M-CSF–driven 
macrophage differentiation, we analyzed the effects of a set of 16 overlapping peptides 
covering the entire amino acid sequence of LL-37 (~6 μg/ml; equimolar concentration to 
10 μg/ml LL-37) on the morphological and immunological (CD163/CD14 expression and 
LPS-stimulated IL-12p40 production) characteristics of the resulting macrophages. Light 
microscopy revealed macrophages differentiated under the influence of M-CSF in the 
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presence of the C-terminal peptides 10–16, but not the other peptides, to display the 
typical morphology of Mφ-1 (results not shown). In agreement, the presence of the C-
terminal peptides 10–16, but not the other peptides, during incubation of monocytes with 
M-CSF led to low/undetectable expression levels of CD163 (Fig. 4A). In line with this 
observation, macrophages differentiated in the presence of these peptides produced 
significantly more IL-12p40 on LPS than Mφ-2 did (Fig. 4B). Analyses of the dose-effect 
relations for these C-terminal peptides indicated that peptides 11 and 12 were the most 
effective peptides in modulating M-CSF–driven macrophage differentiation (results not 
shown).  
Fig. 4 Effects of LL-37-derived peptides on the M-CSF–driven macrophage differentiation. Monocytes were 
cultured for 6 d in medium containing M-CSF in the presence of LL-37–derived peptides (peptides 1–16; 6.25  
μg/ml; gray boxes) or as controls LL-37 (10 μg/ml; gray boxes), LG-37 (10 μg/ml; hatched boxes), or no peptide 
(none; white boxes). At day 6, the macrophages were harvested and either incubated with a fluorescently 
labeled mAb against CD163 and FACS for assessment of the expression of this cell-surface marker (A) or 
reincubated for an additional 24 h in medium supplemented with LPS (100 ng/ml) for assessment of the IL-12p40 
production by these cells (B). Box plots display the median, the second and third interquartile, and the lowest 
and highest CD163 or IL-12p40 values. n = 6–7 independent experiments, except peptides 3–5 where n = 3 
independent experiments. *p < 0.05. 
 
Involvement of receptors for LL-37 in its modulatory effects on the M-CSF–driven 
macrophage differentiation Next, we determined the effects of selected activators and/or 
inhibitors of known cell-surface receptors of LL-37 on its effects on the M-CSF–driven 
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macrophage differentiation using CD163 expression and IL-12p40 production as read-outs. 
Our results revealed that the FPRL1 agonist WKYMV(D-Met)-NH2 did not mimic LL-37 in 
modulating the M-CSF–driven macrophage differentiation nor did preincubation of the 
monocytes with the FPRL1- antagonist WRWWWW-NH2 affect the activities of LL-37 on 
macrophage differentiation (results not shown). In addition, preincubation of monocytes 
with pertussis toxin also did not affect the LL-37 activity. Furthermore, the nonselective 
P2X7-antagonist suramin as well as the EGFR tyrosin kinase inhibitor AG1478 failed to 
suppress the effects of LL-37 on M-CSF–driven macrophage differentiation (results not 
shown). In contrast, the LL-37–induced morphological changes (results not shown), 
decreased CD163/CD14 expression and increased IL-12p40 production by LPS-stimulated, 
M-CSF–differentiated macrophages were completely abolished by a 30 min preincubation 
of the monocytes with the endocytosis-inhibitor cytochalasin-D (Fig. 5). 
 
Fig. 5 Effect of preincubation of the monocytes 
with cytochalasin-D on the modulation of the M-
CSF–driven macrophage differentiation by LL-37 
Monocytes were preincubated with cytochalasin- D 
for 30 min or left untreated, then washed and 
incubated in medium containing M-CSF and LL-37 
(or as control no peptide) for 6 d. Thereafter, the 
macrophages were harvested and exposed to 
fluorescently labeled mAbs against CD163 and CD14 
and assessed by FACS the expression of these cell 
surface markers (A). Overlays show the expression 
of CD163 and CD14 by cytochalasin-D–preincubated 
and control macrophages that were cultured in the 
presence of LL-37 (dotted lines) or not (solid lines). 
Boxed numbers represent the MFI (expressed in 
arbitrary units) of the cells. The vertical dotted lines 
represent the MFI. Data are from a representative 
experiment of five independent experiments. LPS-
stimulated IL-12p40 production by macrophages 
resulting from a 6 d culture of cytochalasin-D– 
preincubated and control monocytes in medium 
with M-CSF and LL-37 (gray boxes) or not (white 
boxes) (B). Box plots display the median, the second 
and third interquartile, and the lowest and highest 
IL-12p40 concentrations. n=7 independent 
experiments. *p < 0.05. 
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LL-37 does not affect monocyte viability Monocytes were cultured in medium containing 
M-CSF supplemented with LL-37 (or LG-37 or no peptide) for 24 h and thereafter stained 
with annexin V-FITC and PI. Subsequent FACS analysis revealed that the viability of 
monocytes amounted to 61 ± 3% (n = 3) and that of monocytes treated with LL-37 to 72 ± 
4% (n = 3) and monocytes exposed to LG-37 to 65 ± 4% (n = 3), indicating that LL-37 at the 
present concentrations is not toxic for monocytes. In addition, no effect of LL-37 on the 
viability of monocytes exposed to 10 ng GM-CSF/ml and 50 ng M-CSF/ml was observed 
(results not shown).  
 
Discussion 
The main conclusion from the current study is that LL-37 directs M-CSF–driven monocyte–
macrophage differentiation toward macrophages with a proinflammatory signature and 
redirects fully differentiated Mφ-2. In agreement with reports by others that LL-37 can 
enhance the effects of GM-CSF (18, 21), we found LL-37 to enforce the GM-CSF–driven 
macrophage differentiation. Our conclusion is based on the following findings. First, 
addition of LL-37 to 6 d cultures of monocytes with M-CSF resulted in macrophages with a 
proinflammatory instead of an anti-inflammatory signature. Our observation that LL-37 
added at the start of the monocyte cultures is more effective than when added on the 
second or subsequent days may indicate that LL-37 either affects monocytes more 
effectively than macrophages or it exerts its modulatory effects only when continuously 
present. The actions of LL-37 on macrophage differentiation regarding the cytokine profile 
were independent of the stimulus used for inducing cytokine production. This was found 
for all stimuli used, except ZymA and PAM3, which may be explained by the poor response 
of the macrophages to these two stimuli using IL-10 and IL-12p40 as read-outs. 
Furthermore, it should be noted that the effects of LL-37 on M-CSF–driven macrophage 
differentiation (and fully differentiated Mφ-2) are sequence-specific as the scrambled 
peptide LG-37 was without effect. Secondly, culturing of fully differentiated Mφ-2 for 6 d 
with LL-37 resulted in macrophages producing more IL-12p40 and less IL-10 on LPS 
stimulation than control Mφ-2 did. In agreement, LL-37 promoted the development of 
macrophages with a fried egg-shaped appearance from fully differentiated Mφ-2, 
although the peptide did not affect the CD163 expression by these macrophages. It should 
be realized that the doses of LL-37 used in our study (1–20 μg/ml) are within the 
physiological range, namely, levels of LL-37 at sites of infection, such as tracheal aspirates 
of newborn infants, with an airway infection [LL-37 levels ranging between 5 and 15 
μg/ml; (28)] and psoriasis skin lesions [up to 1.5 mg of LL-37/ml; (29)]. The second 
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conclusion to be drawn from our findings is that the C-terminal part of LL-37 harbors its 
ability to modulate M-CSF–driven macrophage differentiation, because of all tested LL-37–
derived peptides only those comprising the C-terminal part were effective. Dose response 
experiments revealed that the peptides covering residues 11–32 and 12–33 were the most 
effective in modulating macrophage differentiation. Secondary structure prediction (33) 
indicated that these peptides comprise the optimal amphipathic helix among the present 
LL-37–derived peptides examined in this study. Preliminary experiments revealed that 
these C-terminal peptides are more effective than LL-37 in killing of Staphylococcus aureus 
as detected by radial diffusion assays (T. Vos, A. van der Does, B. Ravensbergen, H. 
Beekhuizen, and P. Nibbering, unpublished results). In agreement, is has been reported 
that the LL-37–derived peptides covering residues 13–35 are at least as effective as LL-37 
with respect to LPS neutralization (31), modulation of TLR-mediated responses (34), and 
inducing secondary necrosis of apoptotic neutrophils (35). These structure-function 
studies can be helpful in the design of new candidate peptides for the treatment of 
infections. Experiments with a selection of inhibitors revealed that the cell-surface 
receptors involved in LL-37 signaling, such as FPLR1, P2X7 and EGFR, did not mediate the 
effects of this peptide on the M-CSF–driven macrophage differentiation. The main 
disadvantages of these inhibitors concern the instability of some of them, for example, 
AG1478 and suramin, and their specificity. However, we used stock solutions that were 
adequately prepared and stored for only a limited interval to exclude possible instability 
problems. In previous studies, these precautions allowed us to demonstrate an inhibitory 
effect of AG1478 on TGF-α-induced activation of airway smooth muscle cells and an 
inhibitory effect of suramin on the LL-37–induced activation of these cells (36). 
Nevertheless, based on our results with inhibitors we cannot rule out a possible 
involvement of cell-surface receptors in the effects of LL-37 on M-CSF–driven macrophage 
differentiation. In this connection, experiments with cytochalasin-D-preincubated 
monocytes revealed that LL-37 needs to be internalized by monocytes to affect M-CSF–
driven macrophage differentiation. The possibility that cytochalasin-D has toxic effects on 
monocytes and therefore affects the M-CSF–driven macrophage differentiation is unlikely 
as the viability of the macrophages resulting from cytochalasin-D preincubated monocytes 
and control monocytes did not differ. In addition, we noted that cytochalasin-D pretreated 
and control monocytes differentiated to type-2 macrophages equally well, for example, 
these macrophages express equal levels of CD163 and IL-12p40 production on LPS 
stimulation. The intracellular target of LL-37 in human monocytes could be GAPDH, which 
was recently shown to be also essential for the LL-37–induced activation of p38 MAPK 
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signaling in monocytes (27). Others reported that the LL-37–induced activation of p38 
MAPK signaling in monocytes is enhanced in the presence of GM-CSF, but not M-CSF (21). 
Furthermore, LL-37 internalized by DCs was found to be responsible for the altered 
morphological and functional characteristics of these cells (37). Finally, in view of the 
observed effects of LL-37 alone or in synergy with other mediators on cytokine and 
chemokine secretion of monocytes and macrophages (13, 20, 21), it cannot be excluded 
that LL-37 directs macrophage differentiation via its effects on cytokine 
actions/production. What could be the relevance of the current findings? M-CSF is 
constitutively produced by a variety of cells and circulates at detectable levels under 
steady-state conditions in serum and extracellular space (1). Most macrophage 
populations in the tissues are exposed to levels of tissue-derived M-CSF (38, 39) that are 
sufficient to maintain them in a Mφ-2–like state. However, on encountering infectious 
agents, tissue damage, or other danger signals, the M-CSF–driven macrophage 
differentiation may be counteracted by the local production of inflammatory mediators, 
such as GM-CSF (reviewed in Ref. 1) and LL-37 (28, 29) derived from infiltrating  
neutrophils and stimulated epithelial cells, resulting in macrophages with a 
proinflammatory signature. These macrophages may be effective in recruiting and 
activating other leukocytes resulting in the enhanced clearance of the infection. For 
example, LL-37 can activate macrophages to produce inflammatory cytokines in response 
to microbial stimuli and induce efficient phagocytosis of IgG-opsonized bacteria (40). The 
peptide can modulate the differentiation of monocytes to DCs that promote the 
development of a Th subset expressing high levels of IFN-γ and low/undetectable levels of 
IL-4/IL-5 (18), although maturation of the LL-37–differentiated DCs by several TLR ligands 
may be suppressed (19). In addition, it can enhance plasmacytoid DCs to produce IFN-α in 
response to self-DNA (41).When the infection recedes due to removal of pathogens and 
cellular debris by phagocytes, the levels of LL-37/GM-CSF in the local environment subside 
to homeostatic levels that facilitate differentiation of monocytes to macrophages with the 
“default” anti-inflammatory signature again. These cells suppress the inflammatory 
responses (42, 43) and induce regulatory T cells (3) and mediate tissue repair (44). Taken 
together, we demonstrated that LL-37 can (re)direct macrophage differentiation toward 
macrophages with a proinflammatory profile. These macrophages play important roles in 
the clearance of infections and tissue homeostasis.  
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Abstract The hLF1-11 peptide comprising the first 11 N-terminal residues of human lactoferrin, 
exerts antimicrobial activity in vivo, enhances the inflammatory response of monocytes, and directs 
monocyte-macrophage differentiation toward cells with enhanced antimicrobial properties. Since its 
effects on mononuclear phagocytes are already seen after short incubation of monocytes with hLF1-
11, we hypothesized that the differentiation of these cells toward dendritic cells (DCs) may also be 
affected by hLF1-11. We therefore determined the effects of hLF1-11 and a control peptide on 
human monocyte-dendritic cell differentiation and subsequent T-cell activation. The DCs thus 
obtained were assessed for their antimicrobial activity against the yeast C. albicans. Also, cytokine 
and reactive oxygen species production in response to this yeast was quantified. Results revealed 
that -compared to control DCs- hLF1-11-differentiated DCs displayed enhanced antimicrobial activity 
against C. albicans and produced enhanced amounts of IL-6 and IL-10 upon stimulation with C. 
albicans, whereas IL-12p40 production was reduced. Moreover, 6 day-cultured hLF1-11-
differentiated DCs and control (peptide-differentiated) DCs were stimulated with a memory mix for 
24 h and co-cultured with autologous CD4+ T cells for 72 h; hereafter cytokine production in 
supernatants as well as in T cells was assessed. The hLF1-11-differentiated DCs induced an enhanced 
IL-17 but reduced IFN-γ production by T cells as compared to control DCs. Collectively, the hLF1-11 
peptide drives monocyte-dendritic cell differentiation toward DCs that promote antifungal 
responses and induce Th17 polarization. The ability of hLF1-11 to modulate the hosts’ immune 
response may be key to its potential for treatment of infections with (multi-drug resistant) 
pathogens.
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Introduction 
In tissues dendritic cells (DCs) have the capacity to recognize and process pathogens and 
following their migration to the lymph nodes, present pathogen-derived antigens to T cells 
thereby activating an adaptive immune response. Dendritic cells can differentiate from a 
precursor cell depending on factors present in the local microenvironment. For example, 
when monocytes upon entering tissue encounter inflammatory mediators like cytokines, 
chemokines, complement components and antimicrobial peptides (AMPs), they 
differentiate into immature dendritic cells (iDC). These cells are known for abundant 
expression of pathogen recognition receptors, efficient antigen uptake and processing 
capacities. Upon tissue injury, microbial infection or other danger signals, iDCs mature into 
antigen presenting cells that produce inflammatory mediators, migrate toward lymphoid 
organs and instruct T lymphocytes to proliferate and differentiate into specific T cell 
subsets. This polarization of T cells depends greatly on the DCs and the inflammatory 
mediators present in their environment. Important molecules that influence 
differentiation of monocytes and functional properties of immune cells are antimicrobial 
peptides (AMPs). AMPs are cationic, relatively short and are active against a variety of 
microorganisms including multi-drug resistant pathogens (1). The principal mechanism of 
action of antimicrobial peptides was long thought to be perturbation of the microbial cell 
membrane. However, an increasing number of studies shows the diversity in the 
mechanisms of action of these peptides that have therefore been renamed as host 
defense peptides (HDPs) (2, 3). These mechanisms of action include direct killing of 
pathogens (4, 5), modulation of pathogen development (6, 7) and modulation of immune 
cells (8-10), the latter is now increasingly recognized as being an important contribution to 
clearance of infection. For possible therapeutic application of HDPs, it will be important to 
understand the interactions of these peptides with the hosts’ immune cells. For example, 
cathelicidin-based peptides IDR-1 (11) and IDR1002 (12) have been developed on the basis 
of their ability to affect the host immune system by enhancement of chemokine 
production by innate immune cells. The cathelicidin LL-37 is able to direct both monocyte-
macrophage differentiation (13) as well as differentiation toward dendritic cells that 
promote a Th1 response in vitro (14) through interaction with an intracellular target (15). 
LL-37 is also able to modulate the adaptive immune response by directly affecting the 
maturation of DCs (16). We recently reported that the antimicrobial peptide comprising 
the first 11 N-terminal residues of human lactoferrin, further referred to as hLF1-11, 
enhances the inflammatory response of monocytes and modulates monocyte-
macrophage differentiation; an additional mechanism of action to its already established 
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antimicrobial effects (5,7,17-20). hLF1-11 enhances inflammatory mediator production by 
murine and human monocytes (21) and promotes differentiation of GM-CSF-stimulated 
monocytes toward a macrophage subset that shows enhanced responsiveness to 
microbial stimuli and demonstrates increased clearance of pathogens (8). These effects 
were already obtained after incubation of monocytes with hLF1-11 for 60 min, indicating 
that hLF1-11 can modulate monocytes at an early stage, resulting in long-term alterations. 
Since monocytes can also differentiate toward (immature) dendritic cells, we have here 
investigated the effects of hLF1-11 on monocyte-dendritic cell differentiation. We found 
that when hLF1-11 was present during GM-CSF and IL-4-driven differentiation of 
monocytes toward dendritic cells, the resulting immature DCs displayed enhanced 
antimicrobial properties against C. albicans and -upon maturation- induced IL-17 
production by T cells while reducing IFN-γ production. 
 
Materials and methods 
Peptides The human lactoferrin-derived peptide hLF1-11 (GRRRRSVQWCA; 1.374 kDa) was 
purchased from Peptisyntha (Torrance, CA) and the control peptide (GAARRAVQWAA; 
1.115 kDa) from Isogen (De Meern, The Netherlands). The control peptide shows no 
activity against pathogens in vitro and in vivo (7). The purity of both peptides was >97% as 
determined by reverse-phase high-performance liquid chromatography (HPLC). Stocks of 
the peptides were made in phosphate-buffered saline (PBS, Dept. of Pharmacy LUMC, 
Leiden, The Netherlands) and stored at -20˚C. Endotoxin concentrations were below 
detection level. 
 
Cell culture Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats
 
of 
healthy donors using Ficoll-Amidotrizoate density gradient centrifugation. Monocytes 
were further purified by CD14-positive selection using antiCD14-conjugated magnetic
 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturers’ 
protocol. Next, monocytes (>95% pure, viability >96% as determined by propidium iodide 
staining) were incubated for 7 days in culture medium (RPMI 1640, GIBCO Invitrogen, 
Breda, The Netherlands) containing 10% heat-inactivated fetal bovine serum (FCSi, Greiner 
Bio-One B.V., Alphen a/d Rijn, The Netherlands), 2 mM penicillin, 2 mM streptomycin 
(both PAA GmbH, Pasching, Germany) and 2 mM L-glutamine (GIBCO Invitrogen) 
supplemented with 10 ng/ml recombinant human granulocyte macrophage-colony 
stimulating
 
factor (rhGM-CSF) and 10 ng/ml recombinant human IL-4 (both Biosource, 
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Camarillo, CA). To study the effect of hLF1-11 on differentiation of monocytes into iDCs, at 
the start of the culture monocytes were exposed to various concentrations of either, hLF1-
11 (up to 100 μg/ml) or control peptide (100 μg/ml) or saline as a control. On day 6, the 
immature DCs were matured with heat-killed (30 min at 100 °C) Candida albicans (1x10
7
 
CFU/ml strain Y01-19, Pfizer Inc., Groton, CT) for 20 h. Thereafter supernatants were 
harvested for assessment of cytokine (and chemokine) levels, or immature and mature 
DCs were harvested at day 7 and used for analysis of their capacity to take up dextran, 
phagocytose S. aureus and C. albicans, produce reactive oxygen species (ROS), and 
polarize CD4+ T cell differentiation in co-culture experiments. 
 
Flow cytometric analysis of cell-surface molecule expression by dendritic cells For 
measurements of the expression of a variety of cell-surface molecules, the following 
monoclonal antibodies were used: PE-conjugated antibodies directed against CD11b, 
CD40, CD54, CD80, CD83 and CD86 and FITC-labeled antibodies against HLA-DR, CD14, 
CD206 and CD209 were all obtained from BD Biosciences (Heidelberg, Germany). PE-
conjugated antibody against Dectin-1 was purchased from R&D Systems and Alexa Fluor 
647-conjugated antibody against CD197 from BD Biosciences. DCs were harvested and 
resuspended in ice cold 0.2% PBS/BSA, washed twice and then incubated with the 
selected antibodies for 30 min on ice in the dark. Cell-surface molecule expression was 
assessed on a FACSCalibur and analysed by BD CellQuest software (BD Biosciences). 
Results are expressed as MFI corrected for background measurements. 
 
Flow cytometric analysis of dextran-FITC uptake by dendritic cells The endocytic property 
of the various iDCs was examined by incubation of the cells with 1 mg/ml FITC-labeled 
dextran (Invitrogen) for 2 h at 37°C in culture medium. Background measurements were 
performed at 4°C. After washing, dextran-FITC fluorescence was assessed using a 
FACSCalibur and analysed by BD CellQuest software (BD Biosciences). Results are 
expressed as median fluorescence intensity (MFI) corrected for background 
measurements. 
 
Assays for the phagocytosis of S. aureus and C. albicans by immature dendritic cells 
Phagocytosis of pHrodo-labeled S. aureus was performed as described for macrophages 
(8). Briefly, a stock suspension of pHrodo-labeled S. aureus (Invitrogen) was prepared 
according to manufacturer’s protocol. pHrodo is a dye that is non-fluorescent at neutral 
pH and bright red in acidic environments (e.g. phagolysosome). Equal volumes of iDCs 
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(1x10
6
/ml) and 5-times pre-diluted pHrodo-labeled S. aureus stock were mixed and then 
incubated for several intervals at 37˚C, or as a control, at 4˚C. Thereafter, pHrodo 
fluorescence of the iDCs was assessed on a FACSCalibur. Results are expressed as the 
percentage of pHrodo-positive iDCs. 
Phagocytosis of C. albicans by iDCs was assessed by FACS analysis as described for 
macrophages (8). In short, overnight cultured C. albicans were washed twice in PBS and 
then labeled with 0.5 μM carboxy fluorescein succinimidyl ester (CFSE, Invitrogen) for 30 
min at 37°C in the dark, centrifuged and resuspended in RPMI 1640 supplemented with 
20% human serum (HuS). iDCs were washed twice in PBS/0.2% bovine serum albumin 
(BSA) and then labeled with PE-conjugated antibody against CD54 for 30 min (on ice in the 
dark). Next, these labeled iDCs were mixed with CFSE-labeled C. albicans in a 1:1 ratio and 
incubated for various intervals at 37°C under slow rotation in the dark. The percentage of 
iDCs associated with C. albicans was assessed by determining the percentage of double 
positive iDCs (CD54+/CFSE+) using a FACSCalibur and analysed by BD CellQuest software. 
Control experiments were performed at 4°C to correct for binding of C. albicans to iDCs. 
Results are expressed as percentage iDCs that were positive for both CD54 and CFSE.  
 
Flow cytometric analysis of ROS production by dendritic cells Intracellular ROS 
production by iDCs was quantified using the fluorescent probe 2′,7′-dichlorofluorescein-
diacetate (DCFH-DA) (Invitrogen). In short, iDCs were loaded with 10 μM DCFH-DA for 20 
min at 37˚C in the dark. Thereafter, iDCs were incubated with 1x10
7
 heat-killed C. albicans 
for various intervals. ROS production was measured on a FACSCalibur. Results are 
expressed as median fluorescence intensity (MFI) with interquartile range.  
 
Determination of cytokine levels by ELISA Enzyme-linked immunosorbent assay (ELISA) 
cytosets were used to determine the concentrations of interleukin (IL)-6, IL-10, IL-12p40 
and TNF-α (Invitrogen) according to manufacturers’ instructions.  
 
T cell isolation and DC-T cell co-cultures CD4+ T cells (>95% purity) were obtained from 
the CD14-negative fraction after monocyte isolation (stored at -80˚C) by CD4-positive 
selection using anti-CD4-conjugated magnetic
 
microbeads (Miltenyi Biotec) according to 
manufacturers’ protocol. They were resuspended in IMDM (Lonza, Verviers, Belgium) 
containing 10% heat-inactivated fetal bovine serum (FBSi, Gibco), antibiotics and 2 mM L-
glutamine and left overnight to recover. Immature DCs were reseeded in a 96-wells plate 
(1x10
5
/well). Three hours thereafter cells were stimulated with a mix of LPS (100 ng/ml; 
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Sigma-Aldrich, Zwijndrecht, The Netherlands), purified protein derivative of 
Mycobacterium tuberculosis (PPD, Statens Serum Institute, Copenhagen, Denmark; 5 
μg/ml), tetanus toxoid (TT; 1% of the stock, 80 IE/ml) and heat-killed C. albicans (1 x 
10
6
/ml) for 24 h. Thereafter, DC’s were co-cultured with 1 x 10
6
 autologous T cells for 72 h 
in the presence of TT (1% of the stock, 80 IE/ml) and supernatants were collected and 
assessed for IL-17, IL-10, IFN-γ, IL-2 and IL-4 levels using a custom-made multiplex bead-
array (Bio-Rad, Hercules, CA), according to manufacturers’ protocol. For intracellular 
cytokine staining, cells in the co-culture were incubated with Brefeldin A (BFA, 3 μg/ml, 
Sigma) during the last 18 hours of co-culture, replicates (n = 10) pooled and T-cells were 
labeled extracellular using anti-CD3-AMCyan, anti-CD4-PECy7 and anti-CD25-FITC (all BD 
Biosciences) antibodies. Next, cells were fixed and intracellular labeled using Intrastain 
reagents (DakoCytomation, Heverlee, Belgium)  with antibodies directed against IL-17-PE, 
(Ebioscience, San Diego, CA), IFN-γ-Alexa700 (BD Biosciences) and IL-10-APC (Miltenyi 
Biotec) before acquisition on a LSRII flowcytometer (BD Biosciences) and analysed using 
FlowJo software version 8.7.3 (Tree Star Inc, Ashland, Oregon). The core population of live 
CD3
+
 T cells was analyzed for IL-17 production, while activated and CD3
dim
 T cells were also 
included in IFN-γ production analysis. 
 
Statistical analysis Friedman followed by Dunn’s multiple comparisons post-hoc test or, 
where indicated, Wilcoxon’s test was used to determine the differences between the 
results for hLF1-11-differentiated and control (peptide-differentiated) DCs. Data are 
expressed as median and range. Two sided p-values are reported and the level of 
significance was set at p< 0.05. 
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Results 
Morphology and cell-surface molecule expression by hLF1-11-differentiated and control 
(peptide-differentiated) iDCs and mature DCs First, we inspected the morphology of the 
dendritic cells that had been differentiated in the presence of hLF1-11 or the control 
peptide. The morphology, density and attachment of the cells to the wells did not differ 
between hLF1-11 and control (peptide-differentiated) DCs. Next, we compared cell-
surface molecule expression between hLF1-11-differentiated and control (peptide-
differentiated) iDCs. Results revealed that hLF1-11-differentiated iDCs expressed 
significantly higher levels of CD14, CD80, HLA-DR and Dectin-1, a receptor involved in C. 
albicans recognition, on their cell-surface as compared to control (peptide-differentiated) 
iDCs (Table I). Upon maturation by C. albicans, the expression of the maturation marker 
CD83 as well as the co-stimulatory molecule CD86 by hLF1-11-differentiated DCs was 
significantly decreased as compared to control (peptide-differentiated) DCs (Table I). 
 
Table 1 Cell-surface molecule expression by hLF1-11 and control (peptide-differentiated) DCs  
Immature DCs C. albicans-matured DCs
Control hLF1-11 Control peptide Control hLF1-11 Control peptide
CD14 LPS co-receptor 2 (1-3) 4* (2-7) 2 (1-3) 3 (2-7) 2 (1-6) 2 (0-6)
CD83 Maturation marker 1 (0-4) 2 (0-3) 1 (0-3) 32 (21-54) 22* (12-42) 36 (26-74)
CD197 CCR7 8 (5-17) 12 (7-19) 10 (7-16) 29 (26-34) 27 (21-42) 32 (24-38)
CD54 ICAM-1 199 (123-241) 138 (92-245) 183 (109-256) 881 (512-1190) 1025 (500-1434) 850 (356-1155)
CD40 Co-stimulatory 52 (30-81) 57 (31-89) 56 (20-68) 86 (52-127) 77 (42-127) 70 (26-104)
CD80 B7.1 5 (0-9) 7* (0-19) 4 (0-7) 32 (24-83) 29 (18-90) 30 (29-99)
CD86 B7.2 14 (0-26) 7 (2-48) 11 (4-25) 407 (233-459) 247* (217-375) 382 (317-466)
HLA-DR MHC class II 46 (24-100) 63* (36-252) 45 (21-73) 170 (97-399) 138 (86-517) 147 (68-365)
CD11b CRIII 294 (131-382) 261 (104-299) 288 (201-379) 278 (183-320) 224 (189-304) 269 (226-396)
CD206 Mannose receptor 45 (32-71) 33 (22-152) 54 (27-75) 30 (17-45) 31 (16-44) 33 (19-53)
CD209 DC-SIGN 44 (29-66) 44 (19-74) 42 (23-54) 41 (23-49) 41 (26-51) 33 (23-50)
Dectin-1 β-glucan receptor 13 (9-23) 19* (13-39) 12 (7-19) 20 (10-25) 19 (11-28) 21 (14-34)
 
Results are expressed as median fluorescence intensity (MFI) and corrected for background fluorescence. Data 
are expressed as median and range within experiments with at least six different donors. *, p< 0.05  
 
Endocytic and phagocytic properties of hLF1-11-differentiated and control (peptide-
differentiated) DCs To investigate whether hLF1-11-differentiated DCs also displayed 
differences in their functional activities, we compared endocytic and phagocytic capacities 
of iDCs differentiated in the presence of hLF1-11 with those of control (peptide-
differentiated) iDCs. No significant difference in dextran uptake between hLF1-11-
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differentiated iDCs and control (peptide-differentiated) iDCs was observed (Fig. 1A). In 
addition, phagocytosis of S. aureus by hLF1-11-differentiated iDCs did not differ from that 
by control (peptide-differentiated) iDCs (Fig. 1B). However, the percentage of C. albicans-
phagocytosing hLF1-11-differentiated iDCs was significantly higher than that of control 
(peptide-differentiated) iDCs (Fig. 1C). Control experiments at 4˚C revealed that 
approximately 10% of the iDCs bound C. albicans at all intervals, independent of the 
presence of hLF1-11 or control peptide during differentiation (data not shown).  
 
Fig. 1 Endocytosis of dextran-FITC and uptake of 
C. albicans and S. aureus by hLF1-11- or control 
(peptide-differentiated) immature dendritic cells 
Monocytes were cultured with rhGM-CSF and IL-4 
in the presence of hLF1-11 (100 μg/ml, dark gray 
bars), control peptide (100 μg/ml, light gray bars) 
or no peptide (open bars). At day 7, iDCs were 
harvested, washed and cultured for 2 h in the 
presence of dextran-FITC, thereafter the amount 
of dextran uptake by these cells was assessed 
using flow cytometry (A). Furthermore, after 60, 
90 or 120 min co-incubation of the iDCs with 
pHrodo-labeled S. aureus, the percentage of 
pHrodo-positive iDCs was determined using flow 
cytometry (B). Lastly, iDCs were co-incubated 
with CFSE-labeled C. albicans and after 15, 30 and 
60 min co-incubation, the percentage of iDCs 
associated with C. albicans was determined using 
flow cytometry (C). Boxes represent medians and 
second and third interquartiles, whiskers 
represent range within experiments with 6-10 
different donors. *, p<0.05 
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ROS production by hLF1-11-differentiated and control (peptide-differentiated) iDCs in 
response to C. albicans Since hLF1-11-differentiated iDCs displayed enhanced 
phagocytosis of C. albicans, we considered the possibility that more antimicrobial 
functions of these cells were enhanced in response to C. albicans. We therefore 
determined the production of reactive oxygen species by the various iDCs in response to 
this yeast. Results revealed that hLF1-11-differentiated iDCs produced significantly more 
ROS 30 and 60 min after stimulation with C. albicans than control (peptide-differentiated) 
iDCs (Fig. 2). ROS levels decreased 90 min after stimulation with C. albicans, however 
hLF1-11-differentiated DCs still produced at that point significantly more ROS than control 
peptide-differentiated DCs. 
 
 
Fig. 2 Intracellular ROS 
production by hLF1-11 and 
control (peptide-
differentiated) immature 
dendritic cells Monocytes 
were cultured with rhGM-
CSF and IL-4 in the 
presence of hLF1-11 (100 
μg/ml, dark gray bars), 
control peptide (100 μg/ml, 
light gray bars) or no 
peptide (open bars) and 
labeled at day 7 with DCFH-
DA. Next, the labeled iDCs 
were stimulated with heat-
killed C. albicans and the MFI was assessed directly and after 30, 60 and 90 min as a measure of ROS production. 
Boxes represent medians and second and third interquartiles, whiskers represent range within experiments with 
8 different donors. *, p<0.05; ** p<0.01  
 
Differential cytokine production patterns in hLF1-11-differentiated DCs and control 
(peptide-differentiated) DCs Another functional property of DCs is the production of 
inflammatory mediators. We therefore assessed pro- and anti-inflammatory cytokine 
production by the various DC groups in response to C. albicans. Results showed that heat-
killed C. albicans-matured hLF1-11-differentiated DCs produced significantly more IL-6 and 
IL-10 and less IL-12p40 than control (peptide-differentiated) DCs (Fig. 3). The production 
of TNF-α did not differ between the various groups of DCs (Fig. 3).  
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Fig. 3 Cytokine profiles of hLF1-11- and control (peptide-differentiated) dendritic cells in response to heat-
killed C. albicans  Monocytes were cultured with rhGM-CSF and IL-4 in the presence of hLF1-11 (1, 10, 100 
μg/ml; dark gray bars) or control peptide (CP, 100 μg/ml; light gray bars) for 6 days. Thereafter, cells were 
stimulated with 1x10
7
 heat-killed C. albicans for 20 h and then supernatants were collected and assessed for IL-6 
(A), IL-10 (B), IL-12p40 (C) and TNF-α (D) levels. Values are expressed as fold increase of cytokine production 
compared to control DCs (none, no peptide; open bars). Data are expressed as boxes and whiskers, boxes 
represent medians and second and third interquartiles, whiskers represent range within experiments with 7-8  
different donors. *, p<0.05; **, p<0.01 as compared to control and control peptide-differentiated DCs 
 
Polarization of CD4+ T cells by hLF1-11-differentiated or control (peptide-differentiated) 
DCs Since the innate activities of hLF1-11-differentiated DCs differed from that of control 
(peptide-differentiated) DCs, we compared their T cell activating capacities. First, the 
supernatants of the co-cultures of hLF1-11-differentiated DCs -matured by a memory mix- 
with autologous CD4+ T cells, were found to contain significantly more IL-17 (p<0.05) and 
more IL-10 (p=0.06), but less IFN-γ (Fig 4A) than co-cultures with control (peptide-
differentiated) DCs. In these cultures, IL-2 was out of range and no IL-4 was detected (data 
not shown). Next we determined the percentage of T-cells expressing the various 
cytokines (IL-17, IL-10 and IFN-γ) by performing intracellular cytokine staining. Results 
revealed that enhanced percentages of IL-17-producing T cells and reduced percentages 
of IFN-γ producing T cells were found in the co-cultures with hLF1-11-differentiated DCs as 
compared to control (peptide-differentiated) DCs (Fig. 4B). IL-10 producing T cells were 
present at very low frequencies and no difference in percentages of IL-10-producing T cells 
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were found between the different groups (Fig. 4B), suggesting that IL-10 in the 
supernatants of the co-culture (Fig 4A) is mainly derived from the DCs.   
 
Fig. 4 Cytokine profile by CD4+ T cells after co-culture with hLF1-11 and control (peptide-differentiated) 
dendritic cells Monocytes were cultured with rhGM-CSF and IL-4 in the presence of hLF1-11 (100 μg/ml; dark 
gray bars), control peptide (CP, 100 μg/ml; light gray bars), or saline (open bars) for 6 days. Thereafter, cells were 
stimulated with heat-killed C. albicans (5x10
5
/ml), purified protein derivative of M. tuberculosis (PPD; 5 μg/ml), 
tetanus toxoid (TT; 150 lf/ml) and LPS (100 ng/ml) for 24 h. Next, cells were washed and CD4+ T cells from the 
same donor and TT were added to the culture. 72 h later, supernatants were harvested and assessed for IL-17, IL-
10 and IFN-γ (A) and IL-4, IL-2 levels (data not shown). Next, intracellular cytokine production by the T► 
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►lymphocytes in the co-culture was assessed by addition of brefeldin A for the last 16 hours of the co-culture (3 
µg/ml). T cells were stained for intracellular IL-17, IL-10 and IFN-γ (B) Data are expressed as boxes and whiskers, 
boxes represent medians and second and third interquartiles, whiskers represent range within experiments with 
6-8 different donors. *, p<0.05  
 
Discussion 
In this study we demonstrate that the presence of hLF1-11 during differentiation of 
monocytes into dendritic cells results in DCs that promote antifungal responses and 
induce Th17 polarization. This conclusion is based on the following findings. First, 
phagocytosis of C. albicans and ROS production in response to this yeast were elevated in 
hLF1-11-differentiated DCs as compared to the control (peptide-differentiated) DCs, while 
phagocytosis of S. aureus by hLF1-11-differentiated DCs was not enhanced. Second, the 
production of IL-6 and IL-10 by hLF1-11-differentiated mDCs in response to C. albicans was 
significantly enhanced, while IL-12p40 production was reduced as compared to control 
(peptide-differentiated) DCs. Incubation of hLF1-11-differentiated DCs with bacterial 
stimuli like LPS or LTA resulted in a significant (p< 0.05) reduction of TNF-α and IL-12p40 
(without affecting the IL-6 and IL-10 levels) as compared to control (peptide-
differentiated) DCs (data not shown). These data indicate that the presence of hLF1-11 
during monocyte-DC differentiation has differential effects on the cytokine profile of the 
resulting mDC upon maturation by fungal or bacterial stimulation. Interestingly, we 
reported earlier that the presence of hLF1-11 during GM-CSF-driven differentiation of 
monocytes into macrophages, results in macrophages that also display enhanced 
production of IL-10 but not IL-12p40 or TNF-α in response to C. albicans (8). In addition, 
these macrophages displayed enhanced antimicrobial properties against C. albicans, but 
also S. aureus and displayed enhanced expression of pathogen recognition receptors like 
dectin-1. One possible explanation for these partial overlapping effects of hLF1-11 on 
monocyte-macrophage and monocyte-DC differentiation is the following. GM-CSF is 
known to be involved in regulation and enhancement of myeloperoxidase -the 
intracellular target of hLF1-11 (van der Does et al, submitted)- during monocyte-
macrophage differentiation, whereas GM-CSF and IL-4 or with IL-4 alone diminished 
myeloperoxidase expression as compared to freshly isolated monocytes. As dendritic cells 
are obtained in vitro by incubation of monocytes with a combination of GM-CSF and IL-4, 
possible hLF1-11 is less able to affect monocyte-DC differentiation than monocyte-
macrophage differentiation. Some properties of hLF1-11-differentiated dendritic cells and 
macrophages might therefore be overlapping between these cell types, while others are 
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not. Interestingly, as Dectin-1 expression was also significantly enhanced by hLF1-11-
differentiated iDCs, it is tempting to speculate that myeloperoxidase might be involved in 
signaling leading to dectin-1 expression.  
The most striking finding of this study is that hLF1-11 drives differentiation of monocytes 
toward DCs that promote Th17 polarization. The development of Th17 cells is linked to 
activation of several receptors including dectin-1 and CD206 (24,25,26), as recognition of 
C. albicans by these receptors is associated with Th17 responses. Also cytokines like IL-6, 
IL-1β and IL-23 can facilitate Th17 polarization. Th17 responses are thought to be 
important in host defense against fungi and S. aureus (27,28,29,30) especially at epithelia 
and mucosa. In addition, IL-17 is involved in the influx of neutrophils and can induce 
production of cytokines/chemokines and antimicrobial peptides by epithelial cells (31). 
Although Th17 cells are part of the adaptive immune response, they serve mainly to 
regulate innate immune responses (32). Besides promoting Th17 polarization, hLF1-11-
differentiated DCs also reduced IFN-γ production by CD4+ T cells. It could be that this 
reduction of Th1 polarization is the consequence of the enhanced IL-10 production by the 
hLF1-11-differentiated DCs in the co-cultures (33). Interestingly, the effects of hLF1-11 on 
monocyte-DC differentiation differ from those reported for other AMPs/HDPs, such as the 
human cathelicidin LL-37 and α- and β-defensins. Davidson et al. (14) showed that the 
presence of LL-37 during monocyte-DC differentiation resulted in DCs promoting IFN-γ-
producing T cells. Kandler et al. (16) have shown that this peptide inhibited the response 
iDCs toward microbial stimuli such as LPS, thereby indicating that LL-37 reduced 
maturation of these cells. Human defensins HNP-1 and hBD-1 promoted the activation and 
maturation of DCs and stimulated the production of TNF-α, IL-6, and IL-12p70 but not IL-
10. Clearly, AMPs/HDPs differentially affect the differentiation and subsequent maturation 
of DCs (34). The concentration of hLF1-11 in the present study (100 μg/ml) is determined 
by dose response experiments with monocytes, macrophages and dendritic cells. hLF1-11 
has been shown to be effective in mice up to concentrations of 4 mg/kg body weight, 
which corresponds to injection of 100 μg/mice. However, it should be realized that 
extrapolation of in vitro to in vivo levels is difficult since the local concentration of the 
peptide at the site of infection remains unknown. Together, these data show that hLF1-11 
is able to modulate monocyte-dendritic cell differentiation, resulting in DCs displaying 
enhanced antimicrobial activities against C. albicans and promoting Th17 polarization 
after co-culture with CD4+ T cells. The immunomodulatory properties of hLF1-11 may aid 
in balancing the immune responses of the host leading to the resolution of infections with 
(multi-drug) resistant pathogens.  
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Abstract Due to their abilities to eliminate pathogens and to modulate the hosts’ immune response, 
antimicrobial peptides are considered as potential alternative for classical antibiotics in the 
treatment of infection. We recently reported that hLF1-11; an eleven amino acid antimicrobial 
peptide derived from the N-terminus of human lactoferrin, modulates the LPS-induced 
inflammatory response of human monocytes and directs the GM-CSF-driven monocyte-macrophage 
differentiation toward macrophages with enhanced antimicrobial effector functions. In this study we 
focused on the identification of the cellular target of hLF1-11 that mediates these effects and found 
that hLF1-11 binds to and subsequently enters human monocytes. Pull-down assays using monocyte 
lysates with hLF1-11-coated columns resulted in the isolation of a single protein of approximately 
110 kDa, identified by mass spectrometric analysis as human myeloperoxidase (MPO). The hLF1-11 
peptide inhibited chlorination and peroxidation activity of MPO, whereas ABAH, an inhibitor of the 
enzymatic activity of MPO, mimicked the effects of hLF1-11 on the inflammatory response by 
monocytes, i.e., it reduced production of reactive oxygen species and enhanced production of IL-10 
in response to LPS. Similarly to hLF1-11, the MPO-inhibitor affected monocyte-macrophage 
differentiation as assayed by IL-10 production upon LPS stimulation and phagocytosis of 
Staphylococcus aureus. Experiments with a set of hLF1-11 peptides with a single amino acid 
substituted by alanine, identified the cysteine at position 10 as pivotal in hLF1-11 to enable it to 
inhibit myeloperoxidase activity and affect monocyte function.  
We conclude that hLF1-11 exerts modulatory effects on monocytes by specific inhibition of 
myeloperoxidase activity. These findings merit further research regarding the development of hLF1-
11 as possible therapeutic agent in disease states in which myeloperoxidase activity plays an 
unfavorable role. 
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Introduction 
Over the past 60 years, the usage of antibiotics, in both humans as well as in the 
veterinarian field, has resulted in the emergence of multi-drug resistance of a variety of 
microorganisms (1-3). This was helped by the ability of the latter to rapidly evolve and 
adapt, and in stressful environments to select for useful genotypes among multiple 
mutants. Nowadays, antibiotic-resistant microorganisms present a major problem for both 
the medical community as well as for society. The emergence of multi-drug resistant 
pathogens underscores the need for reconsidering current usage of antibiotics, and shows 
that novel antibiotics with a mode of action different from current anti-infectives are 
urgently needed. In the past decennia, the development of antimicrobial agents has 
mainly focused on ways to eliminate the pathogen, either by a direct microbicidal activity 
or by stopping the microorganisms in their growth, allowing the hosts’ phagocytic cells to 
ingest and kill the invaders. Recently, research has shifted toward exploring the possibility 
for an alternative way of coping with infections, through modulation of the hosts’ immune 
system, thereby enhancing its ability to reduce pathogenic load.  
Promising candidates in this respect may be found in the class of antimicrobial peptides 
(4-6). Antimicrobial peptides are cationic, relatively short and active against a variety of 
microorganisms, including many multi-drug resistant pathogens. In addition to their ability 
to directly kill pathogens, many antimicrobial peptides -also called host defense peptides 
(HDPs)- have immunomodulatory properties. This quality makes them possible candidates 
to serve as an alternative for current anti-infectives. In addition, identification of the 
(intra)cellular target(s) of AMPs in immune cells could provide the basis for further 
development of agents that modulate the (innate) immune response. Extracellular 
receptors for AMPs on immune cells have been reported to mediate for example 
chemotaxis of neutrophils and monocytes (7). However, uptake of AMPs like LL-37 and 
IDR-1 by immune cells was found to be essential for their ability to induce the production 
of cytokines/chemokines by immune cells and to exert antimicrobial functions (8,9).   
The lactoferrin-derived peptide hLF1-11, a synthetic peptide comprising the first 11 N-
terminal residues of human lactoferrin, displays in addition to its antimicrobial effects (10-
14) also immunomodulatory properties by enhancement of cyto- and chemokine 
production by murine and human monocytes (15). Moreover, it directs the GM-CSF-driven 
monocyte-macrophage differentiation toward an IL-10-producing macrophage subset that 
shows increased responsiveness toward microbial stimuli and enhanced phagocytosis and 
intracellular killing of pathogens (16). As this peptide displays potential for development 
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as a therapeutic agent, the aim of the present study was to identify the cellular target(s) of 
hLF1-11 that mediate(s) these immunomodulatory effects.  
Materials and Methods 
Peptides The synthetic peptide comprising the first eleven amino acids of human 
lactoferrin (further referred to as hLF1-11; GRRRRSVQWCA) was purchased from 
Peptisyntha (Torrance, CA). The control peptide: GAARRAVQWAA, N-terminal biotinylated 
hLF1-11 (hLF1-11-biotin), N-terminal biotinylated control peptide (control peptide-biotin) 
and a set of alanine-substituted peptides were from Isogen (De Meern, The Netherlands). 
The purity of the peptides was determined by reverse-phase high-performance liquid 
chromatography and exceeded 97%. All peptides were endotoxin free. Immediately 
before use the peptides were dissolved in phosphate buffered saline (PBS; pH 7.4; 
Department of Pharmacy, LUMC).  
 
Isolation of human monocytes Human monocytes were isolated from buffycoats from 
healthy donors by Ficoll Amidotrizoate (Department of Pharmacy, LUMC) density gradient 
centrifugation. Monocytes were further purified by CD14-positive selection using anti-
CD14-conjugated magnetic
 
microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) 
according to the manufacturers’ protocol. The resulting suspension comprised of 
approximately 96% monocytes with a viability exceeding 98% as determined by annexin V 
and propidium iodide staining 2 h after isolation. 
 
Interaction of hLF1-11 with human monocytes Monocytes were incubated with 10 μg/ml 
hLF1-11-biotin at 37˚C and 4˚C for several intervals up to 70 min, then washed with ice-
cold PBS and incubated with phycoerythrin-labeled streptavidin (Invitrogen, Breda, The 
Netherlands) for 15 min on ice. Hereafter, the monocytes were washed and the mean 
fluorescence intensity (MFI) of the cells was assessed by flow cytometry on a FACSCalibur 
and analysed using BD CellQuest software (BD biosciences, Heidelberg, Germany). To find 
out whether the hLF1-11 peptide enters cells we incubated monocytes with 100 μg/ml of 
hLF1-11-biotin or saline for 15 or 60 min at 37˚C or for 60 min at 4˚C. Thereafter, the cells 
were fixed with 4% paraformaldehyde for 10 min, washed three times with PBS and 
adhered on labtek II cc
2
 slides (Nunc, Rochester, NY) by 15 min of incubation. Next, the 
cells were carefully washed with PBS supplemented with 0.05% Tween20 and 
permeabilized with 90% methanol for 10 min. Finally, these cells were washed with PBS 
and incubated with Alexa 647-labeled streptavidin (Invitrogen) for 30 min. After rinsing, 
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the cells were incubated with rhodamine-labeled wheat germ agglutinin (WGA, 
Invitrogen) for 20 min to stain the membranes. Then, cells were washed and mounted 
with Vectashield containing DAPI (Vector Laboratories, Amsterdam, The Netherlands). 
High quality, 3D stacks of optical sections were obtained with a Marianas
TM
 digital imaging 
microscopy work station (Zeiss 200M, Zeiss, Göttingen, Germany) using a 63x oil-
immersion objective and a Z-stepsize of 0.25 µm. Finally, 3D image acquisition, 
deconvolution and automated image analysis were performed under full software control 
(SlideBook version 5.0, Intelligent Imaging Innovations, Denver, CO). 
 
Isolation of the cellular target(s) of hLF1-11 in human monocytes Monocytes (3 x 10
7
/ml) 
were lysed by keeping them on ice for 30 min in TNE-buffer [10 mM Tris-HCl (pH 7.5), 150 
mM NaCl, and 2 mM
 
EDTA] containing a protease inhibitor mixture (Pierce Biotechnology, 
Rockford, MA)
 
and 1% Nonidet P-40. Lysates were centrifuged for 10 min at 10.000 x g and 
supernatants were stored at -80˚C. Next, hLF1-11 target proteins were isolated from these 
supernatants using the biotinylated protein interaction pull-down kit from Pierce 
Biotechnology according to the manufacturers’ protocol. In short, hLF1-11-biotin or 
control peptide-biotin was immobilized on a streptavidin column. Next, these columns 
were incubated for 2 h with monocyte lysate supernatant and after several washings, 
proteins were eluted with the manufacturers’ elution buffer. Eluted samples were dried in 
a centrifugal vacuum concentrator (Eppendorf, Hamburg, Germany) and taken up in a 
small volume of elution buffer. Next, 20 μl of this sample was mixed with 5 μl of 5x 
concentrated non-reducing loadingbuffer (100 mM Tris-HCL, 4% w/v SDS, 50% glycerol 
and 0.05% bromophenolblue) and then subjected to SDS-PAGE on a 10% or 15% SDS-
polyacrylamide gel. After electrophoresis, the gel was fixed overnight in 50% methanol, 
12% acetic acid, 0.05% formaldehyde and then washed three times for 20 min in 35% 
ethanol. Next, the gel was sensitized for 2 min in 0.02% sodium thiosulfate and washed 
three times for 5 min in water, followed by staining of the proteins for 20 min in 0.2% 
(wt/v) silver nitrate and 0.076% formaldehyde. After washing, the gel was developed using 
6% (wt/v) Na2CO3, 0.05% formaldehyde, 0.0004% (wt/v) Na2S2O3 for maximal 5 min, after 
which the reaction was stopped with 50% methanol and 12% acetic acid.  
 
In-gel tryptic digestion and mass spectrometry Protein bands were excised from the gel, 
cut into small pieces, and washed with 25 mM NH4HCO3 followed by dehydration with 
100% acetonitrile (ACN) for 10 min. For reduction and alkylation, dried gel particles were 
first incubated with 10 mM dithiothreitol for 30 min at 56°C. Following dehydration with 
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ACN, gel plugs were subsequently incubated in 55 mM iodoacetamide for 20 min at room 
temperature. After two rounds of washing with 25 mM NH4HCO3 and dehydration with 
100% ACN, the gel particles were completely dried in a centrifugal vacuum concentrator 
(Eppendorf). The dried gel particles were re-swollen for 15 min on ice after the addition of 
15 μl of a trypsin solution (Sequencing Grade Modified Trypsin, Promega, Madison, WI; 5 
ng/μl in 25 mM NH4HCO3). Following this, 20 µl of 25 mM NH4HCO3 was added and the 
samples were kept on ice for an additional 30 min. Tryptic digestion was subsequently 
performed overnight at 37 °C. The overlaying digestion-solution containing the tryptic 
peptides was collected (extract 1). One additional round of extraction with 20 µl 0.1 % TFA 
was used to extract peptides from the gel plugs and this extract was pooled with extract 1.   
MALDI-ToF(-ToF) analyses was performed on an Ultraflex II mass spectrometer (Bruker 
Daltonics, Bremen, Germany) using dihydroxybenzoic acid (5 mg/ml in 50% ACN/0.1% 
trifluoroacetic acid) as a matrix. The mass spectrometer was used in the positive ion 
reflector ion mode. Spectra were imported in Flexanalysis 3.0 (Bruker) for smoothing, 
baseline subtraction and peak picking. Peak lists were searched against the human IPI 
database (Date of release 23-08-2010, 89486 sequences) using the Mascot search 
algorithm (Mascot 2.2, Matrix Science, London, UK). Trypsin was selected as the enzyme 
and one missed cleavage was allowed. Carbamidomethylcysteine was selected as a fixed 
modification and oxidation of methionine as a variable modification. The MS tolerance 
was set to 50 ppm. 
 
Assays for MPO enzymatic activity The effect of hLF1-11 and the control peptide on 
myeloperoxidase enzymatic activities was assessed using a myeloperoxidase inhibitor 
screening assay kit of Cayman Europe (Tallinn, Estonia). Both the chlorination activity and 
the peroxidation activity were assessed following manufactures’ instructions. Several 
concentrations of hLF1-11 or control peptide were mixed with MPO in the presence of a 
reactivity mixture containing H2O2 and substrate. Both chlorination and peroxidation 
activity were measured at an excitation wavelength of 485 nm and an emission 
wavelength of 535 nm. 
 
Measurement of intracellular reactive oxygen species in human monocytes Intracellular 
ROS production by human monocytes was assayed using the fluorescent probe 2′,7′-
dichlorofluorescein-diacetate (DCFH-DA; Invitrogen). In short, monocytes were incubated 
with hLF1-11, control peptide, no peptide or the myeloperoxidase inhibitor ABAH (Merck 
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Chemicals Ltd. Nottingham, UK) for 1 h at 37˚C. Next, 10 μM DCFH-DA were added to the 
culture and incubated for 20 min at 37˚C in the dark. Thereafter, monocytes were 
stimulated with 100 ng/ml LPS for various intervals. ROS production was measured on a 
FACSCalibur and analysed with BD CellQuest software. Results are expressed as median 
fluorescence intensity (MFI) with interquartile range.  
 
Cell cultures Monocytes were resuspended in RPMI-1640 (Invitrogen, Breda, The 
Netherlands) supplemented with 2 mM L-glutamine (Invitrogen), 100 U/ml penicillin (PAA 
GmbH, Pasching, Germany), 100 mM streptamycin (PAA GmbH), and 10% inactivated fetal 
bovine serum (Invitrogen), further referred to as standard medium. Monocytes were 
cultured at a concentration of 1x10
6
 cells/ml of standard medium at 37˚C and 5% CO2. 
Monocytes were exposed to the different peptides or ABAH immediately at the start of 
the culture and 1 h thereafter these cells were stimulated with 100 ng/ml LPS (Sigma-
Aldrich). About 18–20 h thereafter the supernatants were collected for assessment of 
cytokine levels. To investigate the effects of hLF1-11 on GM-CSF-driven monocyte-
macrophage differentiation, monocytes were incubated in culture medium supplemented 
with GM-CSF (5 ng/ml) in the presence of hLF1-11, control peptide, ABAH or solvent 
control. On day 6, the cells were stimulated with LPS (100 ng/ml) or heat-killed C. albicans 
(1x10
7
 CFU/ml) for 20 h; thereafter supernatants were collected for assessment of the 
production of IL-10 using a commercially available ELISA cytoset. Where indicated, 
macrophages were harvested, washed and resuspended in RPMI for assessment of their 
ability to phagocytose bacteria. For this purpose a stock suspension of pHrodo-labeled 
Staphylococcus aureus (Invitrogen) was prepared according to manufacturers’ protocol. 
pHrodo is a dye that is non-fluorescent at neutral pH and bright red in acidic environments 
(e.g., the phagolysosome). Equal volumes of macrophages (1x10
6
/ml of medium) and 5-
times pre-diluted pHrodo-labeled S. aureus stock were mixed and then incubated for 
several intervals at 37˚C, or as a control experiment, at 4˚C. Thereafter, pHrodo 
fluorescence by the macrophages was assessed on a FACSCalibur. Results are expressed as 
the percentage of pHrodo-positive macrophages. 
 
Statistical analyses Friedman followed by Dunn’s multiple comparisons post-hoc test or, 
where indicated, Wilcoxon’s test was used to determine the differences between the 
results for hLF1-11-differentiated, ABAH and control (peptide-differentiated) DCs. Data are 
expressed as median and range. Two sided p-values are reported and the level of 
significance was set at p<0.05. 
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Results 
Binding and uptake of hLF1-11 by human monocytes To find out whether hLF1-11 binds 
to and enters cells we incubated monocytes for various time intervals with biotin-hLF1-11 
and assessed fluorescence of these cells by FACS. Results revealed that hLF1-11 binds 
rapidly to monocytes (Fig. 1A) after which the peptide either detaches or enters the cells 
as the fluorescence decreased over time. To discriminate between these two possibilities, 
monocytes were incubated with hLF1-11-biotin for 15 or 60 min at 37°C or 4°C and 
analyzed using fluorescence microscopy. Results showed that hLF1-11-biotin mainly 
associated with the cell membrane of monocytes incubated with hLF1-11-biotin for 15 min 
(data not shown). After 60 min of incubation, hLF1-11-biotin was also localized 
intracellular (Fig. 1B). Similar results were obtained after incubation at 4°C (Fig. 1C), 
suggesting that hLF1-11 passively enters the cells.  
 
Fig. 1 Binding and uptake of hLF1-11 
by human monocytes To assess 
whether hLF1-11 binds to monocytes, 
human monocytes were incubated 
with biotinylated hLF1-11 for several 
intervals. Thereafter, the cells were 
washed, incubated with streptavidin-
PE for 15 min, washed again and then 
the mean fluorescence intensity (MFI) 
of the monocytes was assessed by 
flow cytometry. Results are expressed 
as boxes and whiskers, boxes 
represent medians and second and 
third interquartiles, whiskers 
represent range within 4 independent 
experiments (A). To find out if hLF1-11 
enters human monocytes or detaches 
from the cells, monocytes were 
incubated with biotinylated hLF1-11 
for 60 min at 37˚C (B) and 4˚C (C), 
fixed with 4% paraformaldehyde, 
permeabilized with 90% methanol, and washed with PBS. Thereafter, the presence of this peptide in cells was 
visualized with Alexa 647-labeled streptavidin (left), the cells were stained with rhodamine-conjugated wheat 
germ agglutinin (WGA, a membrane marker; second left) and DAPI (to stain the nucleus; second right). 
Thereafter, cells were analyzed on a Marianas digital imaging microscope using a 63x oil-immersion objective and 
a Z-stepsize of 0.25 μm, scale: 10 pixels is 1 μm. An overlay of the three images is displayed in the right panel.  
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Identification of the intracellular target of hLF1-11 Next, we sought to isolate the 
intracellular binding partner(s) of hLF1-11, using monocyte lysates and hLF1-11-coated 
columns. After elution with PBS, we separated the bound proteins by SDS-PAGE. Results 
revealed that a single protein with an apparent molecular weight of approximately 110 
kDa had bound to hLF1-11, whereas no protein was detected within the eluate from the 
control peptide-coated column (Fig. 2, insert). The hLF1-11 binding protein was subjected 
to in-gel tryptic digestion and identified as human myeloperoxidase (MPO) using MALDI-
ToF mass spectrometry followed by database searching (Fig. 2). MPO was identified as the 
principal binding partner of hLF1-11 in three independent experiments. 
 
 
 
Fig. 2 Identification of myeloperoxidase as the principal binding partner of hLF1-11 in monocytes To investi-
gate the intracellular binding partner of hLF1-11, biotinylated hLF1-11- and control peptide (CP)-coupled 
streptavidin columns were used in pull-down assays using monocytic cell lysates as input. After washing, bound 
proteins were eluted and subjected to SDS-PAGE under non-reducing conditions. hLF1-11 specifically bound to a 
protein with an apparent molecular weight of 110 kDa (insert). Tryptic digestion followed by MALDI-ToF MS 
analysis and database searches using the Mascot search algorithm showed that this protein corresponds to 
human myeloperoxidase (MPO, IPI00236554, Mascot score 241). Fragments indicated with an asterix correspond 
to matched tryptic peptides of MPO and are shown in bold within the primary structure of MPO (total sequence 
coverage 35%). 
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Effects of hLF1-11 on the enzymatic activities of human myeloperoxidase To investigate 
whether hLF1-11 affects the enzymatic activities of myeloperoxidase, we determined both 
the peroxidation as well as the chlorination activity of myeloperoxidase in the presence of 
hLF1-11 or the control peptide. hLF1-11 inhibited both activities of myeloperoxidase in a 
dose dependent fashion (Fig. 3A and B). The control peptide was not able to inhibit 
peroxidation activity of myeloperoxidase. Surprisingly, the control peptide did inhibit the 
chlorination activity of myeloperoxidase although approximately 25 times less efficiently 
than hLF1-11.  
 
Effect of hLF1-11 on the production of reactive oxygen species by monocytes in response 
to LPS Since myeloperoxidase enforces the formation of ROS after initiation of the 
oxidative burst we considered the possibility that binding of hLF1-11 to myeloperoxidase 
and its subsequent loss of enzymatic activity would result in reduced ROS production by 
human monocytes. Therefore, we measured the ROS production by hLF1-11-or control 
peptide-treated monocytes in response to LPS. Results showed that hLF1-11-treated 
monocytes produced significantly less ROS after LPS than control (peptide-treated) 
monocytes (Fig. 4A). In addition, ABAH, a known inhibitor of the enzymatic activities of 
MPO reduced the LPS-stimulated ROS production by human monocytes (Fig. 4B), 
indicating that inhibition of MPO by ABAH mimics the effect of hLF1-11 on ROS 
production. 
Fig. 3 Myeloperoxidase activity in the presence of hLF1-11 and control peptide The peroxidation (A) and the 
chlorination (B) activity by myeloperoxidase were assessed in the presence of several concentrations of hLF1-11 
(dark gray) or control peptide (light gray). The peroxidation assay utilizes the reaction between hydrogen 
peroxide and ADHP (10-acetyl-3,7-dihydroxyphenoxazine), which produces the highly fluorescent compound 
resorufin. The chlorination assay utilizes the non-fluorescent 2-[6-(4-aminophenoxy)-3-oxo-3H-xanthen-9-yl]-
benzoic acid (APF), which is selectively cleaved by hypochlorite (-OCl) to yield the highly fluorescent compound 
fluorescein. The results of a representative experiment (out of three independent experiments) are displayed.  
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Fig. 4 Intracellular ROS production by hLF1-11- or control peptide-incubated monocytes in response to LPS 
Monocytes were cultured in the presence of hLF1-11 (100 μg/ml, dark gray), control peptide (100 μg/ml, light 
gray) or no peptide (open) for 1 h and then labeled with DCFH-DA. Next, the labeled monocytes were stimulated 
with LPS (100 ng/ml) and the MFI was assessed directly by flow cytometry and after 30, 60 and 90 min as a 
measure of ROS production. Data are expressed as boxes and whiskers, boxes represent medians and second and 
third interquartiles, whiskers represent range within experiments with 8 different donors (A). In addition, 
monocytes were cultured in the presence of ABAH (100 μM) or hLF1-11 (100 μg/ml which represents 72 μM) and 
then labeled with DCFH-DA. Next, the labeled monocytes were stimulated with LPS for 60 min. Thereafter, 
intracellular ROS production was assessed by flow cytometry. Data are expressed as boxes and whiskers, boxes 
represent medians and second and third interquartiles, whiskers represent range within experiments with 7 
different donors (B). *, p<0.05 as compared to control monocytes and control peptide-incubated monocytes. 
Wilcoxon’s test was used to determine the significance shown in Fig. 4B 
 
Comparison of the effects of the myeloperoxidase inhibitor ABAH and hLF1-11 on LPS-
induced IL-10 production by monocytes and on monocyte-macrophage differentiation 
To investigate whether the inhibition of myeloperoxidase by hLF1-11 is sufficient for the 
immunomodulatory effects of hLF1-11 we compared the effects of ABAH and hLF1-11 on 
IL-10 production by LPS-stimulated human monocytes (8) and on monocyte-macrophage 
differentiation (9). Results showed that ABAH-incubated and hLF1-11-incubated 
monocytes produced significantly higher levels of IL-10 upon stimulation with LPS than 
control monocytes. The effect of 100 μM ABAH on LPS-induced IL-10 production by 
human monocytes was similar to that of 72 μM hLF1-11 (Fig. 5A). Furthermore, 
macrophages differentiated by GM-CSF in the presence of ABAH displayed significantly 
enhanced levels of IL-10 in response to LPS similar to macrophages differentiated in the 
presence of hLF1-11 (Fig. 5B). The percentage of S. aureus-phagocytosing ABAH-
differentiated macrophages was significantly enhanced in comparison to saline-incubated 
cells but not to DMSO-incubated cells (data not shown).  
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Fig. 5 Comparison of activities of ABAH- and hLF1-
11-incubated monocytes and GM-CSF-
differentiated macrophages Monocytes were 
cultured in the presence of ABAH (100 μM), hLF1-11 
(72 μM) or solvent control for 1 h and then 
stimulated for 24 h with LPS (100 ng/ml). Thereafter, 
supernatants were collected and assessed for IL-10 
production (A). In addition, monocytes were 
cultured with rhGM-CSF in the presence of ABAH 
(100 μM) or hLF1-11 (72 μM) for 7 days. Thereafter, 
IL-10 production by the resulting macrophages after 
LPS stimulation was assessed by ELISA (B) Data are 
expressed as boxes and whiskers, boxes represent 
medians and second and third interquartiles, 
whiskers represent range within experiments with 6-
9 different donors. *, p<0.05 as compared to control 
monocytes or macrophages. 
 
 
 
 
 
 
 
 
 
 
 
 
Identification of amino acids within hLF1-11 primarily responsible for hLF1-11 activity To 
determine which amino acid(s) in hLF1-11 is (are) essential for its MPO-inhibiting activity, 
we assessed for a set of peptides with a single amino acid substitution to alanine, the 
effect on IL-10 production by LPS-stimulated monocytes and the chlorination activity of 
MPO. Results revealed that the cysteine at position 10 was the most important amino acid 
for the enhanced IL-10 production by hLF1-11-incubated monocytes upon LPS stimulation 
(Fig. 6A). In agreement, this amino acid was found to be most important for the hLF1-11-
mediated inhibition of the chlorinating activity of MPO (Fig. 6B).  
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Fig. 6 Effects of hLF1-11 and single alanine substituted analogs on myeloperoxidase activity and on IL-10 
production by monocytes in response to LPS Human monocytes were incubated with hLF1-11 or derived 
peptides in which one amino acid within the hLF1-11 sequence was replaced by an alanine (all 100 μg/ml) for 1 h, 
thereafter the monocytes were stimulated with LPS (100 ng/ml) for 24 h after which the supernatants were 
collected for assessment of the IL-10 levels. Data are expressed as medians and SEM of experiments with 8 
different donors (A). In addition, hLF1-11 and derived peptides in which one amino acid is replaced by an alanine 
(all at a concentration of 8 μg/ml) were compared for their effect on the chlorination activity of myeloperoxidase 
using the myeloperoxidase inhibitor screening kit according manufacturers’ instructions. Data are expressed as 
medians and SEM of 3 independent experiments (B). *, p<0.05 as compared to hLF1-11 as determined by 
Wilcoxon’s statistical test. 
 
Discussion 
Recently, we reported that hLF1-11 has an immunomodulatory activity on monocytes, by 
modifying the LPS-induced inflammatory response and by directing the GM-CSF-driven 
monocyte differentiation toward macrophages displaying enhanced antimicrobial 
activities (15,16). The present findings show that hLF1-11 exerts these effects by specific 
inhibition of MPO activity in monocytes. This conclusion is based on the following 
observations. First, hLF1-11 binds to and is subsequently internalized by monocytes. 
Second, hLF1-11, but not a control peptide, bound to a single protein in lysates of 
monocyte cells, which was subsequently identified as myeloperoxidase. Third, hLF1-11 
inhibits the peroxidation and chlorination activity of human myeloperoxidase. Lastly, the 
myeloperoxidase inhibitor ABAH mimicked the modulatory effects of hLF1-11 on LPS-
induced IL-10 release and reactive oxygen species (ROS) production by monocytes. In 
addition, ABAH mimicked hLF1-11 in the LPS-induced enhanced release of IL-10 by 
macrophages when present during cell differentiation. ABAH also mimicked hLF1-11 in the 
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enhanced phagocytosis of S. aureus by these cells, although the effect of ABAH on 
monocyte-macrophage differentiation seems to be less potent than hLF1-11. Taken 
together, these observations indicate that myeloperoxidase is the prime target of hLF1-11 
regarding mediation of the assessed immunomodulatory activities. Other findings of this 
study pertain to the specific amino acid(s) in hLF1-11 that are pivotal to its effects. The 
alanine scanning experiments revealed that cysteine at position 10 is very important for 
the ability of hLF1-11 to inhibit myeloperoxidase activity. We suggest that hLF1-11 
comprises two regions that are important for its activity, i.e., arginines that most likely 
mediate cell binding and entry (17-20), and cysteine that mediates the inhibition of 
myeloperoxidase enzymatic activity. As four arginines are present in the hLF1-11 peptide, 
it was not surprising that substituting only one of these arginines in hLF1-11 was without 
effect. Since the control peptide lacks two of the four arginines and the cysteine as 
compared to hLF1-11, it most likely lacks the ability to internalize and inhibit MPO activity. 
This would explain why the control peptide did not affect the inflammatory responses of 
monocytes (15), GM-CSF monocyte-macrophage differentiation (16) and why it is not 
active against infections in mice (12). 
The present findings show that myeloperoxidase is a negative regulator of the production 
of IL-10 (and some other cytokines) by LPS-stimulated monocytes. In agreement with this 
finding, others have reported that neutrophils from myeloperoxidase deficient mice 
express higher levels of IL-10 in response to LPS than cells isolated from wild-type mice 
(21). Furthermore, we previously described that hLF1-11 enhanced the mRNA expression 
of IL-10 as well as the NF-κB activation and translocation in LPS-stimulated monocytes 
(15). Apparently, myeloperoxidase negatively affects (a) signal transduction pathway(s) 
regulating the production of IL-10 and possibly more cytokines, because ABAH, an 
inhibitor of myeloperoxidase mimicked these actions of hLF1-11 on IL-6, IL-12p40 and 
TNF-α production by these monocytes (data not shown). Several studies have shown the 
involvement of myeloperoxidase and its products in multiple intracellular signaling 
pathways (22,23). Still, it remains unclear which pathway is related to the effects observed 
in this study and how ROS derived from myeloperoxidase are involved in this 
phenomenon. Clearly, these aspects warrant further investigation.  
Interestingly, there are a few clinical presentations which support the notion that 
myeloperoxidase might be involved as a negative regulator of cytokine production and 
immune responses. Patients with Wegener’s granulomatosis disease, for example, express 
high levels of anti-neutrophil cytoplasmic autoantibodies (ANCA) with specificity for 
myeloperoxidase. It has been shown that the presence of these autoantibodies enhance 
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the phagocytic activitiy, IL-8 production and glucose uptake by neutrophils (24). Also, 
human monocytes that were incubated with IgG from patients with ANCA-positive 
Wegener’s granulomatosis disease, displayed enhanced expression of CD14 and CD18 on 
their cell-surface (25).  
The identification of hLF1-11 as an inhibitor of myeloperoxidase activity raises the 
question about its possible therapeutic potential against pathologies in which 
myeloperoxidase may play an unfavorable role (26). In this context, Liu et al have shown 
that rabbits pre-treated with ABAH and subsequently submitted to myocardial ischaemia 
and reperfusion displayed significantly reduced cardiac caspase-3 activity, suggesting that 
myeloperoxidase is a significant contributor to post-ischaemic cardiomyocyte apoptosis 
(27). Consistent with this notion, myeloperoxidase deficiency appeared to be associated 
with lower incidence of cardiovascular heart diseases (28).  
In conclusion, hLF1-11 modulates the inflammatory response of monocytes after exposure 
to inflammatory stimuli and modulates the GM-CSF-driven monocyte-macrophage 
differentiation by inhibiting myeloperoxidase enzymatic activity. Given preliminary reports 
on the safety of hLF1-11 in human healthy volunteers (29), the present findings merit 
research regarding the further development of hLF1-11 as possible antimicrobial drug and 
therapeutic agent in disease states in which myeloperoxidase plays an unfavourable role.  
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Summary and general discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
The availability of successful anti-infective drugs has taken away much of the prior threat 
of infectious diseases in society in the last century. Overconfidence in the 
accomplishments of antibiotics ‘the miracle drugs’,  however, has now been replaced by 
apprehension, as antibiotic usage in the human and veterinary field has boomed out of 
control and boomerangs back at us with the emergence of multi-drug resistant pathogens. 
Bacteria have developed resistance to most of the existing drugs, making infections 
difficult and sometimes even impossible to treat. A multi-facetted approach will be 
needed to constrain the impact of antibiotic resistance on treatment options in infectious 
diseases. Efforts should include proper education and appropriate antibiotic usage, to 
both physicians and patients and applying strict infection control measures to prevent 
transmission. Furthermore, alternatives to antibiotic usage in veterinary practice and 
agriculture should be identified. In addition to all these measures, it is recognized that 
there is an urgent need for research into and development of new anti-infective drugs as 
the pharmaceutical pipeline of new types of antibiotics has dried up and new anti-
infective drugs will not become available for some time. Infectious diseases societies have 
taken up these issues and advocate major investments in research and development of 
new antibiotics. The development of new antimicrobial agents has mainly focused on 
variants of current anti-infectives. A recognized disadvantage of this approach is the 
experience that sooner or later, these new drugs suffer the same limitations as the 
parental drugs, i.e., in the end emergence of multi-drug resistant pathogens. New long-
lasting anti-infective agents are yet to be successfully developed and therefore research 
into alternative agents is essential (1). Antimicrobial peptides are naturally occurring 
antimicrobial agents of all living beings and these peptides have been pointed out as 
potential candidates for drug development (2-4).  
 
In the past, research into these peptides has focused on their antimicrobial activity. Soon 
it was recognized that some of these peptides, further referred to as host defense 
peptides, have the potential to strengthen or modulate the hosts’ immune response 
resulting in an enhanced resolution of infection (5,6). As host defense peptides act 
indirectly, via the very broad armamentarium of the hosts’ immune systems, development 
of drug-resistance against such peptides is unlikely. This makes host defense peptides a 
promising alternative to current anti-infective agents. Among these peptides, one 
interesting candidate comprises the first eleven amino acids of the N-terminus of human 
lactoferrin therefore named hLF1-11. This peptide appears active against a variety of
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(multi-drug resistant) pathogens (7-9). However, in vitro the antimicrobial activity of this 
peptide is dependent on factors in its environment, such as salt concentration, e.g. the 
peptide is highly active against pathogens in low (10 mM) salt concentrations, but hardly 
active at physiological salt concentrations. Given the natural occurrence of lactoferrin and 
its degradation product lactoferricin, we hypothesized that in addition to its direct 
antimicrobial effects the hLF1-11 peptide displays immunomodulatory activities. Since the 
time-span in the in vivo assays was usually set at 48 h maximum, we focused on possible 
effects of hLF1-11 on cells of the innate immune system, more specifically on monocytes 
and cells derived thereof such as macrophages and dendritic cells. 
 
Effects of hLF1-11 on murine and human monocytes The antimicrobial activity of hLF1-11 
was established in mice first. Therefore, we focused our attention on murine cells and first 
compared the lipopolysaccharide (LPS)-induced cytokine production of hLF1-11-incubated 
murine monocytes to that of control monocytes. The findings showed that hLF1-11 
enhanced the production of IL-6, IL-10, IL-1β and RANTES by monocytes in response to the 
immunoreactive component of the Gram-negative bacterial cell wall, LPS (chapter 2). 
After thus establishing that hLF1-11 has the ability to modulate murine monocyte activity, 
we next investigated the effect of hLF1-11 on human cells, for two reasons. First, we strive 
to reduce the number of animal experiments if an alternative approach to the problem is 
possible, e.g., human blood-derived cells. Secondly, since the ultimate goal would be to 
assess the feasibility and the development of hLF1-11 as potential anti-infective in 
humans, next we focused on the interaction of hLF1-11 with human immune cells. We 
observed that hLF1-11 enhanced the production of almost all cytokines tested and of 
various chemokines by monocytes in response to LPS (chapter 2). As the N-terminus of 
lactoferrin is the major binding site in this molecule for a microbial structure like LPS and 
lipid A (10), we next excluded the possibility that binding of hLF1-11 to LPS was 
responsible for the enhanced cytokine production by hLF1-11-monocytes. In addition, we 
found that in the absence of microbial stimuli hLF1-11 did not exert any action on 
monocytes besides reducing the production of some of the chemokines released by these 
cells. Taken together, these findings indicate that the actions of hLF1-11 are observed 
mainly after exposure of the hLF1-11-incubated cells to a second stimulus. We next 
established that the enhancement of the inflammatory response of monocytes by hLF1-11 
was not limited to LPS and also included other microbial structures, like diphosphoryl lipid 
A, flagellin and CL087. These microbial components are recognized by human monocytes 
and macrophages through specific cell-surface receptors, collectively designated toll-like 
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receptors (TLR), respectively TLR4, TLR5 and TLR7/8. Interestingly, hLF1-11 hardly affected 
the inflammatory response of human monocytes upon stimulation with lipoteichoic acid 
(LTA) or PAM2CSK4, both TLR2 ligands. This was confirmed by measuring downstream 
activation of the transcription factor NF-kB and mRNA production in response to these 
toll-like receptor ligands (chapter 2). Based on our observation that hLF1-11 inhibits 
myeloperoxidase (MPO) (chapter 6) in human monocytes we can offer an explanation for 
the lack of effect of hLF1-11 on TLR2-mediated activation of monocytes. In short, 
activation of monocytes via the various toll-like receptors triggers an oxidative burst and 
induces the release of cytokines/chemokines. However, TLR2 activation by LTA and 
PAM2CSK4 induced a weak cytokine response by human monocytes (chapter 2). It is 
hypothesized that the oxidative burst induced by TLR2 ligands is only weak and therefore 
the role of myeloperoxidase may be small. In such cases, inhibition of myeloperoxidase by 
hLF1-11 might not have enough consequences to result in differences on cytokine level. 
Unfortunately it is not known at what level of the TLR-signal transduction route toward 
cytokine production myeloperoxidase is involved.  
 
Effects of hLF1-11 on monocytes are mediated by inhibition of myeloperoxidase activity 
After establishing the effect of hLF1-11 on human monocytes, we were intrigued to 
identify the target of hLF1-11 on/in monocytes that mediates these effects. We first 
investigated whether hLF1-11 binds to monocytes. Results showed that hLF1-11 binds to 
monocytes within minutes and that binding is followed by internalization within 60 min 
after addition of the peptide. Next, we identified myeloperoxidase as the intracellular 
binding target of hLF1-11 (chapter 6). In addition, we observed that hLF1-11 has the ability 
to inhibit the enzymatic activity of myeloperoxidase. By use of ABAH, a specific inhibitor of 
myeloperoxidase activity, we could establish that the inhibition of myeloperoxidase can 
result in immunomodulating effects, e.g. altered cytokine production, that are comparable 
to those induced by hLF1-11. The involvement of myeloperoxidase in signal transduction 
routes leading to cytokine production has not been described previously. There are, 
however, reports describing the involvement of reactive oxygen species in signal 
transduction pathways leading to cytokine production. In these publications, enhanced 
levels of reactive oxygen species (ROS) are necessary to induce cytokine production 
(11,12). However, based on our data myeloperoxidase appears to be a negative regulator 
of the production of some cytokines (e.g. IL-6 and IL-10) and chemokines; inhibition of 
myeloperoxidase enhances the LPS-stimulated cytokine production by monocytes. Either, 
myeloperoxidase shifts the balance of reactive oxygen species into products less active in 
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intracellular signaling. Or, MPO is - independently of its ROS-producing activities - involved 
in a different signaling pathway that leads to cytokine production. Clearly the intracellular 
pathway involving myeloperoxidase needs to be further deciphered. Interestingly, there 
are a few diseases involving myeloperoxidase that seem to already hint to its participation 
in cytokine production and other immune activities. For instance, Wegener’s 
granulomatosis disease comprises the production of anti-neutrophil cytoplasmic 
autoantibodies (ANCA) with specificity for myeloperoxidase. It has been shown that ANCA 
enhance phagocytosis, IL-8 production and glucose uptake by neutrophils (13). Also, 
human monocytes that were incubated with IgG from patients with ANCA-positive, active 
Wegener’s granulomatosis, displayed enhanced expression of CD14 and CD18 on their 
cell-surface (14).  
To establish which amino acids are essential for inhibition of myeloperoxidase enzyme 
activity we investigated the enzymatic activity of myeloperoxidase in the presence of a set 
of alanine-substituted hLF1-11 peptides, i.e. peptides that had one (different) amino acid 
replaced by an alanine. We thus established that the cysteine in the sequence of hLF1-11 
is essential for the inhibition of myeloperoxidase activity. Consistent with this notion, the 
same amino acid was found to be important for enhanced IL-10 induction by hLF1-11-
incubated human monocytes in response to LPS (chapter 6). As arginine-rich peptides 
easily penetrate cellular membranes (15-17), we suggest that the four arginines in hLF1-11 
are necessary for cell penetration. Thus, hLF1-11 has two important regions: the arginine-
rich penetration site and the cysteine that is responsible for the inhibition of 
myeloperoxidase activity. The results from this study can be used to facilitate the design 
of antimicrobial peptides with the optimal qualities for inhibition of myeloperoxidase.  
 
Modulation of the differentiation of monocytes toward macrophages and dendritic cells 
by hLF1-11 
After thus establishing an action of hLF1-11 on monocytes, we next hypothesized how this 
would affect the differentiation of monocytes into macrophages or dendritic cells. These 
antigen-presenting cells play a major role in the linking of the innate to the adaptive 
components of the immune system. We studied whether monocytes that differentiated in 
the presence of hLF1-11 in vitro displayed a different phenotype and if so, whether such 
an altered phenotype would be potentially beneficial to help clear infection. Results 
revealed effects of hLF1-11 on GM-CSF-driven macrophages differentiation but not on M-
CSF-driven macrophage differentiation (chapter 3). Of interest, GM-CSF was previously 
reported to be involved in the regulation and enhancement of myeloperoxidase activity in 
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monocytes and macrophages, while M-CSF was not (18). In view of the above described 
interaction of hLF1-11 with myeloperoxidase, this might help to explain why the action of 
hLF1-11 was limited to GM-CSF driven macrophages. Moreover, the presence of hLF1-11 
during GM-CSF-driven monocyte-macrophage differentiation resulted in macrophages 
that displayed enhanced IL-10 production in response to several microbial stimuli and 
were more responsive toward these microbial stimuli than unstimulated control cells. 
Also, expression of pathogen recognition receptors like Dectin-1, the mannose receptor 
and others by hLF1-11-differentiated macrophages as well as the phagocytosis of both C. 
albicans and S. aureus by these cells were enhanced as compared to control cells. 
Strikingly, when we incubated monocytes for 60 min with hLF1-11, washed the peptide 
away and then induced differentiation toward macrophages for 7 days, these 
macrophages had a similar phenotype as macrophages that differentiated in the 
continuous presence of hLF1-11 (chapter 3). Taken together, these findings indicate that 
hLF1-11 can prime monocytes in such a manner that upon encountering microbial 
components, these cells differentiate into macrophages with a phenotype that appears to 
be beneficial for resolution of infection (19).  
As hLF1-11 was able to prime these monocytes, we also investigated the effect of this 
peptide on monocyte-dendritic cell (DC) differentiation. Matured hLF1-11-differentiated 
dendritic cells displayed enhanced production of IL-10 in response to heat-killed C. 
albicans. In addition, IL-6 production by these cells was enhanced in response to this 
yeast. These dendritic cells also displayed enhanced expression of Dectin-1, and 
phagocytosis of C. albicans and ROS production in response to C. albicans was also 
elevated (chapter 4). It was noted that hLF1-11-macrophages displayed enhanced 
activities to several pathogens, while for hLF1-11-dendritic cells this change was restricted 
to C. albicans. What could be the explanation for this difference? At present, this is not 
clear. One possible explanation touched upon above could be that GM-CSF is involved in 
regulation and enhancement of myeloperoxidase during monocyte-macrophage 
differentiation (18).  Roy et al reported that monocytes incubated with GM-CSF and IL-4 or 
with IL-4 alone, display diminished myeloperoxidase expression as compared to freshly 
isolated monocytes (20). As dendritic cells are obtained in vitro by incubation of 
monocytes with both GM-CSF and IL-4, it could be that IL-4 diminished the 
myeloperoxidase enhancement, thus preventing some of the actions of hLF1-11. Some 
properties of hLF1-11-differentiated dendritic cells and macrophages might therefore be 
overlapping between these cell types while others are not.  
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Differential effects of hLF1-11 and LL-37 on the differentiation of monocytes toward 
macrophages and dendritic cells  
When studying the effects of hLF1-11 on monocyte-macrophage differentiation, we 
considered the possibility that another antimicrobial peptide i.e. LL-37, similarly affects 
monocyte-macrophage differentiation. LL-37 also modulates monocyte-macrophage 
differentiation, although incubation of the cells with this peptide resulted in a completely 
different macrophage subset as obtained after differentiation in the presence of hLF1-11. 
While hLF1-11 modulates GM-CSF-driven monocyte-macrophage differentiation, LL-37 
modulates M-CSF-driven monocyte-macrophage differentiation resulting in macrophages 
that displayed striking similarities to the GM-CSF-macrophages (chapter 4). As M-CSF-
macrophages display an anti-inflammatory phenotype and GM-CSF-macrophages display a 
proinflammatory phenotype, LL-37 is thus able to completely redirect the phenotype of 
M-CSF-differentiated macrophages toward a proinflammatory phenotype. LL-37 is able to 
induce these effects during differentiation and also upon incubation with already 
differentiated macrophages.   
Investigations on dendritic cell differentiation revealed that in addition to enhanced 
antimicrobial activities against C. albicans, hLF1-11-differentiated dendritic cells were able 
to induce Th17 polarization upon co-culture with CD4+ T cells (chapter 5). T cells co-
cultured with hLF1-11-differentiated dendritic cells produced enhanced levels of IL-17 and 
diminished Th1 polarization as indicated by reduced levels of IFN-γ. IL-17 is associated 
with an enhanced anti-fungal and anti-bacterial response (21,22). In addition, IL-17 is 
involved in the host defense against extracellular pathogens by mediating the recruitment 
of neutrophils and macrophages to the infected site. Also, IL-17 can induce the production 
of cytokines/chemokines and antimicrobial peptides by mucosal epithelial cells (23). 
Others have reported that LL-37 and β-defensins (24) can also modulate monocyte 
differentiation toward dendritic cells. For example, when CD4+ T cells were co-cultured 
with LL-37-differentiated dendritic cells these T cells produced enhanced levels of IFN-γ, 
thereby inducing Th1 polarization (25). Th1 cells drive the protective immune response 
against intracellular pathogens such as Mycobacterium tuberculosis. These data indicate 
that antimicrobial peptides can modulate immune processes, thereby ‘fine tuning’ the 
immune response upon activation. This suggests a possible therapeutic opportunity for 
employment of antimicrobial peptides, i.e., to (re)direct immune responses to enhance 
resolution of infection. Figure 1 has depicted the effects that are described in this thesis of 
hLF1-11 on human immune cells.  
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Fig. 1 Simplified representation of the effects of hLF1-11 on the major characteristics of monocytes and 
monocyte-derived cells in vitro When monocytes are incubated with hLF1-11, this peptide is internalized where 
it binds to and inactivates the enzymatic activities of myeloperoxidase. The hLF1-11-incubated monocytes 
produce upon activation reduced levels of reactive oxygen species and enhanced levels of cytokines and 
chemokines as compared to control monocytes. Monocytes differentiated in the presence of both GM-CSF and 
hLF1-11 become macrophages that display enhanced pathogen recognition receptor expression and 
phagocytosis and killing of S. aureus and C. albicans as compared to control (peptide-differentiated) 
macrophages. In addition, in response LPS, LTA and heat-killed C. albicans these macrophages produce enhanced 
levels of IL-10 as compared to control macrophages. Monocytes differentiated in the presence of GM-CSF, IL-4 
and hLF1-11, become immature dendritic cells that display enhanced expression of Dectin-1 and enhanced► 
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►phagocytosis of C. albicans. These hLF1-11-differentiated dendritic cells also produce enhanced levels of 
reactive oxygen species in response to this pathogen as compared to control (peptide-differentiated) immature 
dendritic cells. Moreover, upon maturation hLF1-11-differentiated dendritic cells produce enhanced levels of IL-
10 and are able to induce Th17 polarization upon co-culture with CD4+ T cells. These T cells produce enhanced 
amounts of IL-17 and reduced levels of IFN-γ. Represented in green: enhancement, red: reduction, black: 
untested. 
 
Future research 
The research laid down in this thesis concerns in vitro experiments only. It should be 
realized that this is an important limitation because extrapolation of the present findings 
to the in vivo situation clearly is not possible without further studies. Thus, future research 
in animal models should shed further light on the contribution of the immunomodulatory 
effect of hLF1-11 to its antimicrobial effects previously described in vitro. For instance, 
experiments in myeloperoxidase knock-out mice could be instrumental in investigating 
whether myeloperoxidase is the main intracellular target mediating the actions of hLF1-11 
in monocytes and monocyte-macrophage differentiation. In addition, cytokine and 
chemokine responses could be measured in the blood of these mice. An alternative 
approach would be to assess that action of hLF1-11 on monocytes of individuals with 
myeloperoxidase-deficiency or monocytes in which myeloperoxidase is silenced.  Recently, 
it has been reported that enhanced levels of IL-10 were present in infected mice that were 
treated with hLF1-11 (7). Moreover, based on our in vitro findings, it is expected that in 
mice that are depleted of monocytes the anti-infective activity of hLF1-11 is reduced (26). 
In addition, a longer in vivo infection set-up could be instrumental in investigating the 
subsequent involvement of components of the adaptive immune system that hLF1-11 is 
known to modulate in vitro. Again, it should be realized that our experiments mainly 
concerned human blood-derived mononuclear cells, and findings may not necessarily be 
identical in the murine model.  
As safety of hLF1-11 in humans has been established (27), the goal of the studies in 
patients should be to obtain proof of principle for the usefulness of hLF1-11 as an anti-
infective agent in a human patient population. Besides experiments that would further 
elucidate the mechanism of action of hLF1-11, one could also research the involvement of 
myeloperoxidase in signal transduction routes that lead to cytokine production. Currently, 
it is not known whether these effects are mediated through the reactive oxygen species 
production route or that myeloperoxidase displays an additional mechanism of action by 
being a component of another signaling pathway. 
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Therapeutical applications 
As a future perspective, we suggest that antimicrobial/host defense peptides like hLF1-11 
and LL-37 might prove useful in several distinct therapeutic applications. Obviously such 
applications are at the end of a long road of development still to come, and some general 
comments and thoughts on possible applications should suffice here. First, LL-37, as well 
as hLF1-11, could act as a single anti-infective agent; either to prevent infection when 
used in a prophylactic approach or to treat infection. As LL-37 and hLF1-11 displayed 
differential effects on the immune system (chapters 3-5), several infectious diseases might 
be treated with different antimicrobial/host defense peptides. For example, 
transplantation recipients are susceptible for infections and need an alternative when 
current antibiotics can no longer perform adequately. hLF1-11 could be involved in an 
alternative treatment for these infections. Host defense peptides like LL-37 and hLF1-11 
can also be applied locally, for example like Stallmann et al. have shown (28). They used 
hLF1-11 as a prophylactic agent in treatment of osteomyelitis (29-31). hLF1-11 in cement 
was injected into the femoral canal of rabbits earlier infected with MRSA. The continuous 
release of the peptide by the cement significantly reduced the bacterial load as compared 
to the control group. In over 75% of the hLF1-11 treated rabbits no growth at all of 
bacteria was detected (32). Also, hLF1-11 could be used in combination with conventional 
antibiotics making use of a synergistic antimicrobial activity. Lupetti et al showed in vitro 
that hLF1-11 at non-candidacidal concentrations exerted synergistical effects with 
fluconazole, results showed this combination to be highly effective against fluconazole-
resistant C. albicans (33). hLF1-11 was necessary to initiate this effect as the observed 
synergistic effect was only induced when C. albicans were pre-incubated with (non-
candidacidal concentrations of) hLF1-11 followed by exposure to fluconazole in 
comparison to no killing effect when the experiment was performed in the opposite order. 
Second, an alternative approach would be to focus on ways to induce endogenous 
antimicrobial peptide synthesis, thereby modulating the host response, and such an 
approach could be employed to treat infections of any kind (34). This could also be 
induced locally resulting in specific targeting of the infection. For instance, experiments 
with butyrate -an inducer of endogenous LL-37 synthesis- have shown that it promoted 
elimination of Shigella (35). Moreover, it is known that vitamin D metabolites regulate the 
expression of LL-37. Vitamin D insufficiency is common still in both industrialized and 
developing nations (36). Recent studies have shown that vitamin D insufficiency is 
associated with a somewhat higher risk of active tuberculosis (37-39). Of note, LL-37 
shows activity against M. tuberculosis and therefore induction of LL-37 transcription by 
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vitamin D could possibly be helpful by treatment of mycobacterial infections (40-42). 
Obviously, the safety and consequences of administration of butyrate and vitamin D 
should be further investigated before application in humans (34). Moreover, additional 
compounds that induce endogenous production of antimicrobial/host defense peptides 
need to be identified, but these preliminary results already seem to indicate the potency 
of this application. Third, as hLF1-11 is a potent inhibitor of myeloperoxidase one can 
think of applications of hLF1-11 as an agent for diseases in which myeloperoxidase plays 
an unfavourable role. Myeloperoxidase has emerged as a potential participant in the 
promotion and/or propagation of atherosclerosis (43). Liu et al showed that pre-
treatment of rabbits that were subjected to myocardial ischaemia and reperfusion with 
ABAH significantly reduced cardiac caspase-3 activity, providing direct evidence that 
myeloperoxidase is a significant contributor to post-ischaemic cardiomyocyte apoptosis 
(44). These results can have implications as they suggest therapeutic interventions, for 
example hLF1-11 may (in part) exert cardioprotective effects by inhibition of 
myeloperoxidase. Lastly, antimicrobial/host defense peptides have been mentioned as 
potent components of vaccine formulations (5,45). The presence of these peptides could 
(re)direct the development of antigen presentating cells toward a type driving a favorable 
immune response to the presented antigen.  
 
Conclusion  
In conclusion, the future of antimicrobial peptides with immune modulating activity 
appears bright as these peptides might be developed further into a novel class of anti-
infectives to which microbial drug-resistance is unlikely to develop quickly. Obviously, 
research on antimicrobial/host defense peptides (including hLF1-11) has to be extended 
before these peptides can be safely introduced in medical practice. It is encouraging to see 
that the safety of hLF1-11 has not been a concern in clinical trial phase I and IIa. Together, 
our findings strongly support the notion that the therapeutic potential of hLF1-11 and 
other small host defense peptides should be investigated further.  
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Inleiding 
De ontdekking van penicilline eind jaren twintig door Alexander Fleming luidde het 
tijdperk van de antibiotica in. Vanaf de jaren ‘40 werden infecties bij mens en dier 
behandelbaar door gebruik van penicilline en later ontdekte antibiotica. Inmiddels heeft 
het gebruik én misbruik van deze middelen erin geresulteerd dat veel bacteriën en andere 
ziekteverwekkers resistent zijn geworden tegen veel van de antibiotica. Overmatig of 
onjuist gebruik van antibiotica heeft zelfs geleid tot micro-organismen die tegen alle 
bekende antibiotica totaal resistent zijn, gedefinieerd als pan-drug resistentie. Vaak wordt 
vergeten dat antibiotica slechts hulpmiddelen zijn, bedoeld om het afweersysteem van de 
patiënt in de gelegenheid te stellen de infectie te overkomen. Geen wonder dus dat 
problemen rond antibiotica resistentie voornamelijk spelen in een ziekenhuis setting, waar 
antibiotica toegepast worden om infecties te bestrijden bij patiënten met een 
verminderde afweer zoals transplantatiepatiënten of hiv-geïnfecteerden.  
Door toenemende resistentie voor de gebruikelijke antibiotica is het noodzakelijk dat er 
snel alternatieven voor deze antibiotica ontwikkeld worden. Het aantal nieuwe middelen 
dat de komende jaren op de markt komt is echter zeer beperkt, en wat er beschikbaar 
komt zijn vaak variaties op al bekende antibiotica. Naast onderzoek gericht op nieuwe 
typen van antibiotica verrichtten universiteiten en bedrijven ook onderzoek naar 
componenten van de afweer van mens en dier, of varianten daarvan, welke als basis 
zouden kunnen dienen voor een nieuw model van infectie-bestrijdende medicijnen. Een 
groep moleculen binnen dit onderzoek zijn de antimicrobiële peptiden (AMPs), kleine 
eiwitten die in staat zijn om ziekteverwekkers te doden. Deze peptiden kunnen van nature 
voorkomen in het lichaam van mens of dier, of ze vormen fragmenten van (grotere) 
eiwitten. Deze peptiden kunnen bovendien in silico ontworpen worden met behulp van 
computer software. Ondanks een grote diversiteit in herkomst hebben AMPs een aantal 
eigenschappen gemeen. Zo zijn ze vaak positief geladen (kationisch), actief tegen 
bacteriën (en door hun geheel ander werkingsmechanisme vaak ook actief tegen 
bacteriën die resistent zijn tegen antibiotica) en kunnen ook anti-schimmel, anti-virale of 
anti-parasitaire activiteiten vertonen. Daarnaast hebben sommige AMPs anti-carcinogene 
of afweerregulerende eigenschappen. AMPs werden in de jaren tachtig van de twintigste 
eeuw eerst geïsoleerd uit poppen van de zijdemot door de Zweedse onderzoeker Hans 
Boman en zijn medewerkers. In de afgelopen 30 jaar zijn er veel meer AMPs geïsoleerd uit 
een verscheidenheid aan planten, bacteriën, dieren en de uit mens. Een interessante 
eigenschap van AMPs betreft hun regulerende effect op het afweersysteem van de 
gastheer. Aangezien het afweersysteem geen onderscheid maakt tussen antibiotica
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resistente en gevoelige micro-organismen, zijn AMPs evenzogoed in staat de gastheer te 
helpen beide groepen micro-organismen te elimineren. Echter, om AMPs in te kunnen 
zetten als therapeutisch middel moet nog veel kennis vergaard worden, te beginnen met 
inzicht in de werkingsmechanismen van deze peptiden.  
In dit proefschrift is onderzoek verricht naar twee AMPs van menselijke oorsprong. Ten 
eerste een AMP bestaande uit de eerste elf aminozuren van het humane antimicrobiële 
eiwit lactoferrine, genaamd hLF1-11. Lactoferrine is een lichaamseigen eiwit dat aanwezig 
is in moedermelk, speeksel, traanvocht, en in granules, blaasjes, die aanwezig zijn in een 
bepaald type afweercel genaamd de neutrofiele granulocyt. Het eiwit bestaat uit 693 
aminozuren en heeft een breed scala aan eigenschappen waaronder antimicrobiële, 
ontstekingsremmende en afweerregulerende activiteiten. Lactoferrine is bij het publiek 
bekend geworden vanwege stier Herman. Bij deze genetisch gemodificeerde stier was een 
stukje DNA ingebouwd zodat zijn vrouwelijke nakomelingen humaan lactoferrine zouden 
produceerden in hun melk. Een van de belangrijkste werkingsmechanismen van 
lactoferrine is het binden van ijzer: hiermee wordt een molecuul dat van essentieel belang 
is voor de groei van bacteriën weggevangen en wordt verdere uitbreiding van de infectie 
tegengegaan. Binnen de eerste 47 aminozuren van de N-terminus van het lactoferrine 
eiwit bevinden zich twee kationische domeinen. Uit onderzoek is gebleken dat het eerste 
kationische domein, aminozuur 1 tot 11, het meest actieve domein is wat betreft de 
activiteit van lactoferrine tegen bacteriën en schimmels. Het peptide dat zo ontstaat, 
hLF1-11 genaamd, is in staat gebleken om de uitgroei van methicilline-resistente 
Staphylococcus aureus (MRSA) en fluconazole-resistente Candida albicans in een 
muizenmodel in te dammen. Ondanks dat hLF1-11 in vivo in staat blijkt micro-organismen 
in hun uitgroei te remmen, blijkt bij in vitro experimenten dat het doden van de 
pathogeen alleen optreedt in media met een lage zout concentratie en niet bij een 
fysiologische zoutconcentratie (d.w.z., gelijk aan de zoutconcentratie in het lichaam). Op 
grond van onder andere deze bevinding werd verondersteld dat hLF1-11 meerdere 
werkingsmechanismen heeft om infecties te bestrijden, mogelijk los van een direct 
antimicrobieel effect. In dit proefschrift is onderzocht of hLF1-11 een additioneel 
werkingsmechanisme heeft, waarbij door versterken van het afweersysteem van de 
gastheer, een infectie beter kan bestreden worden. Daarnaast is onderzocht, hoe hLF1-11 
deze effecten in afweercellen bewerkstelligt. De achtergrond gedachte is om hierbij 
nieuwe therapeutische interventiemogelijkheden bij infecties aan het licht te brengen. 
Ten tweede is onderzoek gedaan naar een welbekend humaan AMP, genaamd LL-37. Dit 
peptide, dat 37 aminozuren lang is, wordt geproduceerd door een verscheidenheid aan 
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cellen in het menselijk lichaam, zoals neutrofielen, monocyten en epitheelcellen. Het komt 
tot expressie tijdens een infectie. LL-37 is niet alleen actief tegen een brede diversiteit aan 
ziekteverwekkers, maar is ook in staat de afweer reactie van de mens te reguleren, 
bijvoorbeeld door afweercellen naar een ontstekingshaard te rekruteren, en door het 
aangeboren en adaptieve afweersysteem te beïnvloeden. In dit proefschrift is onderzocht 
of LL-37 vergelijkbare effecten heeft als gevonden voor hLF1-11 op een specifiek 
onderdeel van het afweersysteem, en of deze effecten AMP specifiek zijn.  
 
Dit proefschrift 
In hoofdstuk 1 van dit proefschrift wordt de ontdekking van antimicrobiële eiwitten en 
peptiden kort beschreven en wordt het onderzoek samengevat dat voorafgegaan is aan 
hetgeen in dit proefschrift beschreven wordt. Ook wordt informatie gegeven over het 
lichaamseigen antimicrobiële peptide LL-37 en over het afweersysteem van de mens. Dit 
afweersysteem bestaat uit een aangeboren en een adaptief, verworven systeem. Het 
aangeboren afweersysteem reageert op alles dat als gevaarlijk beschouwd wordt; 
specificiteit ligt besloten in het type reactie dat een lichaamsvreemd molecule oproept. De 
belangrijkste afweercellen die hierbij betrokken zijn, betreffen de neutrofielen en 
mononucleaire fagocyten. Deze laatste groep bestaat uit monocyten, macrofagen en 
dendritische cellen. Deze cellen zijn in staat ziekteverwekkers te fagocyteren (‘opeten’), 
wat de infectie zal helpen beteugelen of zelfs geheel op zal ruimen. Tevens kunnen ze 
componenten van deze ziekteverwekkers op hun oppervlakte presenteren aan T-
lymfocyten welke deel uit maken van het adaptieve afweersysteem. Enkele cellen uit het 
brede repertoire aan T-cellen herkennen de structuur en zullen hierop reageren met een 
specifieke respons tegen de ziekteverwekker.  
Het dierexperimenteel model waar hLF1-11 in beproefd is bestrijkt 48 uur. Dit ligt binnen 
de reactietijd van de aangeboren afweer. Daarnaast bleek hLF1-11 actief in neutropene 
dieren (d.w.z., in complete afwezigheid van neutrofiele granulocyten) en daarom is 
onderzocht of hLF1-11 mogelijk effecten uitoefent op mononucleaire fagocyten, 
afweercellen die in neutropenie immers nog wel aanwezig zijn. Daarbij, hLF1-11 wordt in 
vivo intraveneus ingespoten waardoor monocyten waarschijnlijk deel uit maken van de 
eerste groep afweercellen die met hLF1-11 in contact komen.  
In hoofdstuk 2 staan de resultaten beschreven over de stimulerende effecten van hLF1-11 
op zowel monocyten van muizen als monocyten geïsoleerd uit het bloed van mensen. 
hLF1-11 bleek de reactie van monocyten op structuren van pathogene micro-organismen, 
te versterken. Een opmerkelijke bevinding was dat de reactie van monocyten op alle 
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pathogene structuren die we getest hebben door incubatie van de cellen met hLF1-11 
verhoogd werd, met uitzondering van de reactie op componenten van Gram-positieve 
bacteriën. Zodra afweercellen een infectie in hun nabijheid waarnemen produceren ze 
moleculen die bewerkstelligen dat monocyten vanuit de bloedbaan het weefsel in 
migreren (chemotactische factoren) en daar differentiëren tot macrofaag of dendritische 
cel. Omdat hLF1-11 een modificerend effect had op de reactie van monocyten op 
pathogene structuren, was een logische vervolgvraag of monocyten die met hLF1-11 
geïncubeerd worden ook beïnvloed zouden worden in hun differentiatie tot macrofaag of 
dendritische cel. De resultaten van onderzoek naar deze vraag staan beschreven in 
hoofdstuk 3 en hoofdstuk 4.  
In hoofdstuk 3 hebben we monocyten tot macrofagen gedifferentieerd in de aan- of 
afwezigheid van hLF1-11, en daarna de karakteristieken van de cellen onderzocht. Hierbij 
hebben wij ons gericht op de differentiatie naar een macrofaag met specifiek 
ontstekingsbevorderende eigenschappen (de zogenaamde type-1 macrofaag), dat is een 
macrofaag zoals je die zou verwachten bij een infectie. Macrofagen die gedifferentieerd 
waren in de aanwezigheid van hLF1-11, bleken naast ontstekingsbevorderende ook 
ontstekingsremmende moleculen te produceren. Daarnaast reageerden deze macrofagen 
eerder op pathogene bacteriële structuren dan controle cellen, en waren ze in staat om 
pathogenen sneller te fagocyteren en vervolgens te doden. Opvallend was dat een korte 
blootstelling van slechts een uur aan het begin van de incubatie al voldoende was om de 
differentiatie van monocyten vergelijkbaar te beïnvloeden als wanneer hLF1-11 continu in 
de kweek aanwezig bleef, d.w.z. voor 7 dagen. Dit suggereert dat het effect van hLF1-11 al 
vroeg en snel optreedt, nog voor differentiatie van monocyt naar macrofaag. Aangezien 
een monocyt ook kan differentiëren tot dendritische cel, zijn we in hoofdstuk 4 het effect 
van hLF1-11 op deze differentiatie nagegaan. Als monocyten differentiëren tot een 
dendritische cel in de aanwezigheid van hLF1-11, blijkt deze cel vooral effectiever tegen C. 
albicans te zijn, in vergelijking met controle cellen. Het was opmerkelijk dat, waar de 
fagocytose van C. albicans in aan hLF1-11 blootgestelde dendritische cellen hoger is in 
vergelijking met controle cellen, de opname van MRSA niet aangedaan en onveranderd is. 
Wel produceren dendritische cellen die gedifferentieerd zijn in de aanwezigheid van hLF1-
11 meer zuurstofradicalen en de moleculen interleukine-6 en 10 na stimulatie met C. 
albicans. Zodra een dendritische cel een pathogeen gefagocyteerd heeft, presenteert de 
cel fragmenten hiervan aan T lymfocyten; de dendritische cel wordt dan rijpe dendritische 
cel genoemd. De uitrijping van de dendritische cel in aanwezigheid van een pathogene 
structuur blijkt bij hLF1-11-gedifferentieerde dendritische cellen achter te blijven. 
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Interessant is dat deze cellen in staat blijken om een zogenaamde Th17 reactie te 
induceren, na opkweken van de cellen met T-lymfocyten. Een Th17 reactie wordt in de 
literatuur geassocieerd met een anti-schimmel reactie, en is dus consistent met onze 
eerdere resultaten betreffende een versnelde opname van C. albicans.  
In hoofdstuk 5 worden de resultaten beschreven van onderzoek naar de moleculaire 
mechanismen achter de effecten van hLF1-11 op mononucleaire cellen. Met behulp van 
fluorescentie microscopie is onderzocht of het peptide aan monocyten bindt en/of in de 
cel migreert. Dit zou immers verduidelijken of hLF1-11 via een receptor op de cel 
aangrijpt, of het peptide een target, bindingspartner, binnenin de cel heeft. Met dit 
onderzoek hebben we kunnen aantonen dat hLF1-11 inderdaad in de cel migreert en bindt 
aan een targetmolecuul in de cel. Via een zogenaamd ‘fishing’ experiment met het peptide 
als aas in een ‘vijver’ van gelyseerde, uiteengevallen monocyten, hebben we het molecuul 
dat het sterkste aan hLF1-11 bindt geïdentificeerd als zijnde myeloperoxidase (MPO), een 
enzym betrokken bij de vorming van zuurstofradicalen. Om na te gaan hoe relevant deze 
binding is voor de eerder waargenomen effecten van hLF1-11 op monocyten werd 
onderzocht of hLF1-11 na binding aan MPO het molecuul remt in zijn enzymatische 
activiteit. Dit bleek het geval. Vervolgens konden we met een commerciëel verkrijgbare 
remmer van MPO vergelijkbare effecten in monocyten en macrofagen induceren als 
degene die met hLF1-11 werden verkregen. Door het MPO te binden en de enzymwerking 
te onderdrukken blijkt hLF1-11 in staat om haar regulerend effect op afweercellen en 
daarmee het afweersysteem uit te oefenen. 
Ten slotte hebben we in hoofdstuk 6 onderzocht of het lichaamseigen AMP LL-37 
eveneens de differentiatie van monocyten naar macrofagen beïnvloedt. Dit bleek niet 
alleen het geval, maar ook waren de effecten verschillend van die van hLF1-11 op de 
differentiatie van monocyt naar macrofaag. LL-37 was in staat om de differentiatie van 
monocyt tot een ontstekingsremmende macrofaag om te buigen naar een macrofaag met 
ontstekingsbevorderende eigenschappen. LL-37 kon dit effect zelfs bereiken bij al 
uitgedifferentieerde macrofagen. Aangezien LL-37 normaliter vrijkomt tijdens 
ontstekingsreacties en door het afweersysteem ingezet wordt tijdens infectie lijkt in 
theorie op dat moment een ontstekingsbevorderende macrofaag meer van pas te komen 
dan een ontstekingsremmende macrofaag, bij de beteugeling van de infectie.  
 
Tot slot 
Deze samenvatting begon met de constatering dat er een hoge nood is voor nieuwe 
antibiotica, en dan vooral antimicrobiële middelen die niet slechts een variatie zijn op de 
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al bekende middelen. Tegen veel middelen die op een enkele target binnen de bacterie 
aangrijpen, blijken op den duur resistente micro-organismen geselecteerd te worden. Een 
manier om dit probleem te omzeilen zou zijn om niet rechtstreeks op de bacterie aan te 
grijpen, maar indirect, door sturing en ondersteuning van het afweersysteem. Uit het 
onderzoek beschreven in dit proefschrift blijkt dat hLF1-11 in staat is het aangeboren 
afweersysteem te versterken door de functie van de betrokken afweercellen te 
stimuleren. Het adaptieve, verworven afweersysteem blijkt eveneens beïnvloed te 
worden, al zal verder onderzoek moeten uitwijzen of dit werkelijk bijdraagt aan het 
beteugelen van infectie in vivo. Interessant is dat hLF1-11 ook ontstekingsremmende 
eigenschappen in de onderzochte afweercellen oproept. Zo’n mechanisme zou de mate 
van ontsteking afzwakken en daarmee omliggende weefselschade verminderen. De 
identificatie van myeloperoxidase als belangrijke speler in mediatie van de effecten van 
hLF1-11, suggereert een nieuwe therapeutische target voor stimulatie en versterking van 
het afweersysteem.  
Aangezien LL-37 andere effecten op afweercellen heeft dan hLF1-11, maakt dit onderzoek 
duidelijk dat het mogelijk is om het afweersysteem met antimicrobiële peptiden op 
verschillende wijzen te beïnvloeden. In de toekomst zou het mogelijk kunnen worden de 
afweerreactie tijdens infectie specifiek te sturen door de productie van lichaamseigen 
AMPs te activeren, of AMPs van een andere bron in te zetten als geneesmiddel. Doordat 
AMPs de beperkingen van de huidige antibiotica omzeilen zou een dusdanige ontwikkeling 
kunnen bijdragen aan het snel groeiende probleem van de behandeling van antibiotica-
resistente micro-organismen. 
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